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Abstract 
Neuroblastoma is the most common solid extracranial tumour in children. The 
neuroblastoma SH-SY5Y cell line is a third successive subclone established from a 
metastatic bone tumour biopsy. It can be induced to differentiate (regress) into 
a neuronal phenotype when treated with any of several molecules including 
retinoic acid (RA). This characteristic has been exploited in several studies that 
use the SH-SY5Y cell line as a neuronal model. These studies have had far-
reaching implications in shaping our understanding of certain key aspects of 
neurotoxicity and neurodevelopment yet their genuine relevance becomes 
evident when approached from an oncological point of view, as they provide 
information about the process underlying tumour regression which in turn can 
lead to the development of better therapies for the clinical management of this 
malignancy. 
It has been shown both in vitro and in vivo that several tumours constitutively 
catabolize the essential amino acid tryptophan (Trp) promoting cancer-
associated inflammation, immune response suppression, immune escape and 
tumour outgrowth. The main degradation pathway of Trp is the kynurenine 
pathway: it involves its transformation into several bioactive compounds such as 
kynurenic acid (KA) and quinolinic acid (QA). QA has been implicated in several 
neurodegenerative diseases where it is believed to induce excitotoxic neuronal 
death through the activation of the N-methyl-D-aspartate (NMDA) receptor, a 
type of ionotropic glutamate receptor, as well as by causing oxidative stress and 
energy metabolism disruption. Conversely, KA acts as an NMDA receptor 
antagonist and exerts neuroprotection.  
Similarly, glutamate signaling and its dysregulation has been implicated in the 
development and progression of cancer. Furthermore, several glutamate 
receptor antagonists, including kynurenic acid, have been shown to inhibit the 
proliferation and migration of neoplastic cells. Conversely, it has recently been 
reported that QA increases the proliferation of SK-N-SH cells and protects 
gliomas against oxidative stress by acting as a precursor of NAD+. 
In view of all that has been mentioned thus far, the SH-SY5Y cell line was used 
as a model to investigate the effect of certain Trp metabolites such as QA, KA 
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and 3-hydroxyanthranilic acid (3-HAA) on cellular morphology, viability and 
neurite extension. An important part of this study was to determine whether the 
available methods could reliably be employed to investigate these parameters in 
the SH-SY5Y cell line. It was confirmed that the acquired SH-SY5Y cell line 
retains its ability to differentiate and to die, and that both processes can be 
accurately quantified. Additionally, the optimal culturing conditions for the SH-
SY5Y cell line were determined.  
Treatment with RA (10 µM) was used as a positive control of differentiated SH-
SY5Y cells. Overall, the morphology adopted by cells after QA (50 µM) treatment 
was similar to the one that follows RA-induced differentiation. It was 
demonstrated that QA caused an increase in the neurite/soma ratio in SH-SY5Y 
cells, which was confirmed by Western blot analysis as evidenced by an increase 
in the total cellular content of β3-tubulin. These results were also confirmed by 
a neurite outgrowth assay that selectively quantified the neuritic mass present 
in cultures. However, unlike RA, QA did not decrease the levels of the neuronal 
proliferation marker doublecortin; the term neuritogenesis is therefore more 
appropriately used to refer to the series of morphological and molecular changes 
induced by QA in SH-SY5Y cells. 
The morphological changes induced by QA were not reproduced by application of 
NMDA, nor were they inhibited by blockade of the NMDA receptor with MK-801. 
Furthermore, SH-SY5Y cells were not susceptible to NMDA excitotoxic death. In 
view of this, the expression of GluN1 protein was determined by Western blot. 
GluN1 could not be detected in either undifferentiated or differentiated SH-SY5Y 
cells, confirming that QA-induced neuritogenesis occurs through a mechanism 
independent of NMDAR activation. The results herein contained suggest that the 
SH-SY5Y cell line does not have functional NMDARs, nonetheless it is recognized 
that a more exhaustive study would be necessary to fully establish which 
glutamate receptor subtypes are found in the SH-SY5Y cell line. 
The effect of QA on the production of reactive oxygen species (ROS) was also 
investigated. QA caused an increase in the intracellular levels of ROS as 
evidenced by an increase in the fluorescence of oxidised ethidium. Additionally 
QA-treatment caused an increase in the expression of NRF2, a transcription 
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factor that responds to oxidative stress and which has been implicated in ROS-
induced differentiation in SH-SY5Y cells. 
In contrast, superoxide dismutase (SOD; 300 U/ml) significantly reduced the 
levels of ROS induced by QA treatment, which in turn caused an increase in cell 
proliferation and a reduction in the number of neurites. Similarly, diphenylene 
iodonium (DPI; an inhibitor of NADPH oxidase) also inhibited QA-induced 
neuritogenesis. These results suggest that the action mechanism of QA is mainly 
via the production of ROS, most likely superoxide (O2•-) through NADPH-oxidase.  
Interestingly, nicotinamide (1 nM-1mM; another precursor of NAD+) caused a 
dose dependent increase in the number of neurites and in the expression of β3-
tubulin, which suggests that the action mechanism of QA may be mediated by 
metabolites of the nicotinate and Nam pathway, including NAD+ either before or 
after the induction of ROS. 
Cells were treated with 3-hydroxyanthranilic acid (3-HAA) in order to ascertain 
whether other pro-oxidant molecules could induce neuritogenesis as well. Single 
and repeated application of 3-HAA (100 µM) induced cell death in SH-SY5Y cells. 
Furthermore, when 3-HAA was delivered in combination with SOD, there was a 
shift in the IC50 values indicating that toxicity was potentiated by SOD. Catalase 
(CAT; 100 U/ml) afforded complete protection from the exacerbated damage 
induced by the single co-application of 3-HAA + SOD. However, when repeated 
treatments were performed, CAT no longer afforded any protection. 
Interestingly, the serum concentration in the medium did not affect the IC50 of 
3-HAA but it did modulate the response to CAT, indicating that the specific ROS 
produced after 3-HAA treatment depend on the medium in which 3-HAA is 
delivered. At sublethal doses, 3-HAA interfered with the expression of NeuN 
(neuronal marker) through a mechanism that involves high production of ROS. 
The ability of some kynurenines to induce differentiation and cell death in SH-
SY5Y cells may open new and exciting avenues of research. If these results can 
be confirmed in vivo they could impact the way in which certain neuroblastomas 
are treated.  
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Chapter 1 – INTRODUCTION 
  
This study of the role of kynurenines and oxidative stress in the differentiation 
of SH-SY5Y cells consists of six chapters, including this introductory section. The 
first section of the introduction (1.1) deals with some key aspects of 
neuroblastoma biology and those of the neuroblastoma-derived cell line used in 
the present study (SH-SY5Y).  
In the second section (1.2), glutamatergic transmission and its role as a trophic 
factor involved in cancer pathogenesis is explored, with special emphasis on the 
NMDA ionotropic glutamate receptor on which KA and QA (both members of the 
kynurenine pathway) act as an antagonist and an agonist, respectively. 
The third section of the introduction (1.3) describes the kynurenine pathway and 
the formation of KA, 3-hydroxyanthranilic acid (3-HAA) and QA. It also provides 
evidence for how the kynurenine pathway is involved in preventing effective 
immune responses which in turn contributes to the initiation and progression of 
transformant cells.  
Given that QA is a precursor of NAD+, section 1.4 then describes a possible 
mechanism by which both molecules may also contribute to cancer 
pathogenesis. Oxygen metabolism and the production of reactive oxygen species 
is also discussed in section 1.5, 1.6, and 1.7 of the introduction, as the oxidant 
and antioxidant nature of some kynurenine metabolites has been shown to 
underlie their mechanism of action. Finally, the rationale of the study is 
presented in which the general aims are presented as well as the reason why the 
SH-SY5Y was chosen. This then concludes the introductory chapter. 
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1.1 Neuroblastoma  
Neuroblastoma (NB) is a paediatric solid malignant tumour with broad clinical 
characteristics and patient outcome. The disease was originally described by 
Virchow in 1863 when he clinically characterised an abdominal tumour which he 
designated as a “glioma” (Virchow, 1863). However, the term neuroblastoma 
was coined in 1910 by Wright when he demonstrated that the origin of the 
tumour was from embryonic neuroblasts of the sympathetic peripheral nervous 
system (Wright, 1910). Since then, an immense amount of research has been 
performed to try to understand neuroblastomas.  
Neuroblastoma is almost exclusively a paediatric disease since there are only a 
few occasional cases diagnosed after the age of five. Neuroblastoma is the third 
most common cancer in children after leukaemia and CNS tumours. It is 
therefore the most prevalent solid extracranial tumour of neuroendocrine origin 
in children (Young et al., 1986). More than 600 cases are diagnosed in the United 
States each year, accounting for approximately 15 percent of all paediatric 
cancer fatalities (Goodman et al., 1999). 
It is estimated that in the United Kingdom NB affects approximately 100 children 
each year. This is approximately 8% of the total number of paediatric cancers 
(Stiller and Parkin, 1992). These statistics stress the relevance of NB research, 
and that of the cell lines derived from it, not only as part of a quest to 
accumulate scientific knowledge but also to discover reliable treatment for 
those who suffer it. 
There are five clinically recognised stages for neuroblastomas according to 
localization and age of diagnosis. Stage 1-3 neuroblastomas are unilocular and 
generally appear within the first 1.5 years of age. Patients can be treated by 
surgical methods and have a favourable prognosis (30% survival). Some stage 1-3 
tumours may sporadically turn into benign ganglioneuromas, the survival rate for 
this maturative subtype is at 100%. Stage 4 neuroblastomas are characterised by 
extensive dissemination, patients then have to undergo extensive chemotherapy 
and radiation with a 20% survival rate. Some cases fall into an intriguing 4s stage 
in which spontaneous regression occurs and for which the survival rate is 80-85% 
(Berthold and Simon, 2005; Edsjo et al., 2007). 
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One signature characteristic of neuroblastomas is their clinical heterogeneity, 
understood as the variability in the populations studied (patient age at diagnosis, 
location of the tumour and its clinical stage), the interventions involved, and the 
outcomes measured or prognosis (Lohr et al., 2010). The advent of molecular 
cytogenetics and the successful establishment of tumour-derived cell lines 
uncovered that the clinical heterogeneity observed in neuroblastoma correlates 
with their molecular constitution (Maris and Matthay, 1999). 
Murray and Stout in 1947 discovered that neuroblastomas could be kept in vitro 
from explants of tumours grown in plasma-clot cultures. They also noticed that, 
in vitro, neuroblastoma cells exhibit an immature neuronal phenotype (flat cell 
bodies and few neuritic processes). They noticed that once in culture, 
neuroblastoma readily projected elongated structures similar to axons (Murray 
and Stout, 1947). 
Certain characteristics of neuroblastomas made them ideal cell lines for 
research. Firstly, neuroblastomas can be kept in long-term culture and secondly, 
they can undergo differentiation associated with the appearance of easily 
recognizable properties. Therefore, during the seventies, the isolation and 
characterization of human neuroblastoma cell lines and its subclones was 
performed by several research groups (Goldstein, 1968; Biedler et al., 1973; 
Seeger et al., 1977; Biedler et al., 1978). 
One of the earliest karyotyping studies of neuroblastoma cell lines reported 
numerical chromosome abnormalities in SK-N-SH and SK-N-MC, the ploidy level 
found for each line was 47 and 46 respectively (Biedler et al., 1973).  
Several other groups confirmed the occurrence of numerical chromosome 
abnormalities in these and other neuroblastoma-derived cell lines, as well as in 
explants of primary neuroblastoma tumours (Biedler and Spengler, 1976; 
Balaban-Malenbaum and Gilbert, 1977; Brodeur et al., 1977; Seeger et al., 
1977). 
A meta-analysis of 24 karyotypes of human neuroblastomas, from both tumours 
and cell lines, revealed that in addition to numerical chromosome abnormalities 
(see Table 1), neuroblastomas also have structural chromosome abnormalities 
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corresponding to the loss of the distal part of the short arm of chromosome 1 
(Brodeur et al., 1981). 
 
Table 1 Ploidy level of some neuroblastoma tumours and neuroblastoma-derived cell lines.  
There is a striking correlation between the level of ploidy, tumour malignancy 
and prognosis. The majority of stage 1, 2, and 4S tumours are near triploid and 
show excellent outcome, whereas most stage 4 tumours are diploid or tetraploid 
and have very poor clinical outcomes (Kaneko et al., 1987). 
The differentiation, or regression of some neuroblastomas in stage 4s is a very 
interesting biologic occurrence that is relevant to several branches of biology. 
For instance, in the field of neuroscience, neuroblastoma cell lines have been 
used as a model of neurodevelopment to study some of the occurrences that 
take place during neuronal differentiation such as: reduction in cell 
proliferation, changes in morphology, increases in the expression of neuronal 
cytoskeletal proteins and membrane antigens and finally, the acquisition of 
molecular machinery necessary for the synthesis and storage of monoamines and 
neuropeptides). Once differentiated, neuroblastoma cells are used as neuronal 
model to study the neurotoxic effects of several compounds. 
On the other hand, cancer research on the SH-SY5Y cell line has mainly focused 
on the mechanisms by which immortalised cells regain the ability to halt 
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proliferation and/or to die after treatment with any of several compounds. The 
acquisition of a neuronal phenotype is incidental and not necessarily the 
research focus. The clinical relevance of neuroblastoma differentiation is 
highlighted by cancer research, as is its applicability in the management of this 
malignancy. 
1.1.1 The Neuroblastoma cell line SH-SY5Y  
The SH-SY5Y cell line is a third successive subclone of the parental cell line SK-
N-SH. The SK-N-SH cell line was first subcloned to SH-SY, then to SH-SY5 and 
finally to SH-SY5Y (Biedler et al., 1973). 
Originally, the SK-N-SH cell line was established from a metastatic bone marrow 
biopsy of a four year-old girl. The SK-N-SH cell line contains three 
morphologically and biochemically different cell types: a neuroblastic (N-type), 
a substrate adherent non-neuronal form (S-type), and an intermediate type (I-
type). The N-type cells correspond to sympathoadrenal neuroblasts, which grow 
as poorly attached aggregates of small, rounded cells with short neuritic 
processes. The S-type cells have large, flat soma and resemble non-neuronal 
precursor cells. They are substrate adherent and cell growth is inhibited at high 
confluence. The I-type cells tend to clump together in culture, they are small, 
flattened and moderately adherent and sometimes present small neuritic 
elongations (Ross et al., 1995). 
There is evidence suggesting that the SH-SY5Y cell line is comprised of more 
than two morphologically distinct phenotypes. For instance, in a normal SH-SY5Y 
culture there are adherent and floating cells, both of which are viable. The 
molecular differences between adherent and floating cells have not yet been 
determined since floating cells are discarded during media changes and their 
interference should be minimal. 
Of more biological relevance is the presence of two additional adherent 
subpopulations, within the SH-SY5Y cell line, with different molecular profiles; 
one neuroblastic and the other epithelial-like (Encinas et al., 2000). The 
presence of these two cell types can cause the underestimation of several 
quantifiable parameters. For example, cells presenting the neuroblastic 
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phenotype express tyrosine hydroxylase and dopamine-β-hydroxylase (Ross et 
al., 1983) and respond to NGF (Oe et al., 2005), whereas the epithelial-like 
population does not. 
The origin of both phenotypes remains a matter of debate; they could 
correspond to the N and S types earlier described for the SK-N-SH cell line. An 
initial hypothesis, based on the presence of shared chromosome markers (Ross et 
al., 1983), is that interconversion or trans-differentiation can spontaneously 
occur. However, G-banding, spectral karyotyping (SKY) and fluorescence in situ 
hybridization (FISH) of these population subtypes showed that they have 
different DNA copy number variations (CNVs) which makes clonal expansion of 
one cell type over the other a more likely hypothesis, instead of the 
interconversion model (Cohen et al., 2003). The clonal expansion hypothesis can 
only be true if contamination with other cell types took place during the 
subcloning process. This would be extremely unlikely, particularly in a thrice-
subcloned cell line as is the case of the SH-SY5Y cell line.  
Bacterial artificial chromosome (BAC) microarray-based comparative genomic 
hybridization(CGH) has been used for the analysis of genome-wide chromosomal 
aberrations in SH-SY5Y cells(Do et al., 2007) and SH-EP cells (Do et al., 2011). In 
these studies, unbalanced chromosomal changes (gains and losses) were 
identified at a high resolution (1 Mb), confirming that the neuroblastic and 
epithelial-like cell types have different genomic identities further discrediting 
the interconversion model. CNVs related to tumourigenicity were more 
frequently amplified in SH-SY5Y cells but those related to cell homeostasis were 
more frequently amplified in SH-EP cells. The authors propose that the cancer 
stem cell theory may explain the coexistence and origin of neuroblastic and 
epithelial-like cells in culture (Do et al., 2011).  
The cancer stem-like cell (CSC) theory suggests that, in many tumours, CSCs are 
responsible for cancer initiation, progression and relapse. Since CSCs are capable 
of regenerating themselves, they can produce an unlimited progeny that will 
differentiate (albeit aberrantly) and will not respond adequately to homeostatic 
controls (Aktipis et al., 2013; Beck and Blanpain, 2013). 
Chapter 1   
25 
It has been conclusively shown that there are several cell types within most 
neuroblastoma tumours, particularly reactive Schwann cells, perineurial cells, 
satellite cells and even melanocytes (George et al., 2001; Shimada et al., 2001; 
Fisher and Tweddle, 2012). The evidence presented thus far shows that this 
diversity is also maintained in cell lines derived from these tumours. Whereas 
some of this diversity may arise from the increased mutation rate and genetic 
instability of cancerous cells (Lengauer et al., 1998; Shen, 2011), some may also 
result from the differentiation of cancer stem-like cells which have also been 
found in both tumours and in the cell lines derived from them (Hirschmann-Jax 
et al., 2004; Hansford et al., 2007).  
In a study that set out to determine the effect of hypoxia in SH-SY5Y cells, it 
was found that the hypoxic stimulus enables the purging of the neuroblastoma 
stem cell compartment (Marzi et al., 2007). Furthermore, CD133 (a cell surface 
marker commonly used to identify stem-like cells) is expressed by 8-10% of cells 
in SK-N-SH cultures and by at least 0.5% of cells in SH-SY5Y cultures (Vangipuram 
et al., 2010). A decrease in the number of cells expressing CD133 in each 
subclone is consistent with what would occur during a successive selection of the 
N-type phenotype. Du and collaborators (2008) demonstrated that 
neuroblastoma cells induce the differentiation of bone marrow stromal cells and 
mesenchymal stem cells into glial cells in vitro (Du et al., 2008). Whereas, these 
studies may explain the presence of different cell types in SH-SY5Y cultures and 
why they were not detected during the establishment of this cell line, they do 
not successfully determine the specific origin of these cell types.  
Molecular studies show that N-type, S-type and I-type cells resemble 
sympathoadrenal precursor cells, glial/melanoblastic cells and stem cells, 
respectively (Walton et al., 2004). This has been considered to be an indicator 
of a shared common origin. Such conclusions are unsatisfactory because they are 
based on the premise that similarity reflects evolutionary relationships, which is 
not always the case. Surprisingly, there are no molecular phylogenetic studies to 
unquestionably establish the relationship and origin of the different cell types 
found in neuroblastomas.  
The fact that there are no studies of this kind is partly due to the lack of 
analytical tools necessary to establish evolutionary inferences that are specific 
Chapter 1   
26 
to tumour cells. Recently a new Minimum Event Distance for Intra-tumour Copy-
number Comparisons (MEDICC) algorithm has been developed which can be used 
to quantify tumour heterogeneity as well as to reconstruct phylogenetic 
relationships (Schwarz et al., 2014). Until fairly recently, quantitative and high-
throughput technologies that allow automated and rapid screening of the whole 
genome, transcriptome and proteome had not been applied to neuroblastomas 
and their derived cell lines. Kryh and collaborators (2011) published the first 
high-density single-nucleotide polymorphism (SNP) array study for the SH-SY5Y 
cell line (Kryh et al., 2011). Taken together, these recent developments could 
be used to definitively establish the origin of the different cell types found in 
neuroblastoma tumours, as well as of those types found in cultures. 
Perhaps the most interesting characteristic of the SH-SY5Y cell line is that it is 
able to differentiate into a functional and morphological neuronal phenotype 
after treatment with an array of natural or synthetic chemicals, and with several 
biological factors such as; retinoic acid (RA) (Nicolini et al., 1998), neurotrophic 
factors, or phorbol esters (Pahlman et al., 1995; Kim et al., 1997; Encinas et al., 
1999; Olsson et al., 2000). Therefore, this cell line is one of the most widely 
used models for the study of neuronal differentiation.  
When SH-SY5Y cells undergo differentiation, there is an increase in the number 
of processes as well as an increased accumulation of norepinephrine, neuron 
specific enolase (Aanerud et al., 2012) and other neuronal specific markers 
(Encinas et al., 2000). This cell line exhibits neuronal marker enzyme activity 
(tyrosine as well as dopamine-β-hydroxylases), specific norepinephrine uptake, 
and expresses neurofilament proteins. The SH-SY5Y cell line also expresses 
opioid, muscarinic, and nerve growth factor receptors. There are a number of 
neuroblastoma differentiation protocols available, most of them employing 
treatment of the cells with retinoids and growth factors such as nerve growth 
factor (NGF) alone or in combination. This process was initially discovered to be 
caused by retinoids in vitro, which resulted in the introduction of 13-cis-retinoic 
acid (isotretinoin) as the standard of care for high-risk neuroblastoma (Ferrari-
Toninelli et al., 2010; Gardner et al., 2012; Veal et al., 2013). Indeed, the 
greatest positive clinical impact in the treatment of neuroblastomas has been 
achieved with the use of retinoids as differentiation/regression inducers. The 
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exact mechanism of action of retinoids is not yet fully understood (Reynolds et 
al., 2003a; Reynolds et al., 2003b).   
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1.2 Glutamatergic transmission - a general overview 
Glutamate (Glu), besides being an amino acid, is the most abundant excitatory 
neurotransmitter in the central nervous system (CNS) of mammals. It plays an 
important role in a myriad of neurological processes such as the regulation of 
sensory information pathways, motor coordination, emotions, neuronal 
plasticity, and long-term potentiation, among others (Salt and Herrling, 1991; 
Hassel and Dingledine, 2012). The synaptic transmission regulated by Glu is 
known as glutamatergic transmission. A large number of various types of 
neuronal populations use Glu as a neurotransmitter. It has been suggested that 
approximately 80-90% of all excitatory synapses are glutamatergic (Garey, 1999). 
A considerable amount of energy is required to restore the membrane potential 
of depolarised glutamatergic neuron and a great amount of the overall glucose 
and O2 intake is used within the brain in order to sustain glutamatergic 
transmission (Attwell and Laughlin, 2001). Depending on the downstream 
cascade of events that follows their activation, glutamate receptors (GluR) are 
divided into two classes: ionotropic (iGlu) and metabotropic (mGlu). iGlus are 
ionic channels that after Glu activation suffer conformational changes, enabling 
specific ions to enter the cell. On the other hand, mGlus do not permit the flux 
of ions; they are ligand-binding G protein coupled receptors (GPCRs) that 
activate signal transduction pathways and second messengers upon Glu binding 
(Kim et al., 2008; Hassel and Dingledine, 2012). 
iGlus were originally classified into two groups, NMDA receptors (NMDARs) and 
non-NMDARs, depending on their responsiveness to N-methyl-D-Aspartate 
(NMDA). Non-NMDARs can be further organised into two categories (AMPA 
receptors and kainate receptors) depending on whether they are activated by α-
amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA) or by kainate 
(Lodge, 1997). 
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Table 2 Overview of the molecular families of glutamate receptors. Illustrating both the 
ionotropic (iGlu) and metabotropic (mGlu) glutamate receptors as well as their known 
subunits. Modified from (Kew and Kemp, 2005) and updated with the current iGlu 
nomenclature accepted by the International Union of Basic and Applied Pharmacology 
(IUPHAR) in 2009 (Collingridge et al., 2009) as well as the mGlu nomenclature as accepted 
by NC-IUPHAR Subcommittee on Metabotropic Glutamate Receptors (Alexander et al., 
2011). 
Since the cloning of the first kainate receptor, GluK1, in 1989 (Hollmann et al., 
1989), a total of sixteen mammalian genes encoding for functional iGlus have 
been discovered as well as eight mGlus (Watkins and Jane, 2006). These 
molecular advancements, in conjunction with the analysis of ligand-binding 
selectivity, have led to an accurate classification of GluRs and its subunits which 
reflects their genetic relationship and homology (Kew and Kemp, 2005). 
Each of the two main GluR divisions (iGlu and mGlu) comprise three functionally 
defined groups of receptors. These are made up of several subunits, each 
encoded by a different gene (Table 2). There is a fourth iGlu gene family that 
includes GluD1 and GluD2, however neither seems to form a channel that 
responds to Glu or glycine and therefore their exact role in synaptic transmission 
remains to be elucidated. 
The most recent subunit nomenclature proposed by the International Union of 
Basic and Applied Pharmacology (IUPHAR) in 2009 reflects the genetic 
relationships of the different iGlu subunits with the exception of GluK1–3 and 
GluK4–5, which are encoded by distinct gene families, previously named GluR5–7 
and KA1–2 respectively. All iGlus are formed by the assembly of a particular set 
of subunits (Table 2). AMPA receptors are polymers formed by the assembly of 
GluA1–4, kainate receptors are formed by assembly of the GluK1–5 subunits, and 
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NMDARs by the assembly of GluN1 with GluN2A–D and GluN3A–B (Collingridge et 
al., 2009). 
To date, eight G-protein-coupled mGlus have been discovered (mGlu1-8) as well 
as several splice variants. With the exception of mGluR6, which is confined to 
the retina, all mGlus are expressed in the CNS. They are subdivided into three 
classes based on pharmacological properties, second messenger associations and 
sequence homology (Alexander et al., 2011). 
Class I receptors (mGlu1 and mGlu5) are expressed primarily at postsynaptic 
sites and couple via Gαq/11 leading to phospholipase C activation which in turn 
cleaves phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into diacyl 
glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), (Kew and Kemp, 2005).  
Both Class II (mGlu2 and mGlu3) and Class III (mGlu4, mGlu6, mGlu7, mGlu8) 
mGlus couple via Gαi/o, which inhibits adenylyl cyclase activity, resulting in a 
decrease in the intracellular concentration of cAMP. However, class III mGlus are 
expressed predominantly at presynaptic sites regulating neurotransmitter 
release whereas class II mGlus are expressed both pre- and postsynaptically (Kim 
et al., 2008). 
Other intracellular signaling cascades can be set into motion by all three classes 
of mGlus through coupling to their respective Gα subunit. For instance, Ca2+ 
channels can be regulated by all three classes of mGlus, K+ channels can be 
regulated by both class I and class II mGlus and finally, adenylyl cyclase can be 
activated by class I mGlus (Watkins and Jane, 2006). 
1.2.1 NMDARs 
During the early stages of NMDARs research, binding and patch-clamp studies 
provided evidence suggesting that not all NMDARs behave the same way (Cull-
Candy et al., 1988) Subsequent cloning of the NMDAR subunits yielded more 
information about the specific properties of each individual NMDAR according to 
its subunit composition(Moriyoshi et al., 1991; Cull-Candy and Leszkiewicz, 
2004).  
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NMDA receptors (NMDARs) mediate several important functions in the CNS, yet 
very little is known about the exact stoichiometry of these receptors. The 
stoichiometry of the receptor remains dubious due to contradicting reports 
(Behe et al., 1995; Premkumar et al., 1997). Consequently, there is still 
uncertainty as regards to the exact function, pharmacology and biochemistry of 
the distinct NMDARs subtypes found in the brain tissue.  
Functional NMDARs are made up of monomeric complexes associating in 
different combinations from the subunits GluN1, GluN2 and GluN3. For each one 
of these subunits there are various isoforms with distinct regional distribution 
and electrophysiological properties, thus further increasing the functional 
diversity of NMDARs within the CNS. 
NMDARs are coupled to high conductance cationic channels, which are 
permeable to Ca2+, Na+ and K+. Upon activation of the NMDAR, the ionotropic 
channel will open causing the influx of Ca2+ and Na+ and the efflux of K+. Though 
the current and membrane potential is affected by the added effect of 
individual ions, it has been shown that K+ efflux is regulated by a different 
mechanism than Ca2+ and Na+ influx (Ichinose et al., 2003). 
The first GluRs discovered were the NMDARs. Their characterisation was possible 
due to the ready availability of NMDA and to the existence of relatively specific 
agonists and antagonists. 
The NMDAR is one of the most tightly regulated neurotransmitter receptors; it 
has at least six binding sites for endogenous ligands, which affect the probability 
of finding the channel in its open conformation. For instance, a typical NMDAR 
has a binding site for Glu (found in the GluN2 subunit), glycine, polyamines, as 
well as recognition sites for Mg2+, Zn2+ and H+ which will inhibit ionic flux in 
receptors with bound agonist (Nowak et al., 1984; Hassel and Dingledine, 2012). 
NMDARs are positively modulated by glycine and the channel to which the 
receptor is coupled is blocked in a use- and voltage-dependent manner by 
Mg2+(Danysz and Parsons, 1998). The site of glycine modulation is found in the 
GluN1 subunit. Therefore, the NMDAR can only be activated after a 
depolarization of the postsynaptic membrane releases the Mg2+ ion from the 
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channel’s pore. This mechanism of Mg2+ regulation is responsible for the NMDARs 
contribution to the slow component of the current(Lodge, 1997). It is also the 
reason why NMDAR exhibit a late response to Glu when compared to non-NMDARs 
even though its EC50 is four hundred per cent lower than that of AMPA 
(Dingledine et al., 1999). 
The redox state of the receptor also affects its response. For instance, one of 
the three pairs of cysteine has to be reduced (which increases the currents 
mediated by the receptor) or oxidised, forming disulphide bonds (which reduces 
the currents) (Bough et al., 2006; Karakas et al., 2011). 
The NMDAR is unique in that it needs the simultaneous stimulation of two 
agonists (Glu and glycine) for its activation. The binding site for glycine in the 
NMDAR is different to the one found in the glycine receptor in that it cannot be 
blocked by strychnine nor can it be activated by β-alanine (Karakas et al., 2011). 
Even though glycine and Glu are necessary for NMDAR activation, the receptor’s 
overall electric response will ultimately be regulated by Mg2+, which binds to the 
extracellular region of the pore when the channel is in its open state. Several 
uncompetitive NMDAR antagonists act in a similar way to Mg2+, such as ketamine, 
phencyclidine, dextromethorphan, memantine, and dizocilpine maleate (MK-
801). However, the specific blocking kinetics as well as the voltage dependence 
of each one of these antagonists varies greatly (Rogawski, 1993; Parsons et al., 
1995; Lodge et al., 1996; Danysz and Parsons, 1998). 
The GluN3 subunit forms a channel that is activated by glycine when it binds 
with the GluN1 subunit. The GluN3 subunit has a dominant-negative effect on 
channel behaviour when it is coexpressed with the GluN1 and GluN2 subunits. 
This is possibly due to the fact that the GluN3 subunit decreases the magnitude 
of GluN1/GluN2 receptor-mediated currents by a novel mechanism that involves 
the formation of a narrow constriction in the outer vestibule of the channel, 
making the channel impermeable to sulfhydryl-specific agents (Wada et al., 
2006). 
Another endogenous allosteric inhibitor of the NMDAR acting on the GluN2B 
subunit is H+, as protons reduce the frequency with which the channel opens its 
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pore. For instance, at a pH of 6, the activation of the channel is completely 
supressed (Traynelis et al., 1995). 
Aside from the regulation mechanisms mentioned above, the NMDAR is also 
inhibited in a calcium dependent manner through activation of various calcium-
dependent proteins, including calmodulin, calcineurin, protein kinase C, and α-
actinin-2. It has been shown that an intracellular increase of Ca2+ can activate 
calmodulin, which in turn interacts with the GluN1 subunit leading to a 
reduction in the duration of native NMDAR single-channel openings from 3.5 ± 
0.6 msec to 1.71 ± 0.2 msec (Ehlers et al., 1996). Phosphatase 1 and 2a have 
been shown to regulate the calcium-calmodulin complex through the 
phosphorylation of calcium-calmodulin kinases suggesting yet another regulatory 
mechanism for the activation of NMDAR (Ehlers et al., 1996; Rycroft and Gibb, 
2002, 2004). 
The NMDARs electrophysiological properties mentioned above (permeability, 
modulatory sites, voltage dependence) along with their ability to differentially 
respond to a given stimulus, are some of the underlying mechanisms that 
cooperate to achieve synaptic plasticity. 
Most high affinity glycine B antagonists tested in vitro show very poor blood-
brain barrier permeability and become inactive after systemic administration 
(Danysz and Parsons, 1998). Therein lies the importance of some kynurenine 
pathway members, such as kynurenic acid (KA) and some of its derivatives. 
which act as endogenous antagonists of the NMDAR.  
1.2.2 GluN1 splice variants 
The effect of NMDRs varies significantly depending on their specific subunit 
combination (homoligomeric, heterodimeric and tri-heteromeric), which confers 
them with distinct pharmacological properties that result in the 
activation/inhibition of a large number of signaling pathways. 
The configurational and functional complexity of the NMDARs is further 
increased as GluN1 subunits are prone to post-transcriptional events (RNA 
editing and alternative splicing), which may result in distinct isoforms (eight for 
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the GluN1 subunit) caused by the presence of independent sites of alternative 
splicing. According to this, there are at least a dozen functionally distinct 
NMDARs subtypes though, it has been suggested there could be a considerably 
higher number of these subtypes, especially since receptor subunits might 
undergo further posttranslational and epigenetic modifications (such as 
phosphorylation, glycosylation, and palmitoylation). Each of these modifications 
determines the specific properties of each NMDAR such as its channel functions 
which result in an even more intricate complexity and diversity of signal 
transductions (Paoletti, 2011; Paoletti et al., 2013).  
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1.2.3 Neurotrophic Effect of Glutamate. 
Growth factors (also known as trophic factors) bind to cell-surface receptors to 
initiate signaling pathways that result in the survival, growth and differentiation 
of numerous cell types by promoting the synthesis of various macromolecules or 
by inhibiting their degradation. 
Apoptosis in the developing brain is a naturally occurring process that 
determines adult brain functioning. The inability of cells to undergo apoptosis 
during brain development leads to adult malformations as well as cognitive and 
behavioural deficits (Sastry and Rao, 2000). The signaling mechanism by which 
some cells survive and others are removed involves the competition of 
innervating terminals for trophic factors. The neurotrophic hypothesis states 
that during critical periods of brain development, migrating cells compete for 
limited amounts of trophic factors: those that fail to establish functional 
synapses with their target cells die by apoptosis (Aloe et al., 2012; Serrano-
Castro and Garcia-Torrecillas, 2012).  
Whereas this was initially proved to be true for Nerve Growth Factor (NGF), 
Ciliary Neurotrophic Factor (CNTF) and Glial Derived Neurotrophic Factor 
(GDNF), it is now evident that the trophic effect of Glu receptor activation 
(acting via mGlus or iGlus) is developmental stage dependent and regulates a 
variety of aspects of neurodevelopment such as proliferation, migration, 
differentiation as well as the survival of neurons that managed to establish 
proper connections (Lujan et al., 2005; Jansson and Akerman, 2014). It has been 
shown that selectively blocking GluRs during this critical developmental period 
causes the widespread loss of neurons. Conversely, interfering with the 
physiological removal of redundant cells causes brain malformations. In addition 
to synaptic transmission, the physiological stimulation of GluRs can act as a 
trophic stimulus in the adult brain and is also involved in neuronal plasticity 
(Balazs, 2006). 
For example, Glu acts as a chemoattractant molecule (enhancing migration) on 
neurons in the developing cortex through the activation of the NMDAR (Behar et 
al., 1999). Another example comes from cultured somatosensory relay neurons, 
where NMDAR blockade promotes cell death through the activation of BAX 
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(apoptosis regulator bcl-2-like protein 4) which temporally coincides with a peak 
in cell death and synaptogenesis during development in vivo (de Rivero Vaccari 
et al., 2006). 
Similarly, primary cultures of cerebellar granule neurons undergo apoptosis when 
grown in low potassium (5mM) medium. Under the same conditions, apoptosis is 
prevented by the addition of NMDA (Balazs et al., 1988) or by other depolarizing 
stimuli (Yan et al., 1994). It has been hypothesised that this depolarization 
mimics the in vivo neurotrophic effect that pontocerebellar mossy fibres exert 
on ectopic CGNs or those in the granular layer (Hamori and Somogyi, 1983; 
Berciano and Lafarga, 1988). Conversely, blockade of NMDAR during late foetal 
or early neonatal life causes apoptosis in the rat brain (Ikonomidou et al., 1999). 
Following NMDAR activation, there is an increase in the intracellular 
concentration of Ca2+, which activates protein kinases of the canonical pathway 
Ras-MAPK/ERK, and PI3-K-Akt. These protein kinases will in turn activate 
transcription factors such as CREB, SRF, MEF, NF-κB and Arc ultimately 
regulating the expression of genes involved in survival and synaptic plasticity 
(Zheng et al., 2009). 
It has been suggested that several cancers recapitulate the same underlying 
biology (regarding the trophic effect of Glu) that occurs during the early 
developmental stages of the CNS, where Glu receptor activation acts as a 
trophic factor promoting neuronal migration and survival (Sontheimer, 2008).  
1.2.4 Glutamate Signaling and Cancer 
Although cancer and the loss of tissue homeostasis arise from oncogenic 
mutations rather than by the sole effect of growth factors, the latter play a 
crucial role in the subsequent steps of tumour progression (clonal expansion, 
migration, angiogenesis and colonization). Oncogenic mutations that affect 
signaling pathways activated by growth factors enable tumours to proliferate in 
the absence of growth factors. The ability of uncontrollable propagation and 
migration through deregulation of growth factor receptor activity is common in 
several tumours (Witsch et al., 2010). 
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Due to the overlap between the signaling pathways that follow NMDAR and 
growth factor receptor activation in cancer (in particular the PI 3-K and MAPK 
pathway activated by EGF and FGF) it is not surprising that glutamate was 
suggested as a potential growth factor in tumour development (Li and Hanahan, 
2013). 
A long-standing paradigm suggested that Glu signaling is limited to the central 
nervous system. However this notion has been revised due to several studies that 
have unequivocally proved the existence of GluRs in peripheral organs (Hinoi et 
al., 2004) and neoplastic cells (Kalariti et al., 2005). The widespread expression 
of GluRs in different tissues highlights the importance of studying the role that 
Glu signaling may play in the development of cancer especially in view of the 
fact that cancer stem cells share several characteristics, such as proliferation, 
migration and Glu responsiveness, with neuronal embryonic cells. This was 
recently proven by the differential expression of functional calcium-permeable 
AMPA receptors in glioblastoma brain tumour initiating cells in contrast to 
tumour cultures consisting of non-stem cells (Oh et al., 2012). 
Perhaps the most compelling evidence linking Glu signaling and cancer comes 
from studies showing that excessive Glu release promotes tumour growth 
through the activation of iGlus and mGlus (Ye and Sontheimer, 1999; Rothstein 
and Brem, 2001; Takano et al., 2001; Haas et al., 2005; Kalariti et al., 2005; 
Ishiuchi et al., 2007) . Conversely, it has been shown both in vitro and in vivo 
that Glu antagonists effectively inhibit cancer growth, cell division and 
migration while enabling different human tumour cells (including those of 
nervous system origin) to regain the ability to die (Cavalheiro and Olney, 2001; 
Rzeski et al., 2001; Takano et al., 2001; Rzeski et al., 2005; Stepulak et al., 
2005; Wang et al., 2006; Haas et al., 2007; Namkoong et al., 2007). 
It has been suggested that Glu promotes tumour growth via at least three 
mechanisms: a) the trophic effect leading to cell division and the activation of 
survival pathways such as PI3K and AKT; b) the induction of excitotoxic death in 
surrounding cells; c) the cysteine/glutamate exchanger system and GSH 
production. (Sontheimer, 2008; Herner et al., 2011; Haas et al., 2013; Li and 
Hanahan, 2013; D'Mello S et al., 2014; Stepulak et al., 2014). 
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In a glutamate transport study comparing glioma cells and normal astrocytes, it 
was shown for the first time that gliomas produce high amounts of Glu (100 µM 
within hours) which causes the excitotoxic death of surrounding cells. The 
NMDAR antagonist MK-801 effectively protected surrounding cells from 
undergoing excitotoxic death and phenylglycine derivatives acting on mGlus 
completely inhibited the release of Glu in glioma cells (Ye and Sontheimer, 
1999).  
The release of Glu by gliomas and the subsequent excitotoxic death of 
surrounding neurons may explain the incidence of tumour-associated seizures in 
patients with glioma. Furthermore, it may represent an essential mechanism 
that enables tumoural growth in vivo where the skull limits space as, unless 
normal brain cells are destroyed, tumours cannot expand. Indeed, the NMDAR 
antagonists MK-801 and memantine slow the growth of Glu-secreting tumours in 
situ (Rothstein and Brem, 2001; Takano et al., 2001).  
It has been shown that Glu production in gliomas fuels the cysteine/glutamate 
exchanger system (xCT) by enabling the release of copious amounts of Glu and 
import of the cysteine necessary for the synthesis of glutathione (GSH), a major 
cellular antioxidant that protects tumour cells from endogenously produced 
reactive oxygen and nitrogen species. Pre-clinical data demonstrates that 
inhibition of xCT leads to GSH depletion, which in turn slows tumour growth. 
Conversely, GSH levels positively correlate with tumour resistance to radiation 
and chemotherapy (Sontheimer, 2008). 
Although the majority of paediatric solid tumours of the CNS (including glioma) 
do not express functional NMDAR (Sontheimer, 2008; Brocke et al., 2010), high 
GluN2B expression levels correlated with high vGluT2 (vesicular glutamate 
transporter) expression. Furthermore, the survival of patients with glioblastoma 
is significantly shorter when the expression of GluN2B/vGLUT2 is elevated (Li 
and Hanahan, 2013). Activated NMDARs increase the proliferation of both U87MG 
and U251MG glioma. Conversely, blockade of the NMDAR by MK-801 decreases 
their proliferation (Ramaswamy et al., 2014). Similarly, silencing the GluN2A 
subunit-targeted gene inhibits the proliferation of gastric cancer cells with an 
arrest on the G1-phase of the cell cycle (Watanabe et al., 2008). Analogously, 
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Glun1 knockdown TE671 and A549 cells (lung cancer) exhibit reduced survival as 
opposed to their wild-type counterparts (Luksch et al., 2011). 
A few reports have demonstrated that tumour size, the presence of lymph node 
metastases and the cancer stage correlate to high GluN1 expression in patients 
with oral squamous cell carcinoma (Choi et al. 2004). Additionally, it has been 
shown that the occurrence of somatic mutation in GRIN1 and GRIN2A is a 
common feature in melanomas with the latter being the most prevalent target 
(Wei et al., 2011). It has been reported that the methylation rates of the 
promoter CpG islands of GRIN2B are increased in samples from in situ ductal 
carcinoma (not yet invasive or metastatic) when compared against pre-invasive 
lesions which suggests that methylation of GRIN2B is an early event in mammary 
cancer progression (Park et al., 2011). Taken together, these results suggest 
that hijacking the signaling pathways controlled by NMDARs provides cancer cells 
with a selective advantage that enables them to proliferate.  
Although NMDAR antagonists (such as norketamine 72, memantine and MK-801) 
have little effect on glioma growth in vitro (due to the lack of NMDAR in 
gliomas), preclinical studies have shown that NMDAR antagonist have been shown 
to have antiproliferative and anti-excitotoxic effects in vivo. These results have 
subsequently led to the entering of memantine in a Phase II clinical trial to 
determine its safety/efficacy for patients with glioma (http://Clinicaltrials.gov 
#NCT01260467); the study has been completed but results are not yet available. 
The evidence presented in this section opens up the possibility that other 
endogenous ligands of the Glu receptor such as QA (QA; agonist) and kynurenic 
acid (KA; antagonist), which are both members of the kynurenine pathway, 
could also be involved in the regulation of tumoural development. in vitro 
studies have shown that QA restores cell proliferation in two cell lines derived 
from human colorectal carcinomas (Thaker et al., 2013) and conversely KA 
inhibits growth, DNA synthesis and migration of several cancer cell lines such as 
colon adenocarcinoma (Walczak et al., 2011) and renal cancer cells (Walczak et 
al., 2012).  
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1.3 The kynurenine pathway: a general overview 
The kynurenine pathway is the main catabolic pathway of the essential amino 
acid L-Tryptophan (Trp). Approximately 95% of bioavailable Trp goes through this 
metabolic pathway, and it owes its name to the fact that almost all of its 
metabolites are derived directly or indirectly from L-kynurenine(Figure 1), which 
in turn is the major degradation product of this pathway (Stone and Darlington, 
2002). 
 
Figure 1. Tryptophan metabolism Kynurenine pathway and Methoxyindole pathway. 
Modified (Stone and Darlington, 2002). 
The other route for the transformation of Trp is the methoxyindole pathway in 
which Trp is first hydroxylated, without the indole ring being lost, yielding 5-
hydroxytryptophan and then decarboxylated forming the neurotransmitter 5-
hydroxytryptamine (5-HT, serotonin). This conversion is conducted by 
tryptophan hydroxylase and by 5-hydroxytryptophan decarboxylase respectively, 
and this reaction is the rate- limiting step for the formation of serotonin. 
Serotonin can be subsequently N-acetylated and then O-methylated to form 
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melatonin, a well-known CNS inhibitor of glutamatergic-induced damage (Lapin 
et al., 1998). 
In 1947 the kynurenine pathway was recognised as the major route of Trp 
transformation (Beadle et al., 1947) and for a long time the interest in this 
pathway depended mainly on its role during the synthesis of nicotinamide 
adenine dinucleotide (NAD+) and NAD+ phosphate (NADP), which participate in 
various cellular processes related to hydride transfers and redox reactions. 
It was not until 1973 that the psychoactive nature of some kynurenines was 
discovered regarding depression (Lapin, 1973) and shortly afterwards other 
neuroactive properties were attributed to kynurenines, specifically the ability of 
QA (QA) to cause convulsions when injected intraventricularly to mice (Lapin, 
1978). 
In 1981 it was finally discovered that QA excites glutamatergic neurons through 
activation of N-methyl- D-aspartate (NMDA) receptors (Stone and Perkins, 1981). 
It then became apparent that QA could be involved in the pathogenesis of 
various neurodegenerative diseases where such excitatory amino acid receptors 
had been implicated and excitotoxic damage observed (Mattson, 2007).  
Further research on the kynurenine pathway led to the discovery of kynurenic 
acid (KA), a broad-spectrum inhibitor of excitatory amino acid receptors (Perkins 
and Stone, 1982; Nemeth et al., 2005) which has neuroprotective properties. KA 
allosterically antagonises the NMDAR at the glycine site on the receptor complex 
and thus acts as a neuroprotectant against excitotoxic insults where NMDA 
overactivation occurs. KA can also presynaptically inhibit α7 nicotinic 
acetylcholine receptor (Schrocksnadel et al., 2003) thus regulating not only 
glutamatergic but also cholinergic synaptic transmission (Carpenedo et al., 
2001). 
The enzymes involved in the kynurenine pathway have been the subject of much 
study as regulating their activity could shift the kynurenine metabolism towards 
either harmful (QA, 3-HK 3-Hydroanthranilic acid) or neuroprotective (KA) 
compounds. Indeed, the kinetics and substrate selectivity of most kynurenine 
Chapter 1   
42 
enzymes has been elucidated and reasonable success has been made in the 
development of inhibitors. 
1.3.1 Principal Metabolites and enzymes of the Kynurenine 
Pathway 
Most Trp is metabolised in the liver, and substrate flux is regulated by 
tryptophan 2, 3-dioxygenase (TDO) which is the initial, rate-limiting and highly 
substrate-specific enzyme of the kynurenine pathway. TDO is responsible for the 
cleavage of the indole ring of Trp, forming N-formylkynurenine and then 
kynurenine (Bender and McCreanor, 1982; Stone, 2001). In extrahepatic tissues, 
the predominant enzyme carrying out the above transformation is an heme 
enzyme called indoleamine 2,3-dioxygenase (IDO) which, interestingly, is the 
only enzyme, aside from superoxide dismutase, that can use O2•- as a substrate.  
Of particular interest, in neuroscience, is IDO since it is the enzyme found in 
neuronal cells. Nonetheless, it is worth noting that TDO is expressed in 
astrocytes and is of importance when considering the role of microglia in the 
physiology of the CNS, particularly during immune activation (Fuhrmann et al., 
2010).  
The next step in the kynurenine pathway is the conversion from formyl-
kynurenine to kynurenine (KYN) that is catalysed by formamidase (see Figure 1). 
KYN can be found throughout the mammalian body (in the liver, kidney, spleen, 
lung, intestine, blood and brain). It is well transported across the blood-brain-
barrier by the neutral amino acid carrier (Fukui et al., 1991). The exact function 
of KYN has eluded researchers for a long time since no direct cytoprotective or 
cytotoxic effects could be attributed to it.  
Previous studies suggested that the binding of KYN (from the degradation of Trp 
by IDO) to the aryl hydrocarbon receptor (AHR) could lead to the generation of 
Tregs (Mezrich et al., 2010). AHR is a xenobiotic receptor that functions as a 
transcriptional master molecule for drug-metabolizing enzyme genes 
Interestingly, there had been some clues pointing to the possibility that an 
endogenous ligand of the AHR could be found among tryptophan metabolites of 
the kynurenines pathway. For instance, Tryptophan photo-derivatives and 
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indigoids (indigo and indirubin) had previously been reported to be agonists of 
the AHR in vivo (Helferich and Denison, 1991; Peter Guengerich et al., 2004). 
Tryptophan photo-derivatives, indigoids and kynurenines are all indole-derived 
compounds with a similar structure to xenobiotic ligands (planar halogenated 
aromatic hydrocarbons) of the AHR. Furthermore, an overlap had also been 
found between the roles of IDO and AHR in immune regulation, inflammation and 
carcinogenesis (Stevens et al., 2009). Until recently, the relevance of KYN relied 
exclusively on the fact that it is a precursor of both KA and QA. However, a 
novel role for KYN in the facilitation of tumour-immune escape has been 
discovered in glioma cell lines and glioma-initiating cells, which will be discussed 
in section (1.3.5).  
The transformation of kynurenine by kynurenine hydroxylase or kynureninase 
generates more than twenty kynurenine metabolites, classified initially as a) 
NMDA agonists (such as QA and picolinic acid) or b) free radical generators (such 
as 3-HK and 3-HAA), a classification that is nowadays obsolete considering the 
close interrelationship between kynurenine metabolites and the generation of 
oxidative stress (Oxenkrug, 2007). 
1.3.2 Kynurenic Acid 
Kynurenic acid (KA) is an endogenous molecule found in the human brain at a 
concentration of approximately 50 pmol/g under normal physiological conditions 
(Moroni et al., 1988; Turski et al., 1988; Turski et al., 1989; Moroni et al., 
2012). It is believed that the astroglia are the main source of the KA found in the 
brain (Speciale et al., 1989; Eastman et al., 1994). 
Kynurenic acid (KA) is produced by the transamination of kynurenine (KYN). In 
human, rat and mouse, this reaction can be catalysed by four kynurenine 
aminotransferases (KAT); KAT I/glutamine transaminase K/cysteine conjugate β-
lyase 1, KAT II/aminoadipate aminotransferase, KAT III/cysteine conjugate β-
lyase 2, and KAT IV/glutamic-oxaloacetic transaminase 2/mitochondrial 
aspartate aminotransferase (Stone, 1993; Han et al., 2010). 
It has been speculated that KATI and KATII are the main enzymes responsible for 
KA production in the mammalian brain, given their specificity and abundance in 
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the brain (Guidetti et al., 2007). The notion that KATII has a very high specificity 
for KYN has been challenged more recently. KATII is able to transaminate 16 out 
of 24 amino acids and it can use 16 α-oxo acids as amino-group acceptors (Han 
et al., 2008). It is important to mention that a more recent review generated a 
substrate profile for all KATs. This study generated a comparison of the 
biochemical and structural characteristics of mammalian KATs proving that all 
four KATs are multifunctional enzymes that share many substrates and therefore 
have overlapping biological functions (Han et al., 2010). 
Even though KA is a compound that has been known for more than 150 years 
(Liebig, 1853; Asayama, 1916), its ability to antagonise the neuronal excitatory 
response to QA, quisqualate, NMDA and Glu was not described until 1982 
(Perkins and Stone, 1982). Kessler and colleagues, using receptor binding assays, 
(Kessler et al., 1989a; Kessler et al., 1989b) discovered that KA binds to the 
glycine B site of the NMDAR. 
Electrophysiological analysis in infant rat hemisected spinal cords showed that 
with increasing concentrations of KA, there were parallel shifts in the 
concentration-response curve to NMDA, and that dose ratios above 3×10-3 M 
produced a flattening of the NMDA curve (Birch et al., 1988) This demonstrates 
that KA has an antagonist effect on the NMDAR. KA can efficiently inhibit 
glutamatergic neurotransmission. It blocks both the allosteric glycine B site, IC50 
of 43 mM ([3H]glycine binding) and the Glu binding site (Danysz et al., 1989a, b; 
Kessler et al., 1989b; Danysz and Parsons, 1998). Interestingly, endogenous, 
physiological levels of KA have been shown to prevent Glu-induced neuronal 
death. It has been shown that when KA is applied exogenously, it decreases the 
activation of NMDARs (Birch et al., 1988; Velisek et al., 1995). It is still unclear 
whether the levels of KA found in the brain are sufficiently high to block the 
NMDAR and whether, under certain conditions, the levels can oscillate more, 
rendering KA a more powerful regulator of NMDAR. 
There is data showing that the levels of KA are affected under several 
physiological conditions, for example in aging animals (Gramsbergen et al., 
1992), or pathological ones such as excitotoxic events (Wu et al., 1992b; 1992a), 
epileptic seizures of the nucleus accumbens, system infection (Heyes and 
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Lackner, 1990; Heyes et al., 1990; Heyes et al., 1992), Huntington’s disease 
(Connick et al., 1988; 1989) and Down’s syndrome (Baran et al., 1996). 
The KA concentration, as well as that of other kynurenines, fluctuates during 
development. It is initially high in prenatal rodents (300 fmol/mg of protein), 
reduced at birth and up to the first postnatal week, and then finally increased 
again thereafter (Beal et al., 1992; Cannazza et al., 2001). Questions have been 
raised about the efficiency of KA on its own and whether this can be increased 
by co-administering KA with adjuvants or compounds like Probenecid that inhibit 
brain efflux, by administering KA precursors such as 4-chlorokynurenine, or by 
inhibiting the subsequent catabolic break down of KA. 
It has been suggested that concentrations below the micromolar range of KA can 
interact with nicotinic acetylcholine (Schrocksnadel et al., 2003) receptors, 
blocking the α7-nACh subtype with a half-maximal inhibitory concentration of 7 
μM; this probably contributes to its protective properties during excitotoxicity 
(Hilmas et al., 2001). This cross-talk between KA and nicotinic transmission 
could play a role in the development of some brain disorders, like schizophrenia 
and Alzheimer’s disease, where KA levels are elevated and nicotinic functions 
are impaired (Nemeth et al., 2005; Stone, 2007). Unfortunately, KA crosses the 
blood-brain barrier by passive diffusion at a considerably slow rate 1.16 x 10-5 
ml/sec/gr (Fukui et al., 1991). Therefore, the focus of much research has been 
on the theoretical development and synthesis of KA derivatives able to cross the 
blood-brain barrier. 
It has also recently been reported that KA is an agonist of G-protein-coupled 
receptor 35 (Wang et al., 2006; Cosi et al., 2011) as well as an endogenous 
ligand for the human aryl hydrocarbon receptor (AHR); in this context, it is an 
efficient activator of IL6 production in MCF-7 cells. If this observation can be 
confirmed in vivo, it would have wide ranging implications in determining how 
the AHR may be activated in various cell type (DiNatale et al., 2010) 
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1.3.2.1 KA derivatives 
It is obvious that modifying the basic structure of KA and its analogues could 
lead to novel compounds with increased effectiveness. For instance, lipophilic 
and size-limited-disubstitutions with chlorine or bromine in the 5- and 7-
positions of KA increases affinity for glycine B site in rat cortex/hippocampus P2 
membrane and in a rat cortical wedge preparation (Foster et al., 1992). 
The effect of these substitutions seems to be additive, in terms of potency and 
selectivity. Chloro, bromo, and methyl groups were found to be the desirable 
substitutions at the 7-position and larger functional groups like iodo and ethyl 
seemed to work best at the 5-position. All compounds with substitutions at 
position 6 showed more affinity for the AMPA receptor, behaving as competitive 
antagonists. Substitutions at the 8-position rendered the entire compound 
inactive in all the receptors (Leeson et al., 1991). 
In rat cortical slices, the halogen substituted derivative 7-chlorokynurenic acid 
(7-Cl KA), in concentrations ranging from 10-100 µM, noncompetitively inhibits 
NMDA responses, yet this effect can be reversed by the addition of glycine to the 
preparations. Radioligand binding experiments showed that 7-Cl KA has a much 
higher affinity for the strychnine-insensitive glycine-binding site (Kemp et al., 
1988). 
The halogenated KYN derivatives, 7-chlorokynurenic acid (7-Cl-KA) and 5,7-
dichlorokynurenic acid (5,7-Cl2-KA), show a very high potency and selectivity for 
NMDAR in vitro (Leeson et al., 1991). 7-Cl KA also showed anticonvulsant and 
neuroprotective properties after intracerebroventricular administration (Singh et 
al., 1990; Namba et al., 1993; Bonina et al., 2000). 
However, once 7-Cl-KA and 5,7-Cl2-KA are administered systemically, their 
potency and minimal blood brain barrier permeability render these derivatives 
inefficient (Leeson and Iversen, 1994). Administering direct precursors such as L-
4-chlorokynurenine (4-Cl-KYN) and L-4,6-dichlorokynurenine (4,6-Cl2-KYN), 
manages to increase the brain level of 7-Cl-KA and 5,7-Cl2-KA, respectively 
(Hokari et al., 1996). 
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More recently, in an effort to generate masked compounds that go through the 
blood-brain barrier, three new esters have been synthesised by chemical 
conjugation with essential nutrients like glucose and galactose (Bonina et al., 
2000). 
1.3.3 3-Anthranilic Acid (AA), Hydroxykynurenine (3-HK) and 3-
Hydroxyanthranilic acid (3-HAA) 
Kynurenine (KYN) is the substrate of three competing enzymes: KATs, kynurenine 
3-monooxygenase and kynureninase. These enzymes catalyse the degradation of 
KYN to KA, 3-HK and anthranilic acid (AA),.), respectively. The activity of 3-
monooxygenase is higher than that of kynureninase, therefore an increase in the 
levels of KYN will predominantly lead to an increase in the concentration of 3-HK 
rather than to that of AA. 
Kynureninase (EC 3.7.1.3) is also able to catalyse the transformation of 3-HK into 
3-HAA. Initially, It was believed that 3-HK was the main source of 3-HAA due to 
the fact that kynurenine 3-monooxygenase has a higher affinity than 
kynureninase for KYN (Bender and McCreanor, 1982). For instance, no labelled 
[13C6]QA was formed in medium containing labelled [13C6]AA, but [13C6]QA was 
produced in medium containing labelled L[13C6]Trp (Saito et al., 1993a). 
However, more recent pharmacokinetic studies suggest that it is the preference 
of kynureninase for 3-HK over KYN (265-fold preference) which explains why the 
majority of peripheral 3-HAA comes directly from 3-HK (Lima et al., 2009; 
Phillips, 2011). 
In DB/2 mice, Chiarugi et al. (1995) showed that inhibition of kynurenine 3-
monooxygenase by intraperitoneal administration of m-nitrobenzoylalanine 
(mNBA) and of kynureninase by o-methoxybenzoylalanine (oMBA) increases the 
levels of KYN and KA in the brain, blood, liver, and kidney. Furthermore, the 
same treatment offers protection against spontaneous locomotor activity and 
audiogenic convulsions. These results indicate that the predominant pathway of 
3-HAA formation is via 3-HK hydrolysis and that its pharmacological modulation 
has a positive effect on behavioural parameters. 
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In Swiss male mice, intraperitoneal administration of KYN increases the brain 
and blood content of KA, 3-HK and AA. Inhibition of kynurenine 3-
monooxygenase by mNBA decreases the brain content of 3-HK and 3-HAA but it 
increases the levels of KA and AA. Conversely, mNBA decreases the blood 
content of 3-HK but not that of 3-HAA which suggests that in peripheral tissues 
and in blood, hydroxylation of AA may be the predominant pathway of 3-HAA 
formation. The results regarding oMBA (the inhibitor of kynureninase) are 
inconsistent: oMBA did not reduce the levels of 3-HAA in either blood or brain 
and the concentration of AA was affected in a dose dependent matter not only in 
the brain but also biphasically in the periphery (Chiarugi et al., 1996). It has 
recently been suggested that the synthesis of previous kynureninase inhibitors 
had been based on mechanistic considerations and ignored in the primary 
substrate binding mode and in substrate-enzyme interactions necessary for in 
silico directed drug design (Lima et al., 2009). In fact, another molecule that 
acts as a kynureninase inhibitor has been recently synthesised, namely 3-
hydroxyhippurate (Phillips, 2011). 
There is evidence that challenges the predominance of 3-HK as the main 
precursor of 3-HAA in the brain and AA in the periphery. In blood, AA produces 
more 3-HAA due to the unspecific microsomal hydroxylation that occurs in the 
liver (Ueda et al., 1978). 
Exposure of rat cortical brain slices to 1mM of AA and 3-HK resulted in a rapid 
and transient increase in the concentration of 3-HAA (Baran and Schwarcz, 
1990). In the brain, the maximal 3-HAA production from AA is 11-fold higher 
compared to the maximal 3-HAA production from 3-HK. Conversely, in the 
spleen, 3-HK is a better precursor of 3-HAA (Baran and Schwarcz, 1990). The 
conclusion from these studies is that, within the brain, AA is a better precursor 
of 3-HAA contrarily to what happens in the periphery (Schwarcz et al., 2012). 
Other studies, regarding the predominance of AA or 3-HK as a precursor of 3-
HAA, suggest that no generalisations can be made in terms of localization (brain 
or periphery) since this will vary according to the species and the cell type 
analysed within these locations (Fujigaki et al., 1998; 1999). 
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Therefore, despite the fact that the degradation of 3-HK by 3-monooxygenase is 
the most recognised metabolic pathway of 3-HAA formation, the contribution 
and importance of AA in 3-HAA generation should not be ignored. 
For many years, the focus of kynurenine research has been on the direct effects 
of QA and KA on NMDAR as electrophysiological studies of 3-HK and 3-HA have 
not been able to establish a direct effect on neuronal transmission (Stone, 
1993). However, AA, 3-HK and 3-HAA have been described as pro- and 
antioxidant molecules in biological systems that can affect the complex 
processes in which the redox state of the cell is involved. 
It has recently been discovered that xanthurenic acid (a product of 3-HK) and 
cinnabarinic acid (an oxidation product of 3-HAA) can activate Glu metabotropic 
receptors (Fazio et al., 2012; Copeland et al., 2013). 
1.3.3.1  Role of 3-HK and 3-HAA in pathological events 
3-HK and 3-HAA are both toxic to different cell types due to their conversion to 
quinonimines and subsequent generation of ROS (Okuda et al., 1998; Goldstein 
et al., 2000; Morita et al., 2001; Fatokun et al., 2008b; Lee et al., 2010). 3-HAA 
can undergo autoxidation producing H2O2, hydroxyl radicals and superoxide anion 
(O2•-) all of which are ROS that have been widely implicated in cell death 
mechanisms (Manthey et al., 1992). 
The physiological levels of 3-HAA and 3-HK are within a nanomolar 
concentration, although micromolar levels have been detected in patients with 
hepatic encephalopathy, Huntington’s disease, PD and (HIV)-1-associated 
dementia. It has been shown that 3-HK and 3-HAA cause cell death of primary 
cultures with apoptotic features, such as condensed and fragmented nuclear 
morphology, DNA fragmentation and an increase in caspase activity (Vamos et 
al., 2009). 
The treatment of monocyte-derived cell lines (U937 and THP-1) with 200γmol/L 
3-HAA for 48 hours induced apoptosis. The toxicity induced by 3-HAA was 
reduced by the addition of the antioxidant trolox or α-tocopherol as well as by 
allopurinol, a xanthine oxidase inhibitor. Apoptosis was potentiated in the 
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presence of ferrous and manganese ions. In this study, SOD was unable to rescue 
the cells from apoptosis and catalase provided only slight protection. These 
results suggest that 3-HAA acts through a mechanism that involves ROS 
production, most likely H2O2 (Morita et al., 2001). 
Different compounds such as epigallocatechin 3-gallate, N-acetylcysteine, 
catalase and allopurinol can protect against caspase activation and cell death 
induced by 3-HK. This indicates that the neurotoxic effects of 3-HK are mainly, if 
not entirely, due to an increase in the production of ROS which will lead to 
caspase activation (Okuda et al., 1998; Nemeth et al., 2005). 
There also seems to be a difference on the susceptibility to these compounds 
depending on the cell type. For instance, in one study, it was shown that 
cortical and striatal neurons are more susceptible to 3-HK toxicity than 
cerebellar granule neurons. This difference in susceptibility may be due to the 
specific transporter activities present in these neurons. In the same study 3-HAA 
was also less potent at inducing damage than 3-HK. When 3-HAA was used, a 
concentration higher than 10μM for 48h was necessary to induce cell death as 
opposed to just 1µM when 3-HK was used (Okuda et al., 1998). Interestingly, 
toxicity is attenuated by catalase, but not by either SOD or desferrioxamine 
(Smith et al., 2007). In MC3T3-E1 osteoblast-like cells, 1mM 3-HK but not 3-HAA 
(also 1mM) significantly reduces viability 24 hours after treatment (Fatokun et 
al., 2008b). 
Changes in the concentration of AA, 3-HAA and 3-HK have also been reported to 
occur in some pathological conditions. For instance, patients with osteoporosis 
have lower baseline levels of 3-HAA and high levels of AA when compared with 
healthy individuals. In this study, the patients receiving therapy for a period of 
two years showed an improvement in bone density that correlates with a 
reversal of the 3-HAA:AA ratio to control levels (Forrest et al., 2006). 
In patients with advanced Huntington’s disease, the ratio of 3-HAA and AA is also 
affected, with AA levels higher than those of 3-HAA when compared to healthy 
individual or to patients at early stages of the disease progression (Stoy et al., 
2005; Forrest et al., 2010). 
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1.3.3.2 Autoxidation of 3-HAA 
The complete autoxidation of 3-HAA involves several steps and transient 
intermediaries that produce various ROS. However, three main reaction steps 
can be outlined.  
 
Figure 2 Three-step reaction for the complete oxidation of 3-HAA. First, 3-HAA is oxidised to 
anthranilyl radical, which upon a second oxidation forms quinoneimine. The imine is then 
condensed with another 3-HAA molecule to form cinnabarinic acid and H2O2. This Scheme 
is consistent with the fact that the cinnabarinic acid production is enhanced by manganese 
ions, cupper and cupper containing superoxide dismutase (SOD). 
First, the o-aminophenol structure of 3-HAA is oxidised to form 
semiquinoneimine (anthranilyl radical) and superoxide (O2•-) followed by a 
second oxidation that produces the p-quinone dimer quinoneimine and O2•-. The 
quinoneimine formed is highly reactive and continues to oxidise. In the third 
part of the process, a series of oxidative modifications and a condensation with 
another molecule of 3-HAA form cinnabarinic acid and hydrogen peroxide (H2O2). 
Cinnabarinic acid is broken down by H2O2, a process that can be prevented by 
catalase (Dykens et al., 1987). Labelling studies using 18O2 show that the C-2 
oxygen in the p-quinone dimer comes from molecular O2, therefore aerobic 
conditions are necessary for the reaction to occur (Manthey et al., 1990). 
Cu-Zn-SOD increases the autoxidation of 3-HAA by a mechanism not fully 
characterised yet. One hypothesis is that the newly formed products of the first 
oxidation of 3-HAA (O2•- and anthranilyl radical) are involved in a backreaction. 
Alternatively O2•- could be neutralising other oxidant agents by switching its 
behaviour into reducing agents, therefore slowing down 3-HAA oxidation. Under 
these two possibilities the dismutation of O2•- by SOD would accelerate 3-HAA 
breakdown (Dykens et al., 1987; Ishii et al., 1990; Christen et al., 1992). 
Another possibility to explain the increased rate of cinnabarinic acid production, 
in the presence of SOD, is that the O2•-, produced during the autoxidation of 3-
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HAA degrades cinnabarinic acid. Thus the co-application of SOD causes an 
apparent increase in its concentration without the actual reaction rate being 
affected (Manthey et al., 1990). This seems an unlikely explanation since it only 
takes into account the increase in the concentration of the final product 
(cinnabarinic acid) but it ignores the decrease in the concentration of the initial 
reactant (3-HAA) in the presence of SOD.  
Interestingly, when added to a phosphate buffer solution, both 3HK and 3-HAA 
are able to generate O2•- and H2O2 in the presence of copper (Cu). At a 
physiological pH and under aerobic conditions, 3-HK and 3-HAA reduce Cu2+ to 
Cu+ and Fe3+ to Fe2+. The metal reduction observed could not be elicited by 
other kynurenines and therefore it is thought to be dependent on the presence 
of the o-aminophenol structure, which both 3-HK and 3-HAA share (Goldstein et al., 
2000). 
In a more thorough study, it has been shown that in the absence of O2, 3-HAA 
reduces Cu2+-Zn-SOD to Cu+-Zn-SOD with a subsequent reoxidation of Cu+-Zn-SOD 
by O2•- which provides Cu-Zn-SOD with the catalytic activity of a superoxide 
reductase to which 3-HAA serves a substrate. Furthermore, in the same study it 
is demonstrated that Mn-SOD does not affect the rate autoxidation of 3-HAA 
which categorically disproves the alleged back reaction of O2•- with the 
anthranilyl radical as a possible mechanism by which Cu-Zn-SOD accelerates the 
autoxidation of 3-HAA (Liochev and Fridovich, 2001).  
Consequently, a more likely hypothesis has been put forward suggesting that SOD 
is directly affecting the rate of 3-HAA autoxidation by a mechanism in which the 
active site of Cu-Zn-SOD undergoes a series of reduction and oxidation cycles 
(just as Cu and Fe have been shown to do on their own). The mechanism 
proposed does not preclude the possibility that Cu-Zn-SOD may oxidise other 
radical intermediates besides 3-HAA. Furthermore, since the mechanism 
suggested requires the presence of O2•- (which may come from the oxidation of 
3-HAA) for the reoxidation of Cu+-Zn-SOD, it may explain why in previous studies 
a direct role was attributed to O2•- in the autoxidation rate of 3-HAA. 
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1.3.3.3  Protection by 3-HAA 
It has been reported that the redox behaviour of 3-HK and 3-HAA, and hence 
their toxicity, depends on different factors such as the presence of redox agents 
like O2 and transition metal ions, in particular iron, manganese and copper. 
The mechanism of action of 3-HAA, even though not as thoroughly studied as 
that of QA, has proven to be a complex process in which 3-HAA metabolism is 
subject to tight regulation. The importance of 3-HAA in healthy organisms is just 
beginning to be elucidated. 
Toxicity for instance does not necessarily mean an overall deleterious effect. 
This is particularly true when discussing it from an organismic point of view, in 
which regionalised events of oxidative stress or even cell death guarantee the 
homeostasis of an organism. Superoxide for example is a very reactive and toxic 
molecule in biological systems and it could easily be considered as detrimental 
to organisms. However, during infection episodes, O2•- is used by the immune 
system to attack pathogens. Similarly, it has recently been reported that, 
despite the oxidising nature of 3-HAA and 3-HK, under certain conditions they 
can behave as antioxidants, protect cells against oxidative damage, inhibit 
inflammation in different models of autoimmune diseases, protect against 
atherosclerosis, and kill activated T cells (but not resting ones) after infection 
(Thomas et al., 1996; Backhaus et al., 2008; Chadha et al., 2009; Lee et al., 
2010; Krause et al., 2011; Piscianz et al., 2011; Zhang et al., 2012b). 
In a model that mimics inflammation of the CNS by exposing human foetal brain 
tissue, or adult human glial cells, to cytokines (10 ng/ml of IL-1 with or without 
1ng of interferon-γ), it was reported that adding 100 µM 3-HAA suppressed glial 
cytokine and chemokine expression and reduced cytokine-induced neuronal 
death. This protection was attributed to the ability of 3-HAA to increase the 
expression of hemeoxygenase-1 (HO-1), an inducible enzyme with anti-
inflammatory and cytoprotective properties. In this study it is suggested that the 
ability of 3-HAA to increase the expression of HO-1 is due to its oxidant 
properties. 3-HAA can induce the antioxidant response element, which is 
activated by the nuclear factor (erythroid-derived-2) like-2 (NRF2), which HO-1 
depends on (Krause et al., 2011). 
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Most studies suggesting that 3-HAA has neuroprotective properties are based on 
the overall effect that 3-HAA has on cell cultures or in vivo; these results should 
be interpreted carefully since low concentrations of almost any drug can cause a 
favourable biological response, a phenomenon known as hormesis.  
Nevertheless some studies have been able to attribute not only beneficial 
properties but also direct antioxidant properties to 3-HAA. One such study used 
a pulse radiolysis technique to investigate the behaviour of 3-HAA in oxidising 
conditions, and it was found that 3-HAA has a high affinity for nitrogen and 
oxygen radicals, and that it can repair the free radical modifications caused by 
the guanosine radical and the chlorpromazine cation radical (Chadha et al., 
2009). 
It has been shown that interferon-γ-induced oxidation of the low density 
lipoprotein (LDL) causes the degradation of extracellular Trp with an increase in 
the levels of kynurenine (KYN), anthranilic acid and 3-hydroxyanthranilic acid (3-
HAA). Furthermore, the oxidation induced by interferon-γ was potentiated in the 
absence of Trp, and the addition of exogenous 3-HAA was able to inhibit the 
oxidation of LDL (Christen et al., 1994). Later studies by the same group showed 
that the inhibition of LDL oxidation by 3-HAA was due to the ability of its 
aminophenol ring to reduce the α-tocopheroxyl radical (a-TO•) which propagates 
peroxidation during the initial stages of the lipid peroxidation. Under these 
conditions, 3-HAA was just as potent an antioxidant as ascorbate (Thomas et al., 
1996). 
Murine RAW 264.7 macrophages that are stimulated with IFN-gamma and 
lipopolysaccharide (LPS) have enhanced levels of NO and increased expression 
inducible nitric oxide synthase (iNOS), heme oxygenase (HO)-1 and indoleamine 
2,3-dioxygenase (IDO). It has been shown that both HO-1 and 3-HAA prevent 
these cells from generating NO by inhibiting the expression of iNOS (Sekkai et 
al., 1997). More recently, it has been shown that 3-HAA acts upstream of the 
HO-1 inhibition of iNOS, and not directly on iNOS. Indeed, 3-HAA acts by 
increasing the expression of HO-1, which in turn will decrease the expression of 
inducible nitric oxide synthase (Oh et al., 2004).  
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Additionally, another report shows that by becoming the main target of NO 
attack, 3-HAA is nitrosated forming o-quinone diazide; this can effectively 
reduce the negative impact that NO has on other component of the cellular 
machinery. In this study, 3-HAA proved to be a better scavenger than N-
acetylcysteine (Backhaus et al., 2008). 
1.3.4 Quinolinic Acid (QA) 
3-hydroxyanthranilic acid 3,4-dioxygenase (3-HAO; EC 1.13.11.6) catalyses the 
conversion of 3-HAA to 2-Amino-3-carboxymuconate semialdehyde from which 
QA is nonenzimatically formed by a spontaneous cyclisation reaction. 
Alternatively, 2-Amino-3-carboxymuconate semialdehyde can be converted to 2-
aminomuconic semialdehyde by α-amino-β-carboxymuconate-epsilon-
semialdehyde-decarboxylase (ACMSD; EC 4.1.1.45). 2-aminomuconic 
semialdehyde is the direct precursor from which picolinic acid is formed (PIC; 
also nonenzimatically). The non-enzymatic transformation of 2-amino- 3-
carboxymuconic semialdehyde to QA occurs when ACMSD is saturated with its 
substrate. It has been suggested that under normal conditions these two 
pathways control equal flux. Thus ACMSD is positioned at a key branching point 
that will determine whether 2-Amino-3-carboxymuconate semialdehyde will be 
converted to QA for NAD+ biosynthesis (discussed in section1.4) or to picolinic 
acid (Grant et al., 2009). 
It has been shown that QA can induce excitotoxic damage, furthermore, when 
administered intracerebrally to rodents and non-human primates, it mimics 
Huntington’s disease (Schwarcz et al., 1983; Beal et al., 1986; Stone, 1993). QA 
has been implicated in the pathogenesis of several inflammatory neurological 
diseases, e.g. Increased levels of QA and its producing enzymes has been 
reported in Alzheimer’s disease, AIDS associated dementia, ischemia, epilepsy 
and Huntington’s disease. In cell culture, acute damage by QA can be achieved 
at micromolar concentrations even after only a few hours’ exposure and chronic 
damage occurs at nanomolar concentrations (Whetsell and Schwarcz, 1989). 
One of the mechanisms underlying QA toxicity involves its ability to stimulate 
glutamatergic receptors which causes an increase in the intracellular 
concentration of Ca2+ and which in turn results in apoptosis and atrophy. For 
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instance, the hippocampus has been found to be very susceptible to damage by 
this particular mechanism. 
Even though QA is an agonist of the NMDAR, it only activates the NMDAR that has 
the right combination of subunits and it does so with very low affinity and 
efficacy. This was proven in Xenopus oocytes transfected with NMDAR, in this 
model, QA did not activate receptors containing GluN1/GluN2C but it did 
activate receptors containing GluN1/GluN2A and GluN1/GluN2B. Nevertheless, 
activation was only achieved at millimolar concentrations and therefore QA is 
considered to be a relatively weak NMDAR agonist (de Carvalho et al., 1996). 
It has been suggested that the toxicity of QA cannot be explained exclusively in 
terms of its excitatory properties on NMDAR, instead several other mechanisms 
may underlie its mechanism of action. For instance, toxicity has been observed 
to occur at doses below what would be necessary for effective NMDAR 
stimulation. In line with this, a growing body of evidence has accumulated that 
clearly shows that there are additional mechanisms involved in QA-mediated 
toxicity. For example, QA has the ability to induce oxidative stress 
independently of NMDAR activation(Rodriguez-Martinez et al., 2000; Santamaria 
et al., 2001) and it can directly disrupt energy metabolism (Ribeiro et al., 2006; 
Schuck et al., 2007b; 2007a). Furthermore, QA acts as a precursor of NAD+ in 
many tissues. For instance, QA will serve as a precursor to replenish NAD+ levels 
in activated leukocytes during immune response when the induction of oxidative 
stress leads to energy depletion in leukocytes (Moffett and Namboodiri, 2003) 
For all these reasons, altering the concentration of QA can have an important 
impact on cellular physiology either by NMDA activation and signal transduction 
or by metabolic regulation of NAD and ROS production. 
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1.3.5 Regulating the metabolism of Trp metabolites. 
It has been suggested that blocking Trp metabolism downstream of KYN, using 
inhibitors of kynureninase and kynurenine 3-monooxygenase, could represent a 
novel and successful therapy in the treatment of several diseases because the 
balance between QA and KA would shift towards the latter (Stone and 
Darlington, 2002). 
The development of pharmacological tools to study the kynurenine pathway in 
vivo has proven to be a difficult task. For instance, many members of the 
kynurenine pathway and enzyme inhibitors currently available, do not cross the 
blood-brain barrier, thus their administration has to be performed 
intracerebrally. 
The large neutral amino acid carrier (L-system) of the blood-brain-barrier 
efficiently transports 3-HK and KYN into the brain. AA uptake by the brain occurs 
by passive diffusion at a considerable rate. Passive diffusion of 3-HAA, KA and QA 
occurs at a lower rate and plasma protein binding interferes with their 
transfer(Fukui et al., 1991). Despite the fact that the tools used so far are not 
ideal, they have been helpful in understanding the role that kynurenines have in 
the brain. 
One such tool is γ-(3-pyridyl)-γ-oxo-α-aminobutyrate, referred to as 
nicotinylalanine, which inhibits kynureninase and kynurenine 3-monooxygenase 
both in vitro and in vivo (Decker et al., 1963). In rodents, nicotinylalanine 
causes an increase in the brain levels of KA without a concomitant increase in 
QA within the brain (Moroni et al., 1991).  
Intraperitoneal injection of nicotinylalanine protects mice against leptazol and 
shock-induced convulsions (Connick et al., 1992) providing evidence to support 
the hypothesis that modulation of the kynurenine pathway can cause an increase 
in the endogenous concentration of KA to levels that can exert neuroprotection. 
Since then, other compounds have been found to successfully increase the level 
of KA, such as mNBA (inhibitor of kynurenine 3-mnooxygenase) and oMBA 
(inhibitor of kynureninase) in the hippocampus (Chiarugi et al., 1996). 
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This modulation can be also accomplished with (R,S)-3,4-dichlorobenzoylalanine, 
formerly known as FCE 28833A and more recently as PNU156561. Systemic 
administration of PNU156561 (400 mg/kg) increases the maximal level of KA to 
120 nM (Speciale et al., 1996) which is much lower than the 15 µM Ki of KA for 
the glycine B site of the NMDAR(Kessler et al., 1989a). Furthermore, in a gerbil 
model of global ischemia, intraperitoneal administration of 1000 mg/Kg of KA 
leads to an increase in the brain levels of KA (30-40 µM). This is the lowest 
concentration able to exert neuroprotection (Salvati et al., 1999). 
The evidence presented in this section shows that research on the kynurenine 
pathway has tended to focus on shifting the balance away from QA and towards 
kynurenic acid by means of inhibitors. However, the local and systemic effect 
that this shift has on the synthesis of nicotinamide adenine dinucleotide (NAD+) 
needs to be studied in greater detail. 
1.3.6 The Kynurenine pathway in cancer pathogenesis 
Over the past decade, there has been a dramatic increase in the experimental 
data supporting the role of IDO-1 as an important immunoregulatory enzyme 
that suppresses T-cell responses and promotes tolerance.  
Early reports documented the ability of IDO to inhibit the proliferation of 
intracellular pathogens and tumour cells in vitro (Carlin et al., 1989). For a long 
time, IDO continued to be considered as part of the host defence system against 
pathogens such as cytomegalovirus, Toxoplasma spp., Rickettsia conorii, 
Chlamydia psittaci, Mycobacterium avium and class B streptococci (Gupta et al., 
1994; MacKenzie et al., 1998; Hayashi et al., 2001). However, the relevance of 
these observations in vivo has recently been questioned in the light of new 
discoveries that link IDO activation to the suppression of T-cell responses.  
An additional immunoregulatory role for IDO was first proposed based on studies 
of mammalian pregnancy in which IDO activation was shown to be necessary to 
avoid spontaneous abortions caused by immune cells that fail to recognise the 
foetus (Munn et al., 1998; Kudo and Boyd, 2001; Li et al., 2003; Moffett and 
Namboodiri, 2003; Schrocksnadel et al., 2003). Furthermore, low levels of IDO 
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activity and hence high levels of Trp have been found during preeclampsia (Kudo 
and Boyd, 2001). 
Subsequently, considerable experimental data from several models has 
accumulated demonstrating that IDO regulates innate as well as adaptive T-cell 
immunity. For example, IDO activation causes a reduction in proliferation in 
peripheral blood mononuclear cells co-cultured with IDO-expressing skin cells 
treated with IFN-γ (Sarkhosh et al., 2003a). Human bone marrow stromal cells 
expressing IDO have an enhanced rate of tryptophan catabolism, which inhibits 
allogeneic T-cell proliferation. The addition of tryptophan in these cultures 
significantly restores the allogeneic proliferation of t-cells (Meisel et al., 2004).  
Fibroblasts expressing IDO and plated within collagen gel suppress the 
proliferation of allogeneic immune cells while remaining viable. The addition of 
an IDO-inhibitor (1-methyl-d-tryptophan) is able to counteract the inhibitory 
effects of IDO (Sarkhosh et al., 2003b). On the other hand, when IDO is 
repressed in a model of animal HIV-1, elimination of infected macrophages is 
enhanced (Potula et al., 2005). 
It was initially proposed that the immunosuppression accompanying IDO 
activation could be explained solely in terms of Trp starvation given that T-cells 
growing in a conditioned medium (in co culture with macrophages) required the 
addition of Trp to proliferate after treatment with macrophage-colony–
stimulating factor (Munn et al., 1999). However, this hypothesis was based on 
largely indirect evidence and ignored the fact that other bioactive metabolites 
are produced downstream and as a consequence of IDO activation.  
More recent studies provide evidence indicating that the immunosuppression 
caused by IDO activation involves at least three mechanisms: a) the removal of 
Trp necessary to proliferate; b) the production and/or accumulation of biological 
active downstream kynurenines; and c) the enhancement of the inhibitory 
potential of kynurenines as a direct consequence of Trp depletion (Munn et al., 
2005). 
For instance, it has been shown that in the presence of extracellular Trp, 
treatment of peripheral blood lymphocytes with KYN and picolinic acid (but not 
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QA) causes a dose-dependent inhibition of proliferation. Conversely, in the 
absence of extracellular Trp, all three metabolites effectively inhibit 
proliferation. (Frumento et al., 2002). Similarly, the downstream metabolites of 
the kynurenine pathway 3-HAA and QA induce the selective apoptosis of murine 
thymocytes and of antigen-specific CD4+ T-helper 1 (TH1) but not TH2 cells both 
in vivo and in vitro (Fallarino et al., 2002; Fallarino et al., 2003). 
Interestingly, a new link has been established between IDO activation, the 
production of 3-HAA and the generation of tolerogenic foxp3+ T-regulatory cells 
(Tregs). in vitro studies have shown that in the presence of kynurenines (before T-
cell cycle arrest due to a critical shortage of Trp) there is an early response that 
includes CD3ζ downregulation and generation of Tregs from naïve CD4+ T-cells 
(Fallarino et al., 2006). Furthermore 3-HAA from IDO induction by dendritic cells 
causes a reduction in CD4+ TH17 cells and a reciprocal increase in the fraction of 
Tregs (Favre et al., 2010). These mechanisms act on specific T-cell subtypes to 
synergistically generate a unified immunosuppressive response with GCN2 (the 
general control non-derepressing 2 protein kinase) as one of the molecular 
sensors of intracellular tryptophan (Munn et al., 2005; Fallarino et al., 2006). 
Tregs in turn cause the induction of IDO in antigen-presenting cells via ligation of 
their CTLA4 (cytotoxic T lymphocyte-associated protein 4) with the CD80/CD86 
found on antigen presenting cells. This has been suggested to be an important 
mechanism by which Tregs induce and maintain peripheral tolerance (Mellor et 
al., 2004; Mellor and Munn, 2004; Puccetti and Grohmann, 2007). Furthermore, 
Tregs enforce dendritic cells and skin grafts to express enzymes that catabolize at 
least five different essential amino acids (including tryptophan), which also 
inhibits T-cells proliferation by decreased mammalian target of rapamycin 
(mTOR) signaling (Cobbold et al., 2009) as well as GCN2.  
This positive-feedback system involving the induction of IDO in dendritic cells, 3-
HAA production, the differentiation of Tregs by 3-HAA and finally further IDO 
induction in dendritic cells, may play a significant role in suppressing an 
effective immune antitumour response. Especially in view of the fact that the 
ratio of TH17-Tregs has replaced the twenty year-old TH1-TH2 paradigm in cancer 
research (Peck and Mellins, 2010).  
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An in-depth review of both paradigms is beyond the scope and aim of this study 
and a difficult one at that, in view of the fact that the exact molecular 
mechanism by which both subsets (TH1-TH2 and/or TH17-Treg) exert their actions, 
continues to be a matter of debate. 
Briefly, the majority of tumours arise as a result of genetic and epigenetic 
changes in a particular tissue. These changes are often accompanied by an acute 
inflammation process, which involves the recruitment of granulocytes, 
lymphocytes (B-cell, T-cell and Natural killer cells), fibroblasts, endothelial cells 
as well as the release of inflammatory cytokines in the area surrounding the 
tumour. All these elements are indispensable participants in the neoplastic 
process and are collectively referred to as the tumour microenvironment. The 
tumour microenvironment determines the invasive potential of a newly formed 
tumour depending on the overall effect it has on cell proliferation, survival, 
angiogenesis and metastasis (Hanahan and Weinberg, 2000). 
Several studies have demonstrated the presence of tumour-infiltrating 
lymphocytes in the lungs of patients with non-small cell lung cancer (Imahayashi 
et al., 2002), in particular of CD4+ T-cells. CD4+ T-cells are significantly 
important in removing cancerous tissue or cells. CD4+ T-cells can be functionally 
divided into TH1, TH2, TH17, and regulatory T cells (Tregs) based on the cytokines 
they secrete (Yusuf, 2014). 
TH1 cells (which produce interleukin-2, IFN-γ, and tumour necrosis factor-alpha) 
are tumour infiltrators that predominantly promote antitumour responses as 
opposed to TH2 cells (which produce Interleukin- 4, 5, 6, 10 and 13) and 
predominantly inhibit antitumour responses. Both have been implicated in the 
development of different types of cancer (Dennis et al., 2013). 
TH17 cells predominantly induce antitumour immunity by facilitating T-cell 
recruitment to the tumour site and CD8+ T-cell priming. In contrast, Tregs 
promote acquired tolerance to tumours. Multiple lines of evidence have 
indicated that Tregs are involved in the control of the local immune response and 
in the growth of human lung cancer (Woo et al., 2002; Erfani et al., 2012; 
Ganesan et al., 2013). In vitro, lung interstitial antigen-presenting cells suppress 
T-cell mediated response by overexpressing IDO. Inhibition of IDO activity results 
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in the spontaneous proliferation of lung T-cells and inflammation. Similarly, 
immunotolerance after transplant is increased when overactivation of IDO occurs 
(Swanson et al., 2004).  
The studies presented thus far demonstrate that the kynurenine pathway plays 
an important role in the regulation of cellular immune responses. This opens up 
the possibility that a link may also exist between the kynurenine pathway and 
cancer pathogenesis. In support of this view, it has been shown that in a 
syngeneic model of Lewis lung carcinoma, the expression of IDO is increased in 
mononuclear cells that surround the tumours as well as in tumour-draining lymph 
nodes. In this study, it is shown for the first time that the inhibition of IDO (with 
1-methyl D-tryptophan; 1-MDT) effectively delays tumour growth (Friberg et al., 
2002).  
In a series of elegant experiments, Uyttenhove and collaborators (2003) provided 
extensive evidence that directly links the expression of IDO with tumoural 
progression; more specifically, that IDO confers suppressor activity to tumours 
and tumour cell lines. First, the constitutive expression of INDO (the gene that 
codifies for IDO) and its presence, as a functionally active protein, was found in 
several tumour cell lines (LB1610-MEL, melanoma line; MZ-PC-1, pancreatic 
carcinoma; NCI-H596, non-small-cell lung carcinoma; LB1263-SCCHN, laryngeal 
carcinoma; LB1165-SCCHN, pharyngeal squamous-cell carcinoma) at comparable 
levels to those found in human placenta. Similarly, IDO expression was detected 
in several human tumours (prostatic, pancreatic, colorectal carcinomas and 
gliomas) but not in normal stromal cells which suggests that IDO expression is 
relegated to the tumour microenvironment (Uyttenhove et al., 2003). The 
intraperitoneal inoculation of syngeneic DBA/2 mice with P815 cells (a 
mastocytoma cell line) induces the formation of tumours. Pre-immunisation with 
P1A antigen protects these mice against tumour formation (Van den Eynde et 
al., 1991). However, when injected with modified P815 cells (in which the 
expression of IDO had been enhanced) the majority of pre-immunised mice 
developed progressive tumours. A positive correlation was demonstrated 
between the rate of tumour progression and the expression of IDO as well as a 
concomitant decrease in the number of P1A-specific T-cells in the tumoural 
cavity (Uyttenhove et al., 2003).  
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It has recently been suggested that the evaluation of tryptophan accumulation 
by positron emission tomography (PET) can improve pre and post-treatment 
delineation of glioblastomas and metastatic brain tumours because it improves 
the delivery of radiotherapy and chemotherapy to more efficient levels. (Kamson 
et al., 2013). 
Moreover, the evaluation of IDO-1 expression has been shown to be a powerful 
predictor of patient outcome in various cancers (Mellor et al., 2005). In the 
particular context of brain tumours, it has been shown that IDO over-expression 
correlates with poor patient outcome which opens up the possibility of using IDO 
as a prognostic indicator and as a discriminatory tool to decide the course of 
treatment (Wainwright et al., 2012).  
Based on preclinical studies showing that IDO inhibition causes tumour 
regression, pharmacologic IDO inhibitors such as 1-DMT and INCB024360 alone or 
in combination with other standard of care chemotherapeutic drugs (Docetaxel) 
are currently being used in phase II clinical trials on patients with advanced solid 
tumours (Wainwright et al., 2013). The results from the two initial studies using 
IDO inhibitors have been long awaited and to date remain unpublished. 
Preliminary results indicate that 1-DMT treatment is well tolerated by patients 
treated with both INCB02436 and ipilimumab (IPI) and may have better outcomes 
as compared to IPI monotherapy (Gibney et al., 2014). Similarly, a phase I trial 
(NCT01219348) has been completed in which the effects and optimal dose of a 
synthetic peptide vaccine that targets IDO was assessed in patients with 
metastatic non–small cell lung cancer (Iversen et al., 2014). It has also been 
suggested that the ratio of KYN/Trp in serum could be used as an alternative 
non-invasive biomarker for evaluating the efficacy of IDO inhibitors in the clinic 
(Muller et al., 2005). 
To date, there are twenty-six clinical trials studying the effect and efficacy of 
cancer therapies targeting IDO alone or in combination with other standard of 
care drugs as part of a multidrug-treatment therapy. For a comprehensive table, 
showing a list of ongoing clinical trials targeting IDO alone or as an adjuvant 
immunotherapy, refer to section 6.2 of the Appendix (page 198 Table 8). 
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As previously mentioned, in addition to IDO, Tryptophan 2,3-dioxygenase (TDO) 
metabolises Trp as well. Although initially believed to be present exclusively in 
the liver, there is now evidence suggesting that it is also expressed in brain 
tissue where it may locally alter the concentration of several kynurenines (Kanai 
et al., 2009). 
Two recent studies outline a critical role for TDO in regulating immune responses 
(Schmidt et al., 2009) and its constitutive expression has been found in several 
cancers (hepatocellular carcinoma, melanoma, and bladder cancer) including 
brain tumours (malignant glioma) (Opitz et al., 2011; Pilotte et al., 2012). In the 
first study, another mechanism for facilitating tumour-immune evasion is 
reported in glioma cell lines and glioma-initiating cells (GICs), where TDO-2 is 
frequently activated and constitutively expressed leading to the production of 
KYN which suppresses anti-tumour immune responses and promotes tumour-cell 
survival and motility by acting as a ligand of the human aryl hydrocarbon 
receptor (AHR) in an autocrine manner (Opitz et al., 2011). The second study 
provides additional evidence supporting the role of TDO expression by cancer 
cells in the promotion of tumoural growth. The authors show that TDO 
expression by tumours prevents their rejection in immunized mice and that, 
upon systemic treatment with a TDO inhibitor, these mice regain the ability to 
reject implanted cancerous cells (Pilotte et al., 2012).  
Both studies provide evidence suggesting that the enzymatic activity of TDO is 
sufficient to alter Trp metabolism and suppress antitumour immune responses 
which may also explain why, in previous studies, no aberrant immunological 
phenotype was found in IDO and GCN2 null mice (Cobbold et al., 2009; 
Prendergast et al., 2010). These recent developments will surely bring with 
them the advent of a new plethora of cancer research trials, this time, targeting 
TDO Instead of IDO. Indeed, several studies have suggested that it is of the 
outmost importance to explore the possibility of a combined therapy using IDO 
and TDO inhibitors in order to increase the efficacy of restoring tumoural 
immune responses (Platten et al., 2012; Ott et al., 2014; Pantouris and Mowat, 
2014). 
Other than the previously direct effect of 3-HAA, QA, and picolinic acid (PIC) on 
immunosuppression (Fallarino et al., 2002; Frumento et al., 2002; Fallarino et 
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al., 2003; Fallarino et al., 2006; Favre et al., 2010), the involvement of the 
metabolites and enzymes of the lower segment of the kynurenine pathway in the 
development of cancer has remained virtually unexplored. Nevertheless, several 
descriptive studies have shown that there is a difference in the concentration of 
several kynurenines between healthy and pathological states such as cancer 
(Schwarcz et al., 2012).  
In patients with primary cervical cancer (PCC), it has been reported that there is 
a change in the systemic concentration of several Kynurenines. For instance, 
whereas there are no changes in Trp and KA concentration between healthy and 
patients with PCC, the activity of IDO and the levels of kynurenic acid are 
significantly lower in PCC patients when compared to controls while the levels of 
QA are significantly higher. Overall the ratio of QA to KA is markedly different 
between healthy individuals and those with PCC (Fotopoulou et al., 2011). 
Additionally, several studies have shown that KA inhibits proliferation and 
migration of Caki-2 and human glioblastoma T98G Cells (Walczak et al., 2011; 
Walczak et al., 2012; Walczak et al., 2014) 
Within and around brain tumours, variable numbers of QA immunoreactive cells 
have been detected. It has been suggested, that this may aid inflammatory cell 
infiltrates during immune tumoural response (Moffett et al., 1997). 
It has been shown that exogenous administration of kynurenines such as KYN and 
QA causes the activation of β-catenin and concomitant proliferation of human 
colon cancer cells as well as increased tumour growth in mice.(Thaker et al., 
2013) 
It has been shown that kynurenines (N-formylkynurenine, N-formylanthranilic 
acid, KYN, AA, 3-HAA) can be detected after Interferon-γ induction of IDO in the 
SK-N-SH neuroblastoma cell line, proving that they possess the main set of 
enzymes of the kynurenine pathway (Werner-Felmayer et al., 1989). Several 
other groups have confirmed this observation (Saito et al., 1993b; Heyes et al., 
1997; Guillemin et al., 2007). 
Guillemin and colleagues (2007) carried out the first complete characterization 
of the kynurenine pathway in primary neurons and in the neuroblastoma cell line 
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SK-N-SH. The authors found that both in primary and SK-N-SH cells, there is a 
balance between TDO and IDO expression whereby in the absence of one, the 
other’s expression is increased. Whereas certain kynurenine pathway enzymes 
were shown to be downregulated (KAT-I, KAT-II) other were upregulated (KMO) 
in SK-N-SH cells. Perhaps most importantly, the authors show that QA increases 
the proliferation of SK-N-SH cells and conversely, PIC reduces it (Guillemin et 
al., 2007). 
Drawing on an extensive range of sources, Adam and collaborators (2012) have 
proposed a compelling new hypothesis that if confirmed, directly links QA 
production to the progression of cancer. The authors suggest that increased 
levels of QA confer a selective advantage to cancerous cells by maintaining a 
high supply of NAD+ (Adams et al., 2012). 
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1.4 Nicotinamide metabolism 
In order to make this section easier to understand it is necessary to make a brief 
list of the common names and synonyms used in the literature to refer to the 
components of the nicotinamide pathway, which is independent from the earlier 
list of abbreviations and easier to refer to, if necessary: 
 NAD+: β-Nicotinamide adenine dinucleotide, β-DPN, β-NAD, Coenzyme 1, 
Cozymase 1, DPN, Diphosphopyridine nucleotide, Nadide. 
 NADH: nicotinamide adenine dinucleotide reduced. 
 NADP+: β-Nicotinamide adenine dinucleotide phosphate, Coenzyme 2, 
Cozymase 2, Codehydrogenase 2, Codehydrase 2 and finally, in the earlier 
literature Triphosphopyridine nucleotide. 
 NADPH: Nicotinamide adenine dinucleotide phosphate reduced. 
 NaMN: Nicotinic acid mononucleotide. 
 NaAD: nicotinic acid adenine dinucleotide, nicotinic acid adenine 
dinucleotide. 
 NaADP: Nicotinic acid adenine dinucleotide phosphate. 
 Nam: Nicotinamide, Niacinamide, Nicotinic acid amide, Pyridine-3-
carboxylic acid amide, vitamin B3. 
 MNam: 1-Methylnicotinamide 
 NMN: Nicotinamide mononucleotide, Nicotinamide ribonucleotide.  
 NA: Nicotinic acid, 3-Carboxylpyridine, 3-Pyridylcarboxylic acid, Niacin, 
vitamin B3. 
 NR: Nicotinamide Riboside, Nicotinamide-β-riboside, N-
Ribosylnicotinamide, 1-(β-D-Ribofuranosyl)nicotinamide. 
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 Qprt: quinolinic acid phosphoribosyltransferase. 
 Nmnat: nicotinamide-nucleotide adenylyltransferase 2, Nicotinamide 
mononucleotide adenylyltransferase 2 (EC 2.7.7.1; EC 2.7.7.18). 
 NNMT: Nicotinamide N-methyltransferase (EC 2.1.1.1). 
 Nadsyn1: glutamine-dependent NAD+ synthase (EC 6.3.5.1). 
 PBEF: nicotinamide phosphoribosyltransferase, Nampt (EC 2.4.2.12). 
 NRK1: nicotinamide/nicotinate riboside kinase (EC 2.7.1.22; EC 
2.7.1.173). 
NAD+ is an oxidizing agent; it accepts electrons from other molecules and 
becomes reduced. NADH can be used as a reducing agent to donate electrons. 
NAD+ and NADH are mainly used by enzymes catalysing substrate oxidation 
whereas NADP+ and NADPH are mainly used by the enzymes catalysing substrate 
reduction. The ratio of NAD+/NADH in the cytosol is approximately 700 to 1 while 
the mitochondrial one is approximately 7 to 8. Contrastingly the concentration 
of NADPH is much higher than the concentrations of NADP+ NAD+, NADH. 
NADP+ and NADPH are molecules involved in redox metabolism, reductive 
biosynthesis, antioxidation and posttranslational modification of several proteins 
(Nelson, 2013). 
Additionally, increasing evidence has pointed to several new biological functions 
that are directly regulated by NAD+ and NADP+ (Belenky et al., 2007). For 
example: a) NAD+ dependent histone deacetylases (sirtuins) regulate mechanisms 
that range from caloric restriction to differentiation; b) poly(ADP-ribose) 
polymerase-1 (PARP-1) which has been widely implicated in DNA-repair 
mechanisms and different types of cell death; c) cyclic ADP-ribose and NaADP, 
both synthesised from NAD+, mobilise calcium from intracellular pools (Ying, 
2008); and finally d) NADPH oxidase (NOX) generation of ROS is implicated in 
processes such as infection cellular response, growth, differentiation and death 
(Maejima et al., 2011). 
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SIRT1 stands for sirtuin (silent mating type information regulation 2 homolog 1). 
It is also known as NAD+-dependent deacetylase sirtuin-1. SIRT1 is the human 
homolog of the protein SIRT2 which is found in S. cerevisiae (Frye, 1999). SIRT1 
functions as a sensor of the ratio of cytosolic NAD+/NADH during episodes of 
glucose deprivation or caloric restriction (when the ratio of NAD+/NADP+ 
increases). For instance, in response to low nutrients or stress conditions, SIRT1 
inhibits skeletal myoblast differentiation (a decrease of the NAD+/NADH ratio 
coincides with skeletal myogenesis, whereas its increase inhibits it). Glucose 
restriction activates 5'-AMP-activated protein kinase (AMPK) which in turn 
activates nicotinamide phosphoribosyltransferase (PBEF), this activation shifts 
the ration of NAD+, NADP+ and nicotinamide and prevents differentiation, 
however SIRT1+/− myoblasts are less sensitive to either glucose restriction or 
AMPK activation and differentiate even under conditions of extremely low 
caloric intake. (Fulco et al., 2008; Saini et al., 2012). SIRT1 deacetylates 
histones and promotes both DNA and histone methylation, therefore increasing 
the positive charges of the histone’s tails and in doing so enables high-affinity 
binding to occur between the histones and the DNA backbone. When this occurs, 
chromatin becomes tightly packed and transcription factors cannot attach to the 
specific DNA sequences of the genes that they regulate, causing transcription 
repression. By affecting chromatin structure, SIRT1 negatively regulates 
chromatin remodelling and gene expression.  
SIRT1 can also deacetylate transcription factors and co-regulators, thereby 
affecting target gene expression positively and negatively; some of these 
transcription factors are p53, forkhead transcription factors (FOXO), p300 
histone acetyltransferase, tumour suppressor protein p73, E2F transcription 
factor 1 (E2F1), DNA repair factor Ku antigen 70-kDa subunit (Ku70), nuclear 
factor kappa-B (NF-κB), and androgen receptor (AR). Since the number and type 
of transcription factors that SIRT1 interacts with is so large, SIRT1 has been 
shown to be involved in diverse cellular processes such as reaction to 
metabolism, stressors, development, longevity, cell cycle, response to DNA 
damage,, apoptosis, autophagy and differentiation (Luo et al., 2001; Brunet et 
al., 2004; Wang et al., 2008; Blander et al., 2009; Ou et al., 2011; Saini et al., 
2012). In mammalian cells SIRT1 also mediates stress adaptation by 
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deacetylating stress-response elements such as FOXO proteins and p53 (Luo et 
al., 2001; Brunet et al., 2004). 
The role of Poly (ADP-ribose) polymerase (PARP) in DNA repair mechanisms has 
been widely documented (Sousa et al., 2012). However, prolonged PARP 
activation markedly reduces cellular NAD+ and ATP content culminating in 
cellular death due to energy deficiency. Interestingly, both PARP-1 and sirtuins 
compete for NAD+ as a substrate and crosstalk between the two has been 
reported to occur (Canto et al., 2013). The interaction between the two could 
therefore determine cell cycle progression, differentiation or death. 
Intracellular NAD homeostasis is maintained by an equilibrium between NAD+ 
degradation and NAD+ synthesis. There are four known NAD+ biosynthesis 
pathways in vertebrates: de novo (from QA formed through the kynurenine 
pathway), Preiss-Handler (salvage from nicotinic acid), salvage from 
nicotinamide and salvage from nicotinamide riboside (NR). All of these pathways 
have one enzyme in common, Nmnat. 
Of particular interest for this project are the de novo pathway and the 
nicotinamide salvage pathway. In the de novo pathway a phosphoribose group is 
added to QA by Qprt to form nicotinic acid mononucleotide (NaMN) by a series of 
enzymatic reactions. An adenylate group is then transferred by Nmnat1, Nmnat2 
and Nmnat3 to form nicotinic acid adenine dinucleotide (NaAD). The final step in 
the reaction is the amidation of the nicotinic acid group in NaAD to a 
nicotinamide (Nam) group by Nadsyn1, forming NAD+. For instance, it has been 
shown that in neurons 3-HK, 3-HAA, QA and PIC significantly increase 
intracellular NAD+ at concentrations below 100 nM but substantially decrease it 
at higher concentrations, which coincides with an increase in extracellular LDH 
activity (Braidy et al., 2009).  
In a further step, some NAD+ is phosphorylated into NADP+ by NAD+ kinase. Both 
NAD+ and NADP+ are oxidising agents involved in a myriad of cellular processes 
such as energy metabolism, mitochondrial function, calcium homeostasis, 
oxidative state, gene expression, differentiation, aging and cell death. 
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All the enzymes that use NAD+ as a substrate will form Nam (which can also be 
ingested) as a by-product. Nam is transformed into NMN by PBEF and then 
adenylylated by Nmnat1-3 to form NAD+ (Figure 3). 
 
Figure 3- Intracellular NAD+ metabolism. de novo (QA), Preiss-Handler (Nicotinic acid, NA), 
salvage (Nam) and Salvage nicotinamide riboside (Nr) pathways. Modified from Belenky et 
al. (2007). 
Nam can be N-methylated by nicotinamide N-methyltransferase (NNMT) to form 
1-methylnicotinamide. Alternatively, nicotinamide can be transformed into 
nicotinic acid (NA) by nicotinamidase. NA acid can be catabolised into two 
elimination products: trigonelline (in plants only) nicotinuric acid (in humans) by 
Glycine N-acyltransferase and Glycine N-acyltransferase-like protein 1,2,3. 
There are two main mechanisms by which NADP+ can be formed, one is the de 
novo mechanism involving NAD+ kinases which phosphorylate NAD+ or 
alternatively through the action of NADPH-dependent enzymes. 
NADPH in turn can be formed from NADH and NADP+ by mitochondrial 
transhydrogenases or from NADP+ by a multiple sequence of steps involving 
different NADP+ dependent enzymes (glucose 6-phosphate dehydrogenase, 6-
gluconate phosphate dehydrogenase, NADP+ -dependent isocitrate 
dehydrogenases, NADP+ dependent malic enzymes, mitochondrial 
dehydrogenase). 
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NAD+ is used by a vast number of protein families, like the mammalian ADP-
ribosyl cyclase CD38. CD38 acts as an ectocyclase that converts NAD+ to the Ca2+ 
-releasing second messenger cyclic ADP-ribose (cADPR). CD38 knockout mice 
exhibit high levels of NAD+, which suggests that under physiological conditions 
NAD+ levels are regulated by CD38. The expression of CD38 is also tissue 
dependent, it is widely expressed on thymocytes, activated T cells, terminally 
differentiated B cells (plasma cells), it is high in kidney and cardiac tissue and it 
is thought to be involved in cellular proliferation and adhesion (Aksoy et al., 
2006). 
NADPH has three main biological functions: a) it is part of the cellular 
antioxidant defence mechanism; b) it donates electrons necessary for the 
reductive synthesis of fatty acids, steroids and DNA (Pollak et al., 2007); c) it is 
a substrate of NADPH-oxidase (discussed in more detail in chapter 1.5.2.2) 
1.4.1 Role of NAD+ in cancer 
It has been suggested that certain inherent properties of tumours (high 
metabolic activity, increased ROS production, increased DNA damage and need 
for reparative enzymes, etc.) result in a high rate of NAD+ consumption. Thus 
having a high NAD+ supply has been suggested to be crucial for the survival and 
proliferation of tumour cells (Holen et al., 2008; Travelli et al., 2011).  
Conversely, low levels of NAD+ potentially jeopardize the ability of transformant 
cells to maintain ongoing cell division. Indeed, tumour’s NAD+ dependency has 
been the target of several successful therapies in which the application of NAD+-
consuming enzymes (PARPs and sirtuins) causes the intracellular depletion of 
NAD+ with concomitant tumoural death (Haigis and Sinclair, 2010; Rouleau et al., 
2010). 
Cancer cells have acquired several adaptations (metabolic transformation) in 
order to meet their particular metabolic requirements. Accordingly, it has been 
shown that several enzymes involved in NAD+ metabolism are differentially 
expressed in tumours when compared to normal tissue. One such enzyme is 
PBEF, which is overexpressed in several solid tumours (Yang et al., 2007; Reddy 
et al., 2008; Bi et al., 2011; Wang et al., 2011) where it may promote 
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angiogenesis by inducing the expression of growth factors and 
metalloproteinases (Drevs et al., 2003; Kim et al., 2007). 
In preclinical studies, two PBEF inhibitors (FK866 and CHS 828) exhibited 
antitumour properties through a mechanism involving NAD+ depletion followed 
by ATP depletion (Hasmann and Schemainda, 2003; Olesen et al., 2008). 
Furthermore, it has been shown that FK866 induces autophagy in SH-SY5Y cells 
(Travelli et al., 2011). These results have subsequently led to the entering of 
both compounds in phase I/II clinical trials for patients with advanced 
malignancies (www.clinicaltrials.gov). 
There are several enzymes involved in the synthesis of NAD+ (approximately nine 
including isoforms) yet only a few of them have been studied as possible 
therapeutic targets in the management of neoplastic malignancies (Chiarugi et 
al., 2012). Thus, it is conceivable that cancer cells can potentially compensate 
for the effect of a single inhibitor and relieve the induced NAD+ deficit. 
Additionally it has been suggested that metabolic targeting represents a great 
selective pressure for the emergence of new, more resistant phenotypes 
(Oliveras-Ferraros et al., 2014). Conversely, the molecular challenges of a 
multifaceted treatment (acting at multiple levels on cellular metabolism) reduce 
the probability of cells adapting and developing resistance (Cantor and Sabatini, 
2012). 
As previously mentioned (Section 1.3.4), ACMSD is the rate limiting enzyme for 
QA production and an inverse relationship has been found between ACMSD 
activity and QA production/excretion in rats (Egashira et al., 2003) and humans 
(Ikeda et al., 1965).  
Adam and collaborators (2012) have proposed that due to the subsequent 
transformation of QA to NAD+ (de novo pathway), ACMSD could also play an 
important role in the maintenance of elevated NAD+ levels in cancer (Adams et 
al., 2012). In support of this hypothesis, the authors present evidence by 
Guillemin (2007) showing that a) in contrast to normal neurons, SK-N-SH cells do 
not express ACMSD which results in the preferential production of QA over PIC; 
b) exogenous application of QA increases the number of cells whereas PIC 
decreases it (Guillemin et al., 2007). Further strengthening the possibility that 
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in certain cancers QA production is favoured over that of PIC, the authors 
present evidence showing that PIC has neuroprotective (Coggan et al., 2009) and 
antiproliferative properties in transformed cells both in vitro (Fernandez-Pol and 
Johnson, 1977) and in vivo (Leuthauser et al., 1982), the latter probably due to 
an increase in the production of tumoricidal NO¯2 by macrophages (Melillo et al., 
1994).  
Additional evidence exists supporting the role of QA in cancer pathogenesis. For 
instance, Qprt (the enzyme transforming QA into NaMN) has been put forward as 
a novel biomarker for thyroid carcinomas (Hinsch et al., 2009). Furthermore, the 
SH-SY5Y cell line (subclone of SK-N-SH) has no endogenous expression of NNMT 
(Parsons et al., 2011) which transforms Nam into 1-methylnicotinamide (MNam). 
This could represent a metabolic adaptation that prevents the loss of Nam 
thereby securing that enough precursor is available for NAD+ formation.  
In a study that set out to determine the role of NNMT on neuronal 
differentiation, the transfection of SH-SY5Y cells with a plasmid encoding for 
NNMT increased the number of neurites and the expression of synaptophysin 
without the induction of terminal differentiation (mitotic stop). Interestingly, 
incubation of wild-type SH-SY5Y cells with 1-methylnicotinamide (MNam) also 
caused an increase in neurite branching (Thomas et al., 2013). 
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1.5 Reactive Oxygen Species (ROS) and Oxidative Stress 
1.5.1 Reactive Oxygen species 
Oxygen (O2) is a chemical element with the electronic configuration of 1 s2 2 s2 2 
p4 which under standard conditions for temperature and pressure is found as 
diatomic molecule with the chemical formula O2. O2 is the final acceptor of 
electrons during oxidative phosphorylation to generate the proton gradient 
necessary for the synthesis of ATP. During oxidative phosphorylation, which 
involves the reduction of O2 to H2O, many partly reduced products are formed; 
these are known as reactive oxygen species (ROS). ROS are also generated during 
the cyclooxygenase pathway or by cellular enzymes such as p450-oxidase, 
xanthine-oxidase and NADPH-oxidase (Halliwell, 2006; Fatokun et al., 2008a). 
The electrons found surrounding atoms and molecules occupy spatial regions 
that are known as orbitals. Each orbital can only fit two electrons at a given 
time. For example, in a covalent bond there are two electrons being shared, 
these electrons are present in the same orbital but have opposite spins. When 
only one electron is present in an orbital, it is said to be unpaired. A free radical 
is a chemical species capable of independent existence and that has one or more 
unpaired electrons (Halliwell, 2006).  
Free radicals generally short-lived molecules as their reactivity allows them to 
remove an electron from other compounds, oxidise it, or yield one of its 
electrons to a recipient compound, rendering it more reactive. For this reason, 
the direct quantification of these compounds is very difficult and the techniques 
used for their study in biological systems is generally based on indirect indicators 
of the oxidative modification of biomolecules and rarely by compounds that emit 
fluorescence after having being oxidised. 
The term reactive species (RS) is a broad category which includes both the 
reactive oxygen species (ROS), as well as the reactive nitrogen species (RNS). 
The term ROS refers to both the free radicals of O2 and to some non-radical 
derivatives of O2 that are oxidant agents and that can be easily converted into 
radicals such as: HOCl, HOBr, O3, ONOO–, 1O2, H2O2. Following a simple 
categorical syllogism: all O2 radicals are ROS but not all ROS are O2 radicals. The 
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term reactive species (RS) is wider and it includes the reactive species of O2, 
nitrogen, chlorine, bromine and those of sulphur (Stadtman, 1992; Halliwell, 
2006; Fatokun et al., 2008a).Table 3 
 
Table 3 Radical and non-radical reactive species. Table listing examples of radical and non-
radical reactive oxygen species (ROS) and reactive nitrogen species (RNS). 
1.5.2 Superoxide Anion 
O2•- is a diatomic molecule in which one electron is unpaired. This radical is 
formed under several physiological conditions such as in the electron transport 
chain where electrons passing though the different complexes can escape and 
attach to O2. Furthermore, O2•- is capable of acting as both a reducing and 
oxidizing agent depending on the nature of the molecule it acts upon. Even 
though O2•- reacts with a limited number of molecules, it is the precursor of far 
more noxious ROS like H2O2. (Valentine et al., 1984; Sawyer et al., 1985). 
1.5.2.1 Xanthine Oxidoreductases 
Another Source of O2•- is through the oxidation of non-radical molecules such as 
epinephrine, dopamine, 6 hydroxydopamine and molecules that contain thiol 
groups like cysteine (Spencer et al., 1998). 
Xanthine oxidoreductases consist of two subunits, with each subunit containing 
three domains: a molybdenum (Mo) containing domain, an iron-sulphur 
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containing domain and a flavin adenine dinucleotide (FAD) containing domain. In 
mammals xanthine oxidoreductases exist in two forms: xanthine dehydrogenase 
(XDH), which is the predominant form in vivo, and xanthine oxidase (XO). XDH 
and XO interconvert by the action of sulphide reagents (thiosulfates). However 
upon proteolysis the transformation of XDH to XO is irreversible(Harrison, 2002). 
Xanthine oxidoreductase catalyses the hydroxylation of hypoxanthine to 
xanthine and of xanthine to uric acid. During the transformation of hypoxanthine 
to xanthine, O2•- and H2O2 are formed by the following reaction: 
Hypoxanthine + H2O + O2  xanthine + O2•- + H2O2 
During the conversion of xanthine to uric acid which is catalysed by the enzyme 
xanthine oxidase O2•- and H2O2 is formed by the following reaction: 
Xanthine + O2 + H2O  Uric acid + O2•- + H+ 
The reduction of O2 by either form of the enzyme will produce O2•- and H2O2. 
XDH reduces NAD+ preferentially but it can also reduce O2. Contrastingly, XO 
cannot reduce NAD+ and will use O2 instead. Xanthine oxidase is activated by the 
Ca2+ entry that follows NMDAR activation (Hille and Nishino, 1995). 
1.5.2.2 NADPH-oxidase (NOX) 
O2•- can also be produced by nicotinamide adenine dinucleotide phosphate-
oxidase (NOX)/ dual oxidase (DUOX) family. NOX is an enzymatic complex made 
up of 6 subunits: the catalytic subunit gp91phox, the small GTPase RAC (both 
membrane bound) together with the regulatory subunits p22phox, p47phox, p40phox, 
p67phox (all of which are cytosolic). For the complex to be active, all the subunits 
need to be present on the membrane, only then will NOX catalyse the formation 
of O2•- from O2. Diphenylene iodonium chloride (DPI) is the most common NOX 
inhibitor used. DPI abstracts an electron from an electron transporter to form a 
radical, which in turn inhibits the respective electron transporter through a 
covalent binding step (Bedard and Krause, 2007). 
NOX plays an important role in many physiological and pathological processes 
through the generation of ROS. During a pathogen infection, phagocytic NOX is 
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activated and the generated ROS have an antibacterial effect. For instance, 
chronic granulomatous disease is characterised by reduced antibacterial capacity 
in phagocytes which is due to their inability to activate NOX. Furthermore, 
catalase-positive organisms (Staphylococcus aureus) can only be killed by 
neutrophils expressing NOX2. The exact mechanism by which NOX-produced ROS 
kill pathogens is not completely understood but it is believed to be partly due to 
changes in phagosomal pH and ionic concentrations. 
There are many reports that show that NOX-produced ROS alter intracellular 
signaling pathways by inhibiting the activity of protein tyrosine kinases and 
changing intracellular Ca2+ homeostasis (Chan et al., 2009). 
1.5.3 Hydrogen Peroxide 
H2O2 is a non-radical ROS present in various biological systems. It can be 
produced through many enzymatic reactions such as those catalysed by 
superoxide dismutase (SOD), the oxidases of D-amino acids, the amino oxidases, 
the glycolate oxidases and by the cyclic redox reactions of compounds like 
catecholamines. Being a far more powerful oxidant, H2O2 is therefore more 
reactive; its targets are also limited but among them is methionine and certain 
reactive cysteines. In the presence of transition metals it can generate OH•- by 
Fenton reactions (Halliwell and Gutteridge, 1992; Koppenol, 2001). 
Fe2+ + H2O2 → Fe3+ + OH· + OH− 
Fe3+ + H2O2 → Fe2+ + OOH· + H+ 
1.5.4 Hydroxyl radical 
OH•- is a highly reactive compound that can cause oxidative damage in different 
biomolecules by chain reactions of free radicals. It can initiate lipid peroxidation 
as well as generate free radicals in proteins and polynucleotides by the 
abstraction of hydrogen atoms. •- 
OH•- can be formed by three mechanisms: 
1. Fenton reactions as shown above. 
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2. The homolytic fission of water by ionizing radiation (Sonntag, 1987). 
3. The homolytic fission of peroxynitrous acid 
HOONO → OH• + NO•2 
1.5.5 Nitric oxide  
NO• is a radical that does not possess an electric charge. Since it is a 
hydrophobic compound, NO• has the ability to easily pass through cellular 
membranes (Beckman and Koppenol, 1996). NO• acts as a vasodilator (Moncada 
and Higgs, 2006), neurotransmitter and second messenger (Stamler, 1994; 
Halliwell, 1999). 
NO forms stable high affinity bonds with heme and non-heme-iron, the binding 
between NO and the ferrous heme groups is rapid and of high affinity and this 
has considerable biological implications in the activation of the soluble 
guanylate cyclase to form Cyclic guanosine monophosphate (cGMP). 
The exact stoichiometry of the nitric oxide synthase (Cecchi et al.) reaction, its 
mechanism, products, prosthetic groups, cofactors (FAD, FMN, 
tetrahydrobiopterin, and heme) and specific favourable conditions continue to 
be a matter of debate. However, it is clear that NO• is generated by NOS 
enzymes that catalyse the NADPH- and O2-dependent oxidation of L-arginine to 
L-citrulline and NO as follows, (Moncada and Higgs, 2006): 
L-arginine + 3/2 NADPH + H+ + 2 O2 = citrulline + nitric oxide + 3/2 NADP+ 
NOS can be activated by the increase in the intracellular concentration of Ca2+ 
by the calcium-calmodulin complex (Alderton et al., 2001). 
Nitric oxide can react with the O2•- radical to form peroxynitrite: 
O2• - + ·NO• → ONOO− 
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Nitric oxide can attach itself to cytochrome oxidase c reducing its affinity to O2 
and therefore affecting the mitochondrial electron flow and the synthesis of ATP 
(Poderoso et al., 1996). 
1.5.6 Peroxynitrite 
ONOO− can be rapidly formed by the molecular interaction of O2•- and nitric 
oxide. ONOO− is a powerful oxidative agent which can cause the nitration of 
guanine and the formation of carbonyl groups as well as other oxidised products 
of proteins like nitrotyrosine (Squadrito and Pryor, 1995) 
The protonation of peroxynitrite leads to the formation of peroxynitrous acid 
(Alvarez et al., 2002). 
1.6 Antioxidant Defences  
Given that ROS are constantly being generated in biological systems as part of 
their normal physiology, a healthy organism needs to remove them to avoid 
oxidative damage. Cells have developed detoxifying mechanisms that will turn 
highly reactive compounds into more stable innocuous ones.  
1.6.1 Superoxide dismutase (SOD) 
SOD dismutates O2•- by adding to it two protons (Fridovich, 1989) as shown in 
the following reaction: 
M(n+1)+-SOD + O2− → Mn+-SOD + O2  
Mn+-SOD + O2− + 2H+ → M(n+1)+-SOD + H2O2. 
Where M = Cu (n=1); Mn (n=2); Fe (n=2); Ni (n=2). 
There are 4 isoforms of this enzyme depending on the cofactor that it is 
attached to. Mn-SOD or SOD2 is mainly found in the mitochondria and requires 
manganese on its active site. 
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Cu-Zn-SOD requires copper and zinc on its catalytic site and it can be 
intracellular (SOD1) or extracellular (SOD3). SOD3 is released to the extracellular 
space and it is mainly expressed on vascular smooth muscle. 
Since the reaction catalysed by SOD produces another non-radical ROS, H2O2, its 
action must be tightly linked to that of other antioxidants (peroxidases, 
catalase, and glutathione peroxidase) that will ultimately turn H2O2 into a less 
reactive compound.  
Alterations in the functioning and structure of SOD have been found to underlie 
the pathogenicity of some neurodegenerative diseases, such as amyotrophic 
lateral sclerosis (Canals et al.) and Friedreich’s ataxia (Beal and Shults, 2003; 
Hart et al., 2005) 
1.6.2 Catalase 
Catalase (Gedik et al.) is an enzyme found in the peroxisomes of mammalian 
cells (Chance et al., 1979) and it catalyses the conversion of H2O2 to water and 
O2 depending on the concentration of H2O2. When the concentration of H2O2 is 
high, the following reaction takes place: 
H2O2 + Fe3+-E → H2O + O=Fe(IV)-E(.+) 
H2O2 + O=Fe(IV)-E(.+) → H2O + Fe3+-E + O2 
However, if the concentration of H2O2 is low and hydrogen donors such as 
methanol, ethanol, phenol, formaldehyde, formic acid and acetaldehyde, are 
present then catalase removes the H2O2 by oxidising its substrate as follows: 
H2O2 + H2R → 2H2O + R 
Catalase acts in conjunction with SOD. However, the levels of catalase in the 
brain are very low when compared to those found in other tissues. 
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1.6.3 Glutathione Peroxidase (GPx) 
GPx is the main enzyme that detoxifies peroxides; it reduces lipid 
hydroperoxides to their corresponding alcohols and reduces free H2O2 in the 
brain (Brigelius-Flohe, 1999). It is found in the cytoplasm and the mitochondrial 
matrix. GPx contains selenium on its catalytic site (Maiorino et al., 1995) and 
breaks down peroxides through the following reactions: 
2GSH + H2O2 → GSSG + 2H2O, 
ROOH +2GSH → ROH +GSSG 
Glutathione needs to be reduced again by glutathione reductase to complete a 
cycle of oxidation and reduction: 
GSSG + NADPH + H+ → 2 GSH + NADP+. 
1.6.4 Α-tocopherol  
Vitamin E refers to four tocopherols and four tocotrienols that are liposoluble 
molecules and constitutive components of membranes. Tocopherols and 
tocotrienols prevent the lipid peroxidation of membranes by eliminating the 
peroxide radicals using OH (Parks and Traber, 2000). They also convert the 
alkyperoxy radicals into hydroxyperoxides and simultaneously into tocopheroxyl 
radicals: 
Toc-OH + LO•2 → Toc- O• + LOOH 
The tocopheroxyl radical is not very reactive and it is partly reduced by 
ascorbate, turning it into tocopherol 
Toc- O• + Ascorbate → Toc-OH + Ascorbyl radical 
α-tocopherol is the most important tocopherol in the brain, if not the only one 
(Roy et al., 2002; Hayton and Muller, 2004) and its deficiency affects the CNS 
more than the peripheral one. This indicates that there exists a tight regulation 
of its levels in the brain (Halliwell, 2006).  
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1.7 Oxidative stress 
Oxidative stress has been defined as a state in which an unbalance between the 
cellular pro-oxidant and antioxidant defences occurs (Chandra et al., 2000; 
Fatokun et al., 2008a), triggering different effects which depend on the cellular 
type and the cell context. 
An intracellular increase and accumulation of ROS can occur both under 
physiological (cell signaling or cell metabolism) and pathological (toxic insults 
and neurodegeneration) conditions. This means that oxidative stress can cause 
cell damage but this damage is not necessarily an intrinsic condition linked to an 
episode of oxidative stress. For instance, several ROS are not removed 
immediately after their generation because they have very important biological 
functions (Gutteridge and Halliwell, 2000). Oscillations between the cellular pro-
oxidant and antioxidant balance are very common in healthy organisms under 
various circumstances. For example: following an infection; during an 
inflammatory response; or, in fibroblasts where O2•- regulates cell division and 
halts the chain reaction of lipid peroxidation as it reacts with the alcohoxyl 
radical. 
The existence of enzymes involved in the generation and removal of ROS (NOX, 
dual oxidase, myeloperoxidase, NOS, heme oxygenase) and the controlled 
regulation and induction of ROS formation in response to growth factors, 
cytokines and Ca2+-dependent signals, suggests a positive selection of pro-
oxidant mechanisms throughout evolution, given its importance in cellular 
physiology. For example, one of the physiological roles of ROS is the modulation 
in the expression of genes that are activated by transcription factors sensitive to 
the intracellular redox state as is the case for the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) (Remacle et al., 1995; Cimino et al., 
1997). 
Once ROS have acted upon their targets, it is necessary to remove them to avoid 
cell damage because of their high reactivity with biomolecules. To accomplish 
this, there are several antioxidant systems within the cell such as glutathione 
and enzymes like SOD and catalase. Some experimental models have shown how 
important these antioxidant systems are for the normal physiology of cells. This 
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is the case for SOD2 (mitochondrial isoform) knockout mice presenting, as a 
result, cardiomyopathy and neurodegeneration (McCord, 1994). 
One of the consequences of ROS unbalance is the structural and functional 
modification of biological macromolecules (DNA, lipids and proteins). These 
modifications can be direct, when ROS act upon the cell’s molecular machinery, 
or indirect when other subproducts of ROS attack the cell’s components. 
Oxidised biomolecules can pose a threat to the cell since they can interfere with 
the normal functioning of the cell’s molecular machinery and also because they 
can propagate the damage onto other biomolecules through free radical’s chain 
reactions (Stark, 2005). 
1.7.1 Lipid Peroxidation 
Lipid peroxidation has been implicated in the pathogenesis of several 
degenerative diseases like atherosclerosis, diabetes, inflammation, 
neurodegenerative disorders, ischemic-reperfusion insults and spinal damage 
(Farooqui and Horrocks, 1998; Stark, 2005; Farooqui et al., 2007). Lipid 
peroxidation disrupts the organization of the cell membrane, which causes 
changes on its properties such as fluidity and permeability; this inhibits certain 
metabolic processes as well as ionic transport (Stark, 2005). 
Oxidative damage to mitochondrial membranes causes a positive feedback loop 
in which more ROS are generated (Green and Reed, 1998). For example, it has 
been shown that the production of lipid peroxides and its aldehydic products, 
depletes the cell of GSH and renders the cell more vulnerable to oxidative 
insults since these compounds are detoxified through the GSH-Px and glutathione 
S-transferase systems.(Arakawa et al., 2007) 
The final products of lipid peroxidation such as malondialdehyde (Lopes et al.), 
4-HNE and acrolein are able to react with diverse molecules, such as proteins, 
through covalent reactions with thiol groups or with the amine group of 
guanosine to form cyclic adducts. Out of all the α, β-unsaturated aldehydes, 
acrolein is the most electrophile and hence it shows great reactivity with 
proteins (Uchida, 1999; Kehrer and Biswal, 2000). 
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1.7.2 Protein Oxidative Modifications 
Oxidative modification of proteins by the action of ROS and RNS is implicated in 
the pathogenesis associated with natural ageing and in the development and 
progression of neurodegenerative diseases (Stadtman, 1992; Stadtman and 
Berlett, 1997). 
The radical OH•- is able to attack the amino acid residues in proteins; these 
reactions induce an extensive protein-protein cross-linking. O2•- can react with 
NO to generate peroxynitrite. This compound, although not a free radical, 
behaves similarly to OH•- inducing protein oxidation and nitration to form 3-
nitrotyrosine (3-NT). 3-NT formation is markedly favoured in the presence of CO2 
and is widely used as a marker of oxidative stress. 
Protein oxidation in various tissues, including the brain, has been proposed as 
one of the underlying mechanisms that explain the functional deficit associated 
with ageing, in particular the oxidative modification and inactivation of 
mitochondrial proteins involved in the electron transport chain. The functional 
repercussions that oxidative damage has on biomolecules depend in great 
measure on the levels of ROS involved, on the level of antioxidant defences 
present and on the rate of exchange of the molecules involved. If the exchange 
rate is continuous, then oxidative damage does not accumulate and it may not 
have critical repercussions on cell functioning. 
1.7.3 DNA Oxidative Damage 
This is not the case for nuclear DNA (NDNA), which possesses all the information 
necessary for the cell to carry out its functions, and which will not be replaced 
during the cell’s life span. Thus, DNA damage represents a serious threat to 
cellular homeostasis. If DNA damage is severe or if its accumulation exceeds the 
cell’s capacity to repair it, then mechanisms of senescence or programmed cell 
death are induced to ensure tissue and systemic homeostasis (Liu et al., 2009). 
It has been observed that sub-lethal doses of H2O2 can cause double-strand 
rupture of the DNA followed by an increase in the levels of p53 and p21 which in 
turn leads to cell cycle arrest (Chen et al., 2004; Chen et al., 2005). If the DNA 
is successfully repaired by the cellular machinery, then progression of the cell 
Chapter 1   
86 
cycle can occur; but if the damage cannot be repaired, then senescence or 
programmed cell death mechanisms will be executed (Chen et al., 2004; Chen et 
al., 2007). Contrarily, if the cell cycle proceeds, then cancer transformation is 
likely to occur.  
Since ROS are the main endogenous agents causing DNA damage, any oscillations 
in their levels or in the levels of antioxidants will have repercussions over the 
cell’s state. For instance, it has been reported that mutations on SOD1 are 
associated with the familial form of Amyotrophic lateral sclerosis (Canals et al., 
2005) and of premature senescence in fibroblasts (Rosen et al., 1993; Blander et 
al., 2003). Similarly, the oxidative damage induced by ROS has been proposed as 
one of the main events underlying the brain damage that follows a 
transient/permanent ischemic process (Chen et al., 1997; Nagayama et al., 
2000). 
The formation and accumulation of 8-hydroxyl-2’-deoxyguanosine (8-oxo-dG) in 
the DNA is one of the most common oxidative base modifications. This 
modification is caused by the OH•- radical and it affects the integrity, expression 
and function of active genes within the cells presenting it (Cui et al., 1996). 
Thus, the levels of 8-oxo-dG have been used as a parameter to determine the 
amount of oxidative lesions on the DNA. It has been argued however, that the 
exact contribution of oxidative damage by ROS is hard to determine because 
some of the guanosine oxidation may occur during the DNA preparation, previous 
to its analysis. This has resulted in significant differences (sometimes three 
orders of magnitude apart) in the results published for 8-oxo-dG (Collins et al., 
2004; Gedik et al., 2005). 
In response to DNA oxidative damage, several widely characterised repair 
mechanisms are activated in order to maintain the genomic integrity and overall 
functioning of the affected genes. One of these repair mechanisms is carried out 
by 8-oxoguanine glycosylase, also known as OGG1, an enzyme present in the 
mammalian brain that works through the base excision pathway and that 
eliminates 8-oxo-dG from DNA (Araneda et al., 2005). 
When discussing DNA damage caused by ROS, it is important to include 
mitochondrial DNA (mtDNA) as well. The mitochondrial genome is a double helix 
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of circular DNA of approximately 16kpb. The mtDNA of mammals contains 37 
genes which codify for the 13 polypeptide components of the electron transport 
chain, the RNAr and the RNAt necessary for intramitochondrial protein synthesis 
(Lin and Beal, 2006).  
MtDNA is extremely vulnerable to ROS attack for several reasons; it is located 
near the internal mitochondrial membrane which is the site of maximal ROS 
production, it has no protecting histones, and mitochondria do not have the 
enzymes necessary for base excision repair (Balaban et al., 2005). Indeed, it has 
been shown that the levels of oxidative damage found in MtDNA are ten-fold 
higher than that found in nuclear DNA for different brain regions (Wallace, 
1992). There is evidence that suggests that MtDNA damage can cause an 
uncoupling of the electron transport chain that further increases the levels of 
ROS, for instance mutation to MtDNA causes such an increase in the intracellular 
levels of ROS (Beal, 2005; Kujoth et al., 2007). 
1.8 ROS in Cancer 
In 1981, Oberley et al determined, for the first time, that a link exists between 
ROS and cancer cell proliferation (Oberley et al., 1981). These observations 
formed the basis for the “free radical theory of cancer”. Since then, numerous 
studies have corroborated that ROS promote uncontrolled cell growth, genomic 
instability and migration (Szatrowski and Nathan, 1991; Petros et al., 2005; 
Kumar et al., 2008; Ralph et al., 2010; Bauer, 2014).  
ROS are potent carcinogens because of their ability to cause DNA damage, gene 
mutations and DNA hypomethylation (previously described in section 1.7.3, page 
85). The most common oncogenic mutations affect several signaling molecules 
such as p53, Raf, retinoblastoma (Rb), protein phosphatase 2A, telomerase, Ral-
GEFs, phosphatidylinositol 3-kinase (PI3K), Ras, Rac, cellular v-myc 
myelocytomatosis viral oncogene homolog (c-Myc), STAT3, NF-κB, and HIF-1a 
(Ralph et al., 2010). In addition to this genotoxic effect, ROS can also promote 
carcinogenesis by acting as second messengers in several signaling pathways or 
by directly activating redox-sensitive transcription factors ultimately modifying 
gene expression (Yang et al., 2013). 
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The exact role that ROS play in cancer has remained hard to determine and 
continues to be a matter of debate because there is evidence indicating that 
ROS can also be detrimental to cancer cells. For instance ROS can induce: a) the 
activation of tumour suppressors such as p53 (Maillet and Pervaiz, 2012; 
Vurusaner et al., 2012; He and Simon, 2013); b) the activation of cell cycle 
inhibitors (Ramsey and Sharpless, 2006; Takahashi et al., 2006); c) DNA damage 
and proliferative arrest (Ogrunc et al., 2014); d) apoptosis (Raj et al., 2011). It 
has also been demonstrated that almost all standard of care chemotherapeutic 
and radiotherapeutic agents induce cell death partly by causing an increase in 
ROS (Gorrini et al., 2013). 
It is becoming increasingly evident that these responses are dependent upon the 
levels of ROS, the duration of exposure, their source and localization, and the 
nature of the ROS involved. Furthermore, even under the same pro-oxidant 
conditions, the cellular response will depend on the specific cellular context of 
each cancer such as the presence of intrinsic levels of antioxidant defences and 
the particular somatic mutations. Ultimately, the ability to execute a particular 
programme after any given stimulus depends on the molecular components 
within each cell and on possible alterations of the cell’s functional properties 
during transformation. 
The two extremes of this broad spectrum of responses, namely proliferation vs. 
cell death, are perhaps the two best studied. The clear pattern that has 
emerged is that, at low levels, ROS contribute to tumour formation by acting as 
signaling molecules that sustain cell proliferation by activating stress-responsive 
survival pathways (Gorrini et al., 2013). On the other hand, high levels of ROS 
cause massive oxidative damage to cellular components and, consequently 
induce the activation of several mechanisms of cell death. As an example, ROS 
are essential for Fas activation and phosphorylation in the extrinsic pathway of 
apoptosis (Medan et al., 2005) and also for the disruption of the mitochondrial 
pore in the intrinsic pathway (Martindale and Holbrook, 2002; Gloire et al., 
2006). At more moderate levels, ROS can induce irreversible senescence-induced 
tumour suppression by blocking cytokinesis acting on the p16INK4a–RB axis 
(Takahashi et al., 2006). 
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More complicating factors in further understanding the role of ROS in cancer 
originate from studies offering evidence that ROS induce differentiation and 
autophagy in normal and transformant cells. The biological significance of 
differentiation in cancer and how it relates to its physiological and 
developmental counterpart in non-transformant cells remains to be determined.  
There is evidence, that partly addresses these questions, which suggests that in 
cancer cells (that have lost the ability to exit the cell cycle normally and/or to 
die) differentiation may represent the only available response to excessive 
oxidative stress and DNA-damage (Yang et al., 2011; Santos et al., 2014). 
Similarly, autophagy may represent either a cellular strategy to temporarily 
withstand stress or an alternative mechanism of cellular death (Filomeni et al., 
2014). It has been suggested that several autophagic pathways may not be 
compromised in cancer because, to a certain extent, their activation guarantees 
cell survival during episodes of metabolic stress. However, when autophagic 
pathways are overstimulated, they can have a detrimental effect on cell survival 
and the rate of tumoural growth. The contrasting cellular responses elicited by 
ROS also indicate that there is an overlap in the pathways that promote cancer 
survival/proliferation and those that cause cancer cells to arrest/differentiate 
and to die (Gupta et al., 2012). 
Stem cell research may offer some information regarding the effect of ROS on 
cellular differentiation. As previously mentioned, (page 23) cancer stem cells 
(CSCs) share several characteristics with normal stem cells such as self-renewal 
and differentiation capacity. Interestingly, it has been suggested that another 
shared attribute between CSCs and normal stem cells is their response to ROS 
(Dayem et al., 2010; Shi et al., 2012). 
Since hematopoietic stem cells (HSCs) are the first and best characterised type 
of adult stem cells, they will be used as an example to illustrate the similarities 
between stem cells and cancer stem cells with regard to ROS. HSCs and 
mammary epithelial stem cells have lower levels of ROS than their differentiated 
progeny (Naka et al., 2008; Zhang et al., 2008). It has been shown that these 
lower levels prevent their differentiation and early exhaustion which is partly 
due to their remaining under hypoxic conditions in a quiescent state (Wilson et 
al., 2009). Furthermore, Human Embryonic Stem Cells (HESCs) continue to 
proliferate and remain undifferentiated when cultured under hypoxic conditions; 
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however, upon transfer to a normoxic atmosphere, spontaneous differentiation 
is induced (Ezashi et al., 2005). This behaviour is believed to be dependent on 
the effect of ROS since O2 alters the rate of oxidative phosphorylation and in 
turn on ROS production (Sauer and Wartenberg, 2005; Zhang et al., 2012a). 
Analogously, CSCs in human and mouse breast tumours maintain lower levels of 
ROS than their cancerous epithelial-like progeny (Toyokuni, 2006; Diehn et al., 
2009; Kim et al., 2012). It has been suggested that whereas high levels of ROS 
are essential for malignant initiation and progression, maintaining low levels of 
ROS is necessary to prevent differentiation and to guarantee the survival of the 
pre-neoplastic foci (Ghaffari, 2008; Gorrini et al., 2013). In line with this, it has 
been shown that ROS induce the differentiation of pheochromocytoma PC12 cells 
(Katoh et al., 1997) through activation of MAPK/ERK (Katoh et al., 1999; 
Goldsmit et al., 2001) and through the direct activation of PKCε (Gopalakrishna 
et al., 2008). Furthermore, the production of ROS seems to be a common 
occurrence in several models of cancer differentiation with a CSC component 
including, but not limited to, human monoblastic leukaemia cells (Kikuchi et al., 
2010) and SH-SY5Y cells (Nitti et al., 2010; Li et al., 2013). 
The main pathways controlling proliferation and/or differentiation in cancer and 
normal stem cells involve the activation of redox-sensitive factors such as 
nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB), nuclear 
factor (erythroid-derived 2)-like factor 2 (NRF2), c-Jun, and hypoxia-inducible 
factor-1α (HIF-1α), Bach1, activator protein-1 (AP-1), signal transducer and 
activator of transcription 3 (STAT3), and others (Martindale and Holbrook, 2002; 
Ranjan et al., 2006; Tiligada, 2006; Zhou et al., 2013). 
1.8.1 NF-κB 
NF-κB was the first transcription factor shown to be redox-regulated. NF-κB is a 
multiprotein complex that regulates many genes involved in inflammation, cell 
survival and differentiation. It is comprised of homo or heterodimers of five 
groups of proteins: NF-κB1 (p50 and its precursor p105), NF-κB2 (p52 and its 
precursor p100), p65/RelA, c-Rel and RelB. Inactive NF-κB is sequestered in the 
cytoplasm when bound to an inhibitory kappa-B protein (IκB; IκBα, IκBβ, IκBγ, 
IκBɛ, Bcl-3, p100 and p105). Upon stimulation (i.e. interleukin-1β, TNF-α, 
Chapter 1   
91 
viruses, TPA, UV light, ionizing radiation, ROS) IκB is phosphorylated and target 
for proteasomal degradation which in turn allows the nuclear translocation of 
NF-κB. Once in the nucleus, NF-κB acts as transcription factor for several target 
genes such as cytokines, chemokines, adhesion molecules and inhibitors of 
apoptosis (Gloire et al., 2006). Additionally, ROS trigger signaling cascades  
leading to the activation and phosphorylation of mitogen activate protein 
kinases (MAPKs; such as ERK). which in turn activates NF-κB and the induction of 
early response genes such as c-jun and c-fos, which are involved in 
differentiation (Bours et al., 2000). See Figure 4.  
Interestingly, it has been shown that NF-κB is activated in certain regions of the 
brain during neurogenesis. Similarly, the expression and activity of NF-κB 
increases during differentiation of human embryonic stem cells (Kang et al., 
2007). Furthermore, in SH-SY5Y cells, NF-κB activation is an early event 
(preceding the appearance of neuronal characteristics) required for 
differentiation to occur after RA and TPA treatment (Feng and Porter, 1999). It 
has been demonstrated that these two compounds increase the levels of ROS 
(Yen and Albright, 1984; Konopka et al., 2008; Kikuchi et al., 2010; Nitti et al., 
2010). Ra-induced differentiation is enhanced in SH-SY5Y cells by IL-1 as it 
causes an increase in the binding activity of NF-κB (Kania et al., 2003). H2O2 has 
also been shown to significantly increase the activity of NF-κB, which coincides 
with the enhanced expression of the dopamine D2 receptor in differentiated SH-
SY5Y cells (Larouche, Berube et al. 2008). 
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Figure 4 Transcription factors activated by ROS. ROS activation of four classical redox-
sensitive transcription factors involved in differentiation, described in text. Abbreviations 
used (in alphabetical order): ARE, antioxidant response element; AP-1, activator protein-1; 
ASK1, apoptosis signal-regulating kinase-1; ERK, extracellular signal-regulated kinase; HIF-
1, hypoxia-inducible factor 1; HRE, hypoxia responsive element; IKK, IκB kinase; JNK, c-Jun 
N-terminal kinase; Keap1, Kelch-like ECH associated protein 1; MAPK, mitogen-activated 
protein kinase; NIK, NK-κB-inducing kinase; NRF2, nuclear factor erythroid 2-related factor 
2; PHD, prolyl hydroxylase; PKC, protein kinase C; TRX, thioredoxin. 
1.8.2 NRF-2 
NRF2 is a redox-sensitive transcription factor involved in the cellular response to 
environmental toxicants and carcinogens (Zhao et al., 2009). Under normal 
conditions, NRF2 is constitutively targeted for proteasomal degradation by Keap1 
(Kelch-like ECH associated protein). However, upon exposure to ROS, NRF2 
disassociates from Keap1, leading to an increase in its protein stability and its 
nuclear translocation where it forms a heterodimer with one of the small Maf 
proteins. The NRF2/Maf heterodimer activates the antioxidant response element 
(ARE) in the promoter of its target genes (such as HO-1, Trx) Additionally, it has 
been shown that PKC phosphorylates NRF2 in its Neh2 domain at Ser-40 which 
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also causes its disassociation from Keap1 (Hayes et al., 2010; Bryan et al., 
2013). Also presented in Figure 4. 
The role of NRF2 as a promoter of cell survival has been extensively examined on 
normal (Reddy et al., 2007) and transformant cells (DeNicola et al., 2011). 
However, recent evidence shows that ROS activation of NRF2 can also promote 
differentiation in B-cells, mouse primary peritoneal macrophages, RAW 264.7 
cells, and mouse neural stem cells (Bertolotti et al., 2010; Kanzaki et al., 2013; 
Santos et al., 2013). In SH-SY5Y cells, an early response following RA treatment 
is the increase in the expression of NRF2 prior to a clear appearance of 
differentiation signs. Furthermore, overexpression of NRF2 alone induces 
differentiation in SH-SY5Y and in primary neuronal cultures (Zhao et al., 2009). 
Similarly, it has been reported that NRF2 is a positive regulator of differentiation 
in U937 human monoblastic leukaemia cells (Bobilev et al., 2011). 
1.8.3 HIF-1 
Hypoxia inducible factor (HIF) is another redox-sensitive transcription factor 
activated during episodes of hypoxia. The extent to which hypoxia increases the 
levels of ROS still remains a matter of debate. However, there is evidence 
indicating that hypoxia (but not anoxia) causes an increase in the production of 
ROS at the mitochondrial complex III (Vieira et al., 2011). Additionally, HIF-1 can 
be activated by hypoxia-independent but ROS-dependent mechanisms (Zhao et 
al., 2014). 
HIF is a heterodimeric protein complex formed by the assembly of α/β subunits. 
The most common HIF isoforms are HIF-1 and HIF-2. Under normal conditions the 
α subunits are targeted for proteasomal degradation by HIF prolyl-hydroxylases 
(PHD) and von Hippel-Lindau protein. ROS promote the stabilisation of the α 
subunits by modulating the activity of PHD (Niecknig et al., 2012) which in turn 
enables the nuclear translocation of HIF and its binding to hypoxia response-
elements in the DNA, thus altering gene transcription. Additionally, ROS activate 
PI3K/Akt and MEK/ERK signaling which increases the expression of the α subunit 
and, as a consequence, increases the transcriptional activity of HIF (Agani and 
Jiang, 2013). It has been reported that ROS regulate normal and malignant 
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hematopoietic differentiation through the activation of HIF-1 (Desplat et al., 
2002; Jiang et al., 2005; Liu et al., 2006; Song et al., 2008; Yin et al., 2011). 
1.8.4 AP-1 
The AP-1 transcription factor is a dimeric complex formed by members of the 
basic region-leucine zipper (bZIP) protein group such as Jun (c-Jun, JunB, JunD), 
Fos (c-Fos, FosB, Fra-1, Fra-2), CREB/ATF (CREB, ATF2, ATF3/LRF1, CREB, Maf 
and others). The target genes and regulation of this transcription factor is very 
complex because there are clearly several possible combinations of subunits that 
will form AP-1 homo- heterodimers (Remacle et al., 1995; Cimino et al., 1997; 
Echlin et al., 2000). 
AP-1 (c-jun/c-fos) is induced in response to ROS such as O2•- and H2O2 (Maki et 
al., 1992; Aggeli et al., 2006) by MAPKs (ERK, JNK, p38 kinase) via two main 
mechanisms: a) thioredoxin (TRX) oxidation and b) inhibition of MAPK 
phosphatases. In the first mechanism, reduced thioredoxin (TRX) inhibits 
apoptosis signal-regulating kinase-1 (ASK-1). However, upon accumulation of 
ROS, TRX becomes oxidised and ASK-1 is activated, leading to the downstream 
activation of MAPKs (JNK and p38) and AP-1 (Cheng et al., 2014). The second 
mechanism involves the oxidation and inhibition of MAPK phosphatases by ROS, 
leading to the increased activity of ERK1/2 and in turn of AP-1 (Yang et al., 
2013), presented in figure 4. There are several important studies showing that 
the activation of AP-1 by ROS induces differentiation in several lines such as P19 
CL6 embryonal carcinoma cells (Murray et al., 2013), immortalised SV-HUC-1 
cells (Liu et al., 2013) and F9 teratocarcinoma stem cells (Yamaguchi-Iwai et al., 
1990; Jin et al., 2002). Additionally, AP-1 inhibition severely enhances the 
aggressiveness of hepatomas (Bitton-Worms et al., 2010). 
From Figure 4 it can be inferred that there is considerable crosstalk between 
these signaling pathways and indeed, this has been experimentally proven and 
also extensively reviewed (Trachootham et al., 2008). A notable example of 
crosstalk between these pathways, in regard to differentiation, comes from a 
study in which the effect of NRF2 on the differentiation of AML cells was shown 
to be tightly regulated by AP-1 activity. (Bobilev et al., 2011).  
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Taken together, these studies provide evidence that ROS play an important role 
in the differentiation of normal stem cells, cancer stem cells, as well as in 
several cell lines that maintain the ability to differentiate, including the SH-SY5Y 
neuroblastoma cell line used in this project. 
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1.9 Rationale of Study 
1.9.1 Reasons for Study 
The literature suggests that a link exists between dysregulation of Glu signaling, 
enhanced Trp metabolism and ROS production in the context of cancer 
development and progression. Consequently, the current study set out to 
investigate how these processes may interact and affect the biology of the 
neuroblastoma-derived SH-SY5Y cell line. 
1.9.2 Reasons for the use of SH-SY5Y cells 
There are many advantages to using SH-SY5Y cells in research, both practical 
and empirical. Besides the obvious advantages that any cell model provides: 
such as low cost, the ability to proliferate for a long time and genetic 
homogeneity, the SH-SY5Y line has the ability to convert Glu to the 
neurotransmitter GABA, and L-tyrosine to L-3,4-dihydroxyphenylalanine (L-
DOPA). This last characteristic makes this cell line an ideal neuronal model to 
study PD dopaminergic transmission, among others (Youdim et al., 2003; Xie et 
al., 2010).  
Furthermore, the fact that the SH-SY5Y cells transition from a malignant 
phenotype into a neuronal phenotype when treated with any of various 
compounds (such as RA), makes this cell line an excellent model system to study 
tumour regression and the effect that various drugs have on this process. 
1.9.3 General Aims  
The initial aim of this PhD project was to determine a method and a cell line 
validation in order to ascertain whether both the SH-SY5Y cell line and the 
methods available could be used to study the effect of kynurenines on the 
survival and differentiation of said cell line.  
Then, based on preliminary results, this study set out to determine the effect of 
some kynurenines (QA, KA, 3-HAA) on the survival and differentiation of the 
neuroblastoma SH-SY5Y cell line. This study also set out to examine the extent 
to which the effect of QA and KA was mediated by their opposite actions on the 
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NMDAR. The involvement of ROS was studied as well. Specifically an attempt was 
made to establish a link between ROS production and the differentiation of SH-
SY5Y cells. 
Finally, this research sought to examine the emerging role of NAD+ metabolism in 
cancer and whether there was evidence suggesting that a relationship existed 
between QA and NAD+ metabolism in the survival and differentiation of SH-SY5Y 
cells. 
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Chapter 2 – MATERIALS AND METHODS 
  
2.1 SH-SY5Y culture procedures 
General laboratory consumables and chemicals were purchased from different 
sources depending on the availability in the stores of the College of Medical, 
Veterinary and Life Sciences (MVLS). 
The following list contains the consumables that were used to maintain the SH-
SY5Y cells: 
2.1.1 Materials 
BD Falcon™; 6-well Multiwell; Plate. Tissue-culture treated polystyrene, flat-
bottom, with low-evaporation lid (353046) 
BD Falcon ™; 12-well Multiwell™; Plate. Tissue-culture treated polystyrene, flat 
bottom, with low-evaporation lid (353043). 
BD Falcon ™; 24-well Multiwell™; Plate. Tissue-culture treated polystyrene, flat 
bottom, with low-evaporation lid (353047). 
BD Falcon™ 96-well Microtest™ Plate. Tissue-culture treated polystyrene, U-
bottom, with low-evaporation lid (353227).  
Millipore filters (Minisart, 0.2μm pore size). 
Corning® 75cm² Rectangular Canted Neck Cell Culture Flasks with Plug Seal Cap 
(Product #430720). 
Corning® CellBIND® 75cm² Rectangular Canted Neck Cell Culture Flask with Vent 
Cap (Product #3290). 
Corning® 150cm² Rectangular Canted Neck Cell Culture Flasks with Plug Seal Cap 
(Product #430823). 
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Corning® 150cm² Rectangular Canted Neck Cell Culture Flasks with Vent Cap 
(Product #430825). 
Corning® 15mL PP Centrifuge Tubes, Rack Packed with Plug Seal Cap (430052). 
Corning® 50mL PP Centrifuge Tubes, Conical Bottom with Plug Seal Cap, Rack 
Packed, Sterile, 25/Rack, 500/Case (430290). 
Laminar flow hood. 
Different sizes of automatic pipettes. 
CO2 incubator. 
Water bath. 
The following list containing all the chemicals used to grow and plate the SH-
SY5Y cells. 
2.1.2 Chemicals 
All the solutions necessary to culture the SH-SY5Y cells were purchased from the 
sources suggested by the European Collection of Cell Cultures. 
From Sigma-Aldrich Company Ltd., Poole, Dorset, UK: 
Foetal bovine serum –heat inactivated (F9665). 
DEPC-Treated water (95284). 
L-Glutamine 200 mM solution (G7513). 
Minimum Essential Medium Eagle (M2279). 
Nutrient Mixture F-12 Ham (N4888). 
MEM Non-essential Amino Acid Solution (M7145). 
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Penicillin 10,000 U and Streptomycin 10mg/ml (P4333). 
Poly-D-lysine (P7280). 
Trypan Blue dye (T8154). 
Trypsin-EDTA solution from porcine pancreas 0.25% (T4049). 
Water sterile-filtered (W3500) 
All chemicals were stored at the appropriate conditions (temperature, humidity 
and light exposure) recommended by the suppliers and/or according to the 
available literature regarding the stability of each compound. 
2.1.3  Medium preparation 
The medium used to resuscitate, grow and differentiate the SH-SY5Y cells was a 
mixture of Eagle’s minimum essential medium and Ham’s F-12 medium 1:1 
(vol/vol), supplemented with 2 mM glutamine, penicillin-streptomycin (1%), non-
essential amino acids (1%) and foetal bovine serum (FBS) at different 
concentrations. 
To maximise the number of cells obtained after resuscitation, the medium used 
contained 15% FBS (resuscitation medium). Once the cell line was established 
and after having been allowed to expand for three days, the concentration of 
FBS was decreased to 10%. This is the FBS concentration in the medium that was 
used to feed growing cultures, as well as to routinely passage them (growing 
medium). Finally, a third concentration of FBS was used when evaluating the 
effect that certain compounds have on differentiation; for these treatments, the 
concentration was decreased to 1% (differentiation medium) to avoid 
interference from mitogenic factors present in the serum. 
To avoid l-glutamine degradation and changes in the initial pH due to nutrient 
breakdown, the medium was used within 5 days from its preparation. All the 
experiments carried out were designed to assess the effect of treatments at 
various time points occurring within 7 days. Therefore it was necessary to 
prepare two batches of medium per experiment. All the reagents used to 
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prepare the medium were of culture quality and the medium was prepared 
under sterile conditions and kept at 4°C. 
2.1.4 Overview 
SH-SY5Y human neuroblastoma cells were purchased from the European 
Collection of Cell Cultures (ECACC, Salisbury, UK) and kept in growing medium. 
Cells were maintained in T75 flasks at an atmosphere of 95% air and 5% CO2 at 37 
°C. 
Cells were subcultured every 72 h, this is approximately the number of days 
necessary for the cultures to reach a confluence of 70-80% which corresponds to 
their log phase of growth and consequently to an optimum viability. 
2.1.5 Cell line Resuscitation. 
SH-SY5Y cells from passage 18 were acquired from ECACC. Upon arrival, vials 
were kept in liquid nitrogen at -240°C and thawed whenever they were needed 
according to the following protocol. 
First, the cryovial was removed from the liquid nitrogen and immediately placed 
in a cooler containing dry ice. The cryovial was then placed in a water bath at 
37°C for two minutes until about 80% of the volume had thawed. The content of 
the cryovial was pipetted out into a T15 flask containing medium with 15% FBS 
and placed in an incubator at 37°C with an atmosphere of 95% air and 5% CO2. 24 
hours after plating, once the majority of the viable cells had attached to the 
flask, the medium was changed in order to remove dead and non-adherent cells 
and to replenish nutrients. Cells were allowed to grow for 2 more days before 
following the cell harvesting protocol, see 2.1.6 
2.1.6 Cell harvesting 
Once the cultures reached the desired confluence, the growing medium was 
removed and the cells were washed with 15mL of PBS at 37°C. Cells were 
dissociated by adding 2mL of a solution containing 0.5% trypsin/EDTA. The 
excess of trypsin solution was removed and the cells were incubated at 37°C for 
1 minute. Once detached, cells were transferred to a 50mL centrifuge tube and 
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the trypsin was neutralised with 10mL of medium containing 10% FBS. A sample 
of 100µL was taken from this cell suspension and mixed with Trypan blue dye 1:1 
(vol/vol). A cell count of viable cells was performed under the microscope using 
a Neubauer haemocytometer.  
Finally, one part of the cell suspension was transferred to T75 flasks at a final 
concentration of 1 x 105 cells/ml (to keep the cultures growing) and another to 
multiwell plates at various concentrations depending on the experimental 
setting, (see chapter 2.1.7). To avoid the loss of neuronal characteristics that 
has been reported to occur in the SH-SY5Y cell line after numerous passages, 
cultures were only split up to twelve times (passages eighteen to thirty). 
2.1.7 Culture plating 
The cells harvested were seeded in different plates depending on the 
experiments performed. 
For all viability assays, cells were plated in 96-well plates at a density of 1 × 105 
cells/ml. For all of the microscopic photography experiments, cells were plated 
in 24-well plates at a density of 1 × 105 cells/ml; this proved to be the ideal 
setting to take good quality micrographs. Micrographs were taken for neurite 
count experiments as well as for the DHE assay. For the latter, poly-D-lysine 
coated cover slips were used during plating. For the neurite outgrowth, assay 
cells were plated in 12-well plates and Millipore inserts at a density of 1 × 106 
cells/ml. To meet the protein requirement for western blotting, cells were 
plated at a density of 2 × 106 cells/ml. All cultures were treated with the 
compounds of interest 48-72 hours after having been plated as this was the time 
when cultures reached a confluence of 70-80%. The only exception was the 
neurite outgrowth assay for which the manufacturer’s guidelines were followed 
(see section 2.3.2.) 
2.1.8 Poly-D-Lysine coating 
Poly-D-Lysine is a polymer that provides cells with a substrate to adhere to 
otherwise smooth surfaces such as glass. Some cell types cannot form a 
monolayer when they are plated unless the surfaces are coated with poly-lysine. 
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SH-SY5Y cells adhere easily to plastic plates but not when glass coverslips are 
used. 
Poly-D-lysine was diluted in sterile water to a final concentration of 15 µg/ml. 
The coverslips were submerged in this solution for two hours at 37°C and then 
rinsed thoroughly since it has been shown that an excess of monomeric poly-D-
lysine can be toxic to certain cell types. 
72 hours after seeding, foetal calf serum (FBS) levels in the medium were 
reduced to 1% and retinoic acid (10 µM) was added to induce a neuronal 
phenotype (Pahlman et al., 1984; Nicolini et al., 1998). RA treated cells are the 
positive control for differentiated SH-SY5Y cells. Unless otherwise stated, all 
treatments were performed on the undifferentiated state. A final concentration 
of 50 nM of QA was used to treat SH-SY5Y cells. In some experiments, cells were 
co-incubated with SOD (300 U/ml) to investigate the role of ROS during 
differentiation,  
2.2 Probes for Cell viability/proliferation 
2.2.1 Fluorescein diacetate (FDA) 
FDA (Sigma F7378), is an esterified compound that can be taken up by living 
cells. In the presence of functional intracellular esterases, the acetate groups 
are removed producing fluorescein which can be quantified 
spectrophotometrically. (Valencia and Moran, 2001). 
A final FDA concentration of 5μg/ml, and 1% ethanol was added to 96 well 
plates. Plates were then incubated for 10 minutes at 37°C and read in a plate 
reader (Fluoroskan Ascent microplate fluorometer, Thermo Scientific) with the 
excitation set at a wavelength of 485nm and the emission at a wavelength of 
538nm. Unless otherwise stated, all viability assays were carried out using this 
method. 
2.2.2 AlamarBlue® 
Alamar blue is an oxidation-reduction indicator that changes colour from blue to 
red, and fluoresces, when reduced by cellular metabolic activity. It has been 
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used to study the proliferation of tumour cell lines and the effects of 
chemotherapeutic drugs, and has been found to provide a rapid, sensitive and 
non-toxic fluorescence assay of cell viability(White et al., 1996). It detects cell 
viability by the transformation of non-fluorescent resazurin into a fluorescent 
dye (resorufin) in response to chemical reduction of culture medium resulting 
from cell growth. Continued cell growth maintains a reduced environment while 
inhibition of growth maintains an oxidised environment. Reduction related to 
growth causes the redox indicator to change from oxidised (non-fluorescent, 
blue) form to reduced (fluorescent, red) form. 
 
Figure 5- The reduction of non-fluorescent resazurin. The transformation yields a highly 
fluorescent red compound, resorufin. 
The alamarBlue® (AB) assay (BioSource International, Nivelles, Belgium) was 
used to determine cell viability. Briefly, after each treatment period, the 
medium was replaced with 100 μl of medium containing 10% v/v of AB. The 
plates were then put back in the incubator for another 6 hours after which the 
absorbance was determined by reading the plates at both 540 nm and at 595 nm 
wavelengths using a spectrophotometric plate reader (DYNEX Technologies, UK). 
The absorbance value of a blank well containing only medium was subtracted 
from all the experimental values. Since there was an overlap in the absorption 
spectra of the oxidised and reduced forms of AB, it was necessary to read at two 
different wavelengths. The two different values from the reading and the molar 
extinction coefficient were used in the following equations to establish the 
concentration of both the oxidised and reduced form of AB. 
1. % of reduced AB = [(εOX)λ2 Aλ1 - (εOX) λ1 Aλ2] ÷ [(εRED)λ1 A’λ2 - (εRED)λ2 A’λ1] × 
100 
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2. % difference in reduction between treated and control cells = [(εOX)λ2 Aλ1 - 
(εOX) λ1 Aλ2] of test agent dilution ÷ [(εRED)λ1 A•λ2 - (εRED)λ2 A•λ1] of 
untreated positive growth control × 100 
Where: 
CRED = concentration of reduced alamarBlue® (RED) 
COX = concentration of oxidised alamarBlue® (BLUE) 
ε
OX = molar extinction coefficient of oxidised alamarBlue (BLUE) 
ε
RED = molar extinction coefficient of reduced alamarBlue (RED) 
A = absorbance of test wells 
A’ = absorbance of negative control well (media + alamarBlue without cells). 
A• = absorbance of positive growth control well 
λ1 =540 nM 
λ2 =595nm 
All the data was normalised to control values (Fatokun et al., 2006).  
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2.3 Neurite Extension. 
2.3.1 Morphology of SH-SY5Y cells 
To study the morphology of living SH-SY5Y cells, the cells were visualised 72 h 
after treatment using an Olympus DP50 inverted phase-contrast microscope 
which was fitted with a digital camera system. The cells were photographed 
using the DPSoft software (Olympus UK Ltd., Southall, UK). For all the 
morphology experiments, cells were plated in 6 well plates at a density of 
1.5x106 per well. This particular setting allows a better visualization of the cell 
bodies and neurites with minimum interference from the plate itself. 
Micrographs were taken immediately after treatments. For all the experiments 
in which a count of the number of cell bodies and neurites was performed, 3 
images from at least 3 separate experiments were analysed. A neurite was 
defined as an outgrowth longer than twice the cell body diameter. The results 
are presented as the ratio of neurites/cell bodies. 
2.3.2 Neurite Outgrowth assay 
To further assess the degree of neurite formation, the Millipore’s NS230 Neurite 
Outgrowth Assay Plus Kit (3 µm) was used. This assay is based on the use of a 
microporous tissue culture insert which contains a permeable membrane with a 
pore size of 3 μm. This assay is ideal for cells projecting neurites and with a cell 
body diameter larger than 3 μm, like the SH-SY5Y cell line as the cell bodies 
remain in the upper side of the insert while the neurites continue to extend 
through the insert membrane. After differentiation occurred, the cell bodies 
were scraped off keeping only the fraction containing neurites. This guaranteed 
that all the measurements came from the neuritic fraction. The kit was used 
according the manufacturer’s guidelines, briefly; 
Cultures are passaged normally and maintained in a growing medium until they 
reach a confluence of approximately 70%. Once the cultures are confluent, 
differentiation is induced for 24 hours by changing the medium of the cultures to 
one containing the differentiation factor of interest (RA 10 µM, 50 ng/ml NGF, 
QA). Cells are then briefly washed with PBS buffer and dissociated using the Cell 
Dissociation Buffer provided (Part No. CS202683). Once the cells have detached 
from the flask they are centrifuged at 200 x g. The pellet is collected and 
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resuspended at a concentration 1x106 cell/ml. The cells obtained are then 
plated in the Millicell inserts provided. For each condition two inserts are used, 
one coated with laminin (1mg/ml), which promotes neuritic adhesion to the 
plate, and another one coated with BSA 100mg/ml (as a negative control). 
After 72 h in the differentiation media, an indirect immunocytochemistry 
protocol is performed against β3-tubulin, using TMB, (3,3',5,5'-
tetramethybenzidine) as the horseradish peroxidase substrate and sodium 
fluoride as the stop solution. All materials, aside from the methanol used for 
fixing the cells, are provided by the manufacturer as part of the kit. There is 
only one modification in the immunocytochemistry protocol which involves the 
removal of the cell bodies following the antibody incubation. Briefly, to visualise 
the cell bodies, an inactive stain solution is added to the top part of the insert, 
the cell bodies are then scraped off using cotton swabs. 
The OD readings for both the laminin and the BSA coated inserts are read at 450 
nm wavelengths with a spectrophotometric plate reader (DYNEX Technologies, 
UK). The OD readings obtained were then used to calculate signal (laminin) to 
noise (BSA) ratios for each treatment. 
2.4  DHE ROS quantification 
Cytosolic DHE exhibits blue fluorescence. However, upon oxidation, this 
compound is converted to ethidium, mainly by O2•-, and it intercalates within 
the cell's DNA. DNA-bound ethidium exhibits bright red fluorescence. After 
treatment, cells were incubated with DHE at a final concentration of 3.2µM for 
20 min, washed twice with PBS and then fixed in 4% fresh paraformaldehyde. 
Cells were then mounted with PBS:Glycerol 1:1 (v/v) and examined with an 
epifluorescence microscope using a Rhodamine filter. Results are expressed as a 
relationship between ethidium positive cells and the total number of cells per 
field. Alternatively, after DHE, incubation cells were washed twice with PBS 
buffer and read in a fluorescence plate reader with the filters set at 535nm 
absorption and 610 nm emission. 
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2.5 Immunocytochemistry 
2.5.1 Materials 
0.1 M phosphate buffer solution 
0.2 M PBS 
0.3% triton solution (in 0.1M PBS) 
1.5% blocking serum solution in PBS and 0.3% triton 
4% or 8% paraformaldehyde solution (in 0.1M phosphate buffer) 
Olympus DP50 Digital camera 
Olympus IX50 Phase-contrast microscope 
Olympus TH3 Light source 
Olympus U-RFL-T Fluorescent light source 
2.5.2  Antibodies 
Anti-NeuN Antibody (mouse), clone A60, Alexa Fluor®488 conjugated (MAB377X) 
FITC-conjugated donkey anti-rabbit antibody (Jackson 711-095-152) 
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2.5.3  Immunocytochemistry protocol 
After treatments, cells were removed from the incubator and washed once with 
PBS at 37°C. PBS was aspirated and cells were fixed for 15 minutes with 100µL of 
a 4% paraformaldehyde (PFA) solution (at 4°C) and gently pipetted into the 
cultures to avoid cell detachment. In order to completely remove PFA, cells 
were washed 3 times for 5 minutes with 0.1M PBS. To prevent non-specific 
binding, the plates were blocked with 1.5% donkey serum in 0.3% Triton for 1 
hour (50 µL). All incubations were performed at room temperature for one hour 
on a gyratory rocking platform to ensure that all the solutions were covering the 
cultures and that the motion was gentle enough to prevent detachment of the 
fixed cells. 
The blocking serum was then removed and 50μl per well of primary antibody was 
added (1:100 dilution in PBS and 0.3% triton). This was followed by an overnight 
incubation at 4°C. A set of wells were incubated as negative controls with just 
50μl of PBS and triton solution, the negative controls were used to calibrate the 
exposure time when photographing the cultures.  
After the primary antibody incubation, the plates were washed 3 times for 5 
minutes with 50μl of 0.1M PBS. From this moment on, the plates were handled 
with care to reduce exposure to direct light. The samples were viewed and 
photographed under the microscope with fluorescent light at a wavelength of 
495 nm/521 nm. 
2.6 Microscopy photography 
For all the experiments requiring micrographs to be taken, the software used to 
capture and process the images was Cell D, (Soft Imaging System GmbH). This 
program has the basic tools to capture, measure and edit. The contrast and 
brightness of some phase-contrast micrographs was modified with Photoshop. 
However, special care was taken to maintain intact all the images from 
fluorescent assays since adjusting them would have interfered with 
quantification. For fluorescent microscopy photography, the exposure time was 
set using the negative control. A first picture was taken in which all the 
background is bright and the exposure time was lowered until there was no 
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background in the image. Once set, the exposure was not changed across 
different fields or wells. Image J (http://imagej.nih.gov/ij/) was used to 
perform cell counts. This software is considered very useful to perform cell 
counts as it saves a layer that can be reviewed later, along with all the marks for 
all the counted individual cells, without modifying the original picture. 
2.7 Protein sample preparation and quantification 
2.7.1 Materials 
BIORAD® protein assay dye (BIORAD®, 500-0006) 
BSA (Sigma, A2153) 
Costar disposable cell scraper (Corning, 3010) 
Eppendorf 5417R centrifuge 
IGEPAL (Sigma, I7771) 
PBS (Gibco, 1010) 
Protease Inhibitor cocktail tablets (Roche, 11 836 170 001) 
Sodium chloride powder (BDH, 102415K) 
Sodium dodecyl sulphate powder (BDH, 442444H) 
Tris powder (Boehringer Mannheim, 708976) 
Triton X-100 (Sigma, T8787) 
2.7.2 Protein preparation 
For the preparation of protein lysates, SH-SY5Y cells were plated in six-well 
plates at a density of 2x106 cells/well. 
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After treatments, culture plates were removed from the incubator and placed on 
ice. The culture medium was aspirated by pipette and the cultures were washed 
once with ice-cold PBS. PBS was also removed and 200µL of radio-immune 
precipitation assay (RIPA) buffer was added to the plates to lyse the cells. RIPA 
buffer was prepared by making a solution containing 50 mM Tris, 150 mM NaCl, 
0.5% Triton, 0.1% SDS, 1% IGEPAL in distilled water. The pH was adjusted to 7.4. 
After 1 minute in RIPA buffer, the cells were scraped off and the buffer/cell 
suspension for each condition was transferred into different Eppendorf tubes. 
This cell suspension was centrifuged at 16,000 X g for 5 minutes at 4°C in an 
Eppendorf 5417R centrifuge. The supernatant was collected and the pellet 
containing the membranes was discarded. 
2.7.3 Protein quantification  
The protein concentrations were determined using the Coomassie Blue Protein 
Assay (BioRad®) 
A protein concentration curve was produced using BSA as a standard. A BSA stock 
solution was prepared by diluting 1 in 10 BSA in distilled water (20mg/100mL). 
From this stock solution further dilutions were prepared in duplicate to have a 
range of protein concentrations (0, 0.25, 0.5, 1.0, 1.5, 2.0mg/ml). 
In order to determine the protein concentration of the experimental samples 
and express it in terms comparable to the concentration curve generated 
(mg/ml), dilutions of the samples had to be prepared, all in duplicate. This was 
done by taking a volume of 4µL of sample and adding 396µL of distilled water 
(1/100). 200µL of BioRad reagent diluted in water (1:1) was added to the 
samples, then vortexed and both the standard curve and the samples were 
transferred into a 96-well plate. The plate was read at 595nm on a plate reader 
(Dynex). A linear regression was performed using the O.D. from the standard 
solutions. The linear equation obtained was then used to calculate the total 
protein concentration in each sample. A total of 20 µg of protein was loaded into 
each lane. 
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Using the lowest concentration found in the samples as a standard, all the other 
samples could then be diluted to contain the same amount of protein per ml. 
2.8 Western Blotting 
2.8.1  Materials 
‘Hypercassette’ film cassette (Amersham RPN12642) 
‘PowerEase® 500’ pre-cast gel system includes powerease® power supply, 
temperature monitoring probe, xcell surelock® mini-cell and Xcell IITM blot 
module (Invitrogen EI8675UK) 
Sponge pad for blotting (Invitrogen EI9052) 
Blotting Roller, 8.6 cm wide (Invitrogen LC2100) 
‘Restore’ stripping buffer (Pierce, 21059) 
Gel Spatula (Invitrogen) 
Photosensitive films (Amersham, RPN3103K) 
Protein transfer chamber (Invitrogen, E19051) 
2.8.2 Chemicals 
PVDF membrane (Invitrogen, LC2005) 
NuPAGE® Novex 12% Bis-Tris gel 1.0 mm, 15 well (Invitrogen, NP0343BOX) 
Antioxidant (Invitrogen, NP0005) 
Methanol (Fisher, M/4056/17) 
Milk powder (Upstate, 20-200) 
MOPS running buffer (Invitrogen, NP0001) 
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Ponceau stain (Sigma, P7170) 
Sample buffer (Invitrogen, NP0007) 
Sample reducing agent (Invitrogen, NP0004) 
SeeBlue protein marker (Invitrogen, LC5925) 
Transfer buffer (Invitrogen, NP0006) 
Tween-20 (Sigma, 27,434-8) 
2.8.3 Antibodies 
All antibodies were obtained from their UK distributors (Millipore, Watford; R&D 
Systems, Abingdon; Santa Cruz, Insight Biotechnology, Wembley). 
Actin, goat polyclonal (Santa Cruz, sc-1615). 
Anti-β3-tubulin, mouse monoclonal clone 2G10 (Millipore, 05-559). 
Donkey anti-goat HRP (Santa Cruz, sc-2020) 
Doublecortin, goat polyclonal (Santa Cruz, sc-8066). 
Goat anti-mouse HRP (Santa Cruz, sc-2005). 
Goat anti-rabbit HRP (Millipore, 12–348). 
GluN1, mouse monoclonal (Millipore, 05–432) 
NRF2, goat polyclonal (Santa Cruz, sc-30915) 
Synaptophysin, mouse monoclonal (Millipore, MAB368). 
VAMP-1/synaptobrevin, goat polyclonal (R&D Systems, AF4828). 
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2.8.4 Gel running procedure 
Loading samples were prepared as follows: 65% adjusted experimental sample, 
25% sample buffer, and 10% reducing agent. The loading samples were then 
vortexed and heated at 70°C in a water bath for 10 minutes. 
While the samples were heating, the gel cassettes were washed with distilled 
water to remove the packing buffer and the lanes were rinsed with MOPS running 
buffer (50mL NuPage MOPS running buffer to make a final volume of 1000mL 
with distilled water). Next, the gel assembly was set up by placing 2 gel 
cassettes facing each other in the gel tank. The middle reservoir formed by the 2 
gel cassettes was then filled with 200mL of MOPS running buffer supplemented 
with 0.5mL of antioxidant. Finally, the outside reservoir of the gels, formed 
between the gel cassettes and the tank itself, was filled with MOPS running 
buffer without antioxidant. 
10µL of see plus 2 (Invitrogen) marker was added to a marker lane at the side of 
the gel as a standard of location/weight in the gel. In the remainder of the 
lanes, 15µL of the adjusted experimental sample was loaded, after ensuring that 
that each lane in fact had 20µg of protein. 
The tank was run at 175V for 1hr and 10 minutes which was found to be the 
optimum condition for the appropriate separation of the proteins studied in this 
project. The intensity of electric current was set to 120mAMP for one gel and 
240mAMP when two were run in one tank. 
2.8.5 Protein transfer procedure 
While gels were running, transfer buffer was prepared by mixing 50mL of 
NuPage® transfer buffer, 200mL of methanol, 1 ml of antioxidant and enough 
distilled water to make a final volume of 1000mL. 800mL of this solution was 
transferred to a tray alongside with all the equipment for gel transfers (sponge 
pads, blotting roller, and filter paper). 
A spatula was used to crack open the gel cassette, half of the cassette was 
removed and the gel indentations that form the lanes were cut and removed. A 
square of filter paper was placed on the gel surface; at this point the other half 
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of the cassette was removed, leaving the gel suspended over the filter paper. A 
PVDF membrane, previously soaked in methanol, was placed on the other 
surface of the gel and on top of this another square of filter paper. This 
membrane sandwich of filter-gel-membrane-filter was then placed on top of the 
sponge pads which, up to this point, had been resting on the cathode core of the 
blotting module. Two more sponge pads were placed on top of the membrane 
sandwich. Finally, the lid or anode core of the transfer assembly was placed on 
top, and the entire blot module was placed in the tank. 
The remainder 200mL of the transfer buffer solution was then added to the 
middle compartment of the Xcell IITM blot module, approximately 1cm above the 
membrane sandwich. The outer compartment, formed by the assembly module 
and the walls of the tank, was filled with distilled water. The volume of distilled 
water used was enough to cover up to ¾ of the blot module  
The powerpack was attached and the unit was run at 30V for 1 hour at 450mAMP 
After this time, the transfer unit was disassembled, the polyacrylamide gels and 
the filters were securely disposed of and the PVDF membrane was soaked in 
distilled water. 
2.8.6 Ponceau staining 
The Ponceau staining technique is a simple and rapid procedure that allowed 
corroboration of the loading uniformity of the samples across the lanes as well 
as confirming that the transfer had been successful. This technique, using 
Ponceau S solution (Sigma, Poole, UK), always followed the transfer of the blots. 
The PVDF membrane were rinsed twice with distilled water, drained and 
submerged in 5mL of Ponceau solution for 5 minutes. The PVDF membrane was 
then quickly rinsed and the protein bands examined and photographed. After 
this, the distilled water was drained and the PVDF membrane was immersed in a 
solution of 0.1M of NAOH for approximately 30 seconds or until the stained bands 
had faded. To ensure that all the Ponceau stain and NAOH had been removed, 
the PVDF membranes were washed twice for 3 minutes  
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2.8.7 Antibody incubation 
The membrane was blocked to avoid non-specific antibody binding with 5% 
skimmed milk in Tris Buffer Saline Tween-20 (TBST; 10 mM Tris pH 8.0, 150 mM 
NaCl, 0.05% Tween-20) at room temperature for 1 hour.  
Incubation with primary antibodies was typically done overnight with agitation 
at 4°C for the following specific antibodies: β3-tubulin (1:1000), synaptophysin 
(1:1000), GAP-43 (1:1000), doublecortin (1:1000), NRF2 (1:500) and GAPDH 
(1:10,000) as a loading control. 
The following day, the membrane was washed with TBST three times for 15 
minutes (with agitation) to remove any unbound primary antibody from the 
membrane and from the dishes where the membranes were kept. 
The membrane was then immersed and stirred for 1 hour in 5mL of a solution 
containing horseradish peroxidase coupled secondary antibody (1:3000) and 5% 
skimmed milk in TBST. Next, the membrane was washed 5 times for 15 minutes 
in TBST in a shaker to remove any unbound secondary antibody. 
2.8.8 Enhanced Chemiluminescence 
To quantify the amount of specific binding between the target protein, the 
primary antibody and the secondary antibody, a chemiluminescence detection 
system was used. A luminol peroxide detection reagent was added to the 
membrane for 5 minutes, during which time the HRP enzyme present in the 
secondary antibody would catalyse the oxidation of luminol. This reaction was 
accompanied by the emission of a low intensity light. Commercially available 
chemiluminescence kits enhance the signal by the addition of other chemicals to 
the reaction; this process is called enhanced chemiluminescence (ECL). The 
signal was visualised using ECL PLUS (GE Healthcare). The kit was used according 
the manufacturer’s guidelines, briefly; 
The detection reagents (solution A and solution B) were removed from the fridge 
and allowed to reach room temperature. Solutions A and B were mixed in a ratio 
of 40:1 (2 ml solution A and 50µL solution B). Once mixed, the solution was kept 
away from direct light at all times, this was achieved by shielding all the 
Chapter 2   
117 
containers used (centrifuge tube and dish) with tin foil. The mixed detection 
reagent was pipetted onto the protein side of the PVDF membrane and covered 
with a square of parafilm® to ensure an even distribution of the solution across 
the membrane. After incubation for 5 minutes, the excess solution was removed 
and the membrane was placed in a developing cassette. 
The cassette was taken into a red-light room, where photosensitive film paper 
was cut to the correct size and placed over the membrane. The time of exposure 
varied according to the intensity of the signal, but in general was between 30 
seconds and 1 minute. Films were then fed into a developing machine (KODAK). 
Quantification of the blots’ size and intensity was measured using the program 
image J (http://imagej.nih.gov/ij/). Corrections accounting to loading 
differences were made using the intensity of the “housekeeping” proteins (actin 
and GAPDH). 
2.9 Statistical analysis 
Data were analysed using one-way ANOVA as almost all the experiments were 
designed to ensure the existence of only one independent variable (drug) and 
one response variable (effect). The exception to this rule was time courses, for 
which a two-way ANOVA was used, followed by a Dunnett’s test (when 
comparing against control only) and Tukey’s post hoc test (when multiple 
comparisons were performed). 
The experiments performed included a very large number of experimental 
conditions, it was therefore not possible to use a follow-up test of planned 
comparisons which, in theory, should have a k-1 number of comparisons. 
Furthermore, there was no strong theoretical basis to design experiments with a 
reduced number of conditions. 
Most of the research conducted was aimed at determining the possibility of 
significant differences occurring within groups (generally speaking this refers to 
the different doses used). Therefore, all the groups were compared equally by 
applying a post-hoc test after the one-way ANOVA. 
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Data are expressed as means ± SE. Statistical significance was set at P <0.05. 
Preliminary statistical analyses were performed using StatView software.  
One-way ANOVA followed by Dunnett’s multiple comparisons test was performed 
using GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolla 
California USA, www.graphpad.com 
A minimum number of conditions and a two-way ANOVA was used for the 
experiments designed to determine whether delivering the drugs in 1% FBS or 
10% FBS medium caused a different cellular response. 
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2.10 Treatments 
2.10.1 Chemicals. 
From Sigma-Aldrich Company Ltd., Poole, Dorset, UK: 
Catalase powder, bovine liver (C1345) 
Diphenylene iodonium chloride (D2926) 
Hydrogen peroxide 30% solution (H1009) 
3-Hydroxyanthranilic acid powder (H9391) 
Kynurenic acid powder (K3375) 
MK-801 maleate (M107) 
N-methyl-D-aspartate powder (M3262) 
QA powder (Q104) 
Retinoic Acid (R2625) 
Superoxide dismutase powder, bovine erythrocyte (S5395) 
Xanthine (X4002) 
Xanthine oxidase (from bovine milk, X4376) 
The majority of compounds used to treat the cells were dissolved in stock 
solutions using sterile water (culture grade). The exception was 3-HAA, KA, RA, 
DHE and H2O2. 
3-HAA can only be solubilised when it is in a protonated state. Hydrochloric acid 
(HCl) 1N was used followed by a pH adjustment to 7.4 using 1M of Tris-HCl, pH 
8.8.  
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To dissolve KA, 1 M NaOH was used; the solution was back titrated with 0.1 M 
HCl to pH 7.4. 
RA was dissolved in ethanol to a final stock solution of 0.01 M (3 mg/ml). To 
treat SH-SY5Y cells, subsequent dilutions were made in the growth medium to 
get a final RA concentration of 10 µM; this in turn yielded a final ethanol 
concentration of 0.1% (v/v) that has no effect on cultures. 
DHE was solubilised in methanol making sure that once treated, the final 
concentration of methanol would not exceed 0.05% (v/v).  
H2O2 was diluted in fresh 10% FBS medium to prepare the desired final 
concentrations. Preparing stock solutions for long-term storage by diluting them 
in culture media is not recommended. However since the prepared solutions 
were used soon afterwards, diluting them in medium reduces stress on the cells 
caused by changes in osmolarity. 
All the solutions used to treat the cells were prepared under sterile conditions, 
heated to 37°C using a water bath (Grant Instruments, Cambridge) and filtered 
prior to use. 
The time spent changing the medium and treating the cells never exceeded five 
minutes after which the cells were always placed in an incubator set to inject 
95% air and 5% CO2 at 37 °C. 
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2.11 Methods (carried out by others) 
2.11.1 High performance liquid chromatography (HPLC). 
The concentration of 3-HAA in cultures and in cell-free preparations was 
measured by HPLC and carried out by Dr. Alexandra Ferguson at the University 
of Glasgow. The methodology described here is only a brief summary based on 
the more complex methodology described and developed by Dr. Gillian Moira 
Mackay for her PhD dissertation(Mackay et al., 2006; Mackay, 2007). 
Method details are given in the Appendix (section 6.1 under “Methods carried 
out by others”). 
2.11.1.1 Sample’s origin 
The samples analysed came from solutions that were used to treat cells seeded 
on 96-well plates. One single treatment was made on day 0 and no medium 
changes were performed. The same solutions that were used to treat the cells 
were pipetted into plates that had no cells growing on them to discern the 
actual cellular contribution to the process. The solutions added to the cells and 
to the wells without cells were: 3-HAA (50 µM and 100 µM) in 1% FBS medium 
with or without SOD (300 U/ml), 3-HAA (50 µM and 100 µM) in 10% FBS medium 
with or without SOD (300U/ml). Cells were treated on day 0 with the solutions 
mentioned above. 900µL per condition were put aside on Eppendorf tubes to be 
used as the 3-HAA concentration present on day 1. Samples were collected 
thereafter on day 1, 2 and 3. A total of 900µL were collected for each condition 
(16 per day), labelled in code (for example, 1D0a meant the sample for day 0 
containing 100 µM 3-haa in 10% FBS without SOD) and frozen. At this point, 
samples were given to Dr. Ferguson to be run through the HPLC knowing only in 
general the range of concentrations used (to adjust the standard curve) and of 
course, that the compound used was 3-HAA (double blind). At the end of the 
HPLC run the data received was 1DOa = 87.95622338 µM. 
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Chapter 3 – OPTIMISING CULTURE CONDITIONS 
AND ASSESSING THE OVERALL STATE OF SH-
SY5Y CELLS 
  
3.1  Introduction 
According to Good Laboratory Practice recommendations (Li et al., 2006) this 
chapter intends to validate the SH-SY5Y cell line as a reliable in vitro model to 
study toxicity and/or differentiation. The findings of this section focus on the 
three key aspects: a) optimization of the culture conditions necessary to grow 
the SH-SY5Y cell line; b) confirmation that the methods employed to evaluate a 
specific parameter (survival and differentiation) are suitable for their intended 
use; and c) comparability studies confirming that the SH-SY5Y cell line acquired 
behaves in accordance to what has been reported in the literature in terms of 
survival and differentiation. 
During the initial stages of this project, it was noted that SH-SY5Y cells are 
highly dependent on serum to proliferate. For instance, the data sheet from the 
cell line’s supplier (ECACC) specifically encourages plating the cells in a medium 
containing up to 15%FBS when first resuscitated. The relevance of finding an 
adequate FBS batch to supplement the medium to be used to grow and treat the 
cells was therefore of the highest priority. 
The SH-SY5Y cell line had already been established in the laboratory and tests to 
find the optimal culturing conditions had already been performed by Dr. Caroline 
Forrest. However, the FBS used to prepare the medium to feed the cells had to 
be changed due to an exhaustion of the FBS batch initially reserved (Sigma F9665 
batch 011k3396). 
Since SH-SY5Y cells can be induced to differentiate into neurons through various 
chemical treatments, it was decided to test the effect of QA on differentiation; 
but first it was necessary to establish a reliable method of inducing and 
evaluating differentiation. 
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In view of the above and aware that the loss of neuronal characteristics has been 
described with increasing passage numbers, we followed the recommendation of 
not using them after passage 38. In this study, two factors (RA and NGF) were 
tested and reported to have neuronal differentiating properties. The use of 10 
µM RA resulted in cells with apparent neuronal morphology (with long, extensive 
network of neurites). This effect was less pronounced after treatment with NGF.  
In order to confirm that the results obtained from the morphological analysis had 
a molecular basis and that cells were indeed undergoing neuritogenesis and not 
simply transient changes in shape the expression of neuronal and proliferation 
markers was evaluated. The expression of cytoskeleton proteins is known to 
increase with the development of neuritic processes (Heraud et al., 2004), in 
particular that of β3-tubulin. As differentiation occurs, the number of 
proliferating cells decreases and so does the expression of doublecortin (DCX). 
DCX is a microtubule associated protein found in migrating neuronal precursors 
as well as in brain areas with high neurogenesis (Couillard-Despres et al., 2005). 
This is also the case in neuroblasts where an inverse correlation between the 
acquisition of a mature neuronal phenotype and the expression DCX has been 
reported (Galderisi et al., 2003) 
For this reason the use of antibodies against β3-tubulin and DCX was evaluated 
after treatments with RA and NGF and it became an essential tool for identifying 
the degree of neurite extension or conversely of proliferation.  
Neuronal synapses are characterised by the presence of synaptic vesicles, 
neurotransmitters, receptors and exocytotic machinery. The synaptophysin 
(SYN)-synaptobrevin (VAMP1) complex is found in mature synaptic vesicles and 
its presence has been used as a marker of functional synapses. In order to 
determine if cell differentiation is also associated with an acquisition of 
functional synapses, the expression of VAMP1 was assessed. 
After a 7 day treatment with 10 µM RA and 50 ng/ml NGF, the expression of β3-
β3-tubulin and VAMP1 increased and there was a decrease in the expression of 
DCX. 
  
Chapter 3   
124 
3.2 Aims and objectives 
 Establish the optimal culture conditions for the SH-SY5Y cell line. 
 Determine what the optimum serum for growing SH-SY5Y cells is 
 Familiarise with the lag, log, and stationary phase of the SH-SY5Y cell line 
in order to establish the best time to subculture and treat the cells. 
 Establish that the acquired SH-SY5Y cell line is able to differentiate when 
treated with RA  
 Confirm that the acquired SH-SY5Y cell line responds the same way as in 
the literature reports regarding H2O2 toxicity. 
 To ascertain if a correlation exists between the morphology and the β3-
tubulin/DCX ratio after differentiation has been induced. 
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3.3  Results 
3.3.1 SH-SY5Y cells show different growing profiles depending on 
the batch of foetal bovine serum (FBS).  
Two different serum batches were tested: Sigma F9665 batch 018k3396 against 
Sigma F9665 batch 098K3396. First, a new vial was unfrozen and plated in a T15 
flask containing medium with 15% FBS from the initial batch (011k3396). After 
resuscitation, SH-SY5Y cells remained in suspension for 24 hours, their cell 
bodies at this stage were bright, round and very small. However, over the next 
24 hours after having been plated, they reattached to the dish surface and 
resumed growth. Cells were fed daily and passaged after three days into a T150 
flask containing 10% FBS from the original batch (011k3396).  
Cells were fed on the third day and subcultured on the 7th day in order to have a 
sufficient number of cells to be plated in 2 different T75 flasks and two 6-well 
plates at a final density of 1 x 105 cells/ml. One flask and one of the 6-well 
plates contained medium with 10% FBS from batch 018K3396 and the other flask 
and 6-well plates contained 10% FBS medium from batch 098K3396. The plates 
were photographed daily and the micrographs obtained were used to count the 
number of cells present in the optic field. After having been photographed, 2 
wells in each plate were scraped and a total cell count was performed by trypan 
blue on day 1, 2 and 3.  
The cell count obtained from both serum batches was compared to the average 
cell count recorded up to that day, making sure it belonged to the cultures 
grown in the original batch of FBS (011k3396). 
After 1 DIV, there were not any apparent qualitative differences the cultures 
grown in batches 018K3396 and 098K3396. The morphology of the SH-SY5Y cells 
in either one of the media was neuroblastic. Approximately 70% of the cells 
present had attached to the plate surface while 30% could still be found in 
suspension (Figure 6 a). Also after 1DIV, the micrograph cell count of the culture 
grown in batch 018K3396 was 42 cells and for the culture grown in batch 
098K3396 was 43 cells (Figure 6 b). Similarly the trypan blue cell count yielded a 
total of 2.2 x 105 cells/ml in the medium with serum 018K3396 and 2.4 x 105 
cell/ml in the 098K3396 one, but this difference was not significant (Figure 6c). 
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At day 2 however, there were significant changes in all of the evaluated 
parameters. Cells grown in the medium containing 018K3396 serum looked 
similar to the way they did the day before; there were no changes in the 
proportion of attached cells vs. the ones in suspension. There were only 45 cells 
per micrograph and the total cell count using trypan blue was 330,381 cells/ml. 
On the other hand, cells grown in medium with 098K3396 serum were bigger (30 
µM), started associating together in clumps of cell bodies and the number of 
cells per micrograph had increased to 70. Similarly, the trypan blue count 
yielded a total of 5.2 x 105 cells/ml (Figure 6). 
 
Figure 6. Foetal bovine serum affects the growth rate of SH-SY5Y cells. A) Phase-contrast 
micrographs of SH-SY5Y cells corresponding to 1, 2 and 72 h after plating B) Graphs 
indicating the number of cells counted from micrographs (by triplicate) taken 1, 2 and 72 h 
after plating. C) Haemocytometer cell count (Trypan blue) 1, 2 and 72 h after plating. Results 
are expressed as percentage of control. Point in graph represent mean ± SEM. *P<0.01, 
**P<0.001 Two-way ANOVA followed by Tukey’s test. n=5. Scale bar=50 µm. 
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The difference in cell proliferation between both sera was more noticeable on 
the 3rd day. Cells in medium from batch 018K3396 were still precariously 
scattered on the plate surface. The number of cells increased only by 
approximately 60% regardless of the counting method used (micrograph count or 
by haemocytometer). 
In contrast, cells plated in medium prepared from batch 098K3396 had already 
reached 70% confluence, approximately. The cells were distributed evenly on 
the plate surface. The micrograph cell count yielded 140 cells per optic field and 
1.2 x 106 cells/ml. 
3.3.2  RA and NGF induce differentiation in SH-SY5Y cells 
3.3.2.1 Qualitative assessment of the morphology 
SH-SY5Y cells were plated in 6-well plates and cultured for 72 h in 10% FBS 
medium after which they were transferred to a 1% FBS medium alone (control) 
or supplemented with either 10 µM RA or 50 ng/ml NGF. Cells were incubated 
for 72 h before being collected for western blotting. Alternatively, cells were 
incubated under the same conditions for 7 days, with a change of fresh medium, 
RA or NGF on the 3rd day, before being collected for western blotting. A total of 
4 independent experiments were carried out each time, using fresh solutions 
prepared from well preserved stocks. 
Since exposure of SH-SY5Y cells to 10 µM RA is the most widely reported inducer 
of differentiation, this treatment was used in several experiments as a positive 
control of differentiation. When cells were differentiated for a period longer 
than 72 h, they were always fed with fresh 1% FBS containing 10 µM RA on the 3rd 
day. 
Undifferentiated SH-SY5Y cells grew in clusters of neuroblastic cells presenting 
flat cell bodies that adhered to the surface onto which they were plated. Their 
cell bodies were elongated and star-shaped with some of the multiple vertices 
thinning until they formed short processes. During the first 24 hours there were 
no obvious differences between control cells (kept in 10% medium) and treated 
cells (Figure 7).  
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Cultures reached a high density within 72 h, this was evidenced by groups of 
cells growing on top of each other, forming a series of multilayers. This effect 
could be observed even before cells reached 70% confluence.  
Despite the fact that SH-SY5Y cells are an adherent cell type, the number of 
adherent and non-adherent cells increased with time. It was not uncommon to 
see some clumps of viable cells sporadically detaching from the plates and 
remaining in suspension as evidenced by the larger round spots in the 
micrographs (Figure 7). 
 
Figure 7. RA and NGF alter the morphology of SH-SY5Y cells. Bright-field micrographs 
taken 3 and 7 days after treatment with 10 µM RA and 50 ng/ml NGF in which morphological 
changes can be observed (neurite, arrow). Scale bar = 100 µm 
24 hours after cells were transferred to a medium containing 1% FBS and 10 µM 
RA, there was an increase in the length of the processes. Some of them were at 
least twice the length of their cell body. The cell body itself began to compact 
and adopted a more circular shape. SH-SY5Y cells were induced to differentiate 
into a more neuronal phenotype by RA and to a lesser extent by 50 ng/ml NGF. 
Cells treated with 50 ng/ml NGF maintained a typical epithelial morphology 
(Figure 7) 3 and 7 days after treatment. 
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To demonstrate that differentiation with RA had occurred, as in several previous 
reports, SH-SY5Y cells were treated with 10 µM of RA and an increase in the 
number of neurite-bearing cells was confirmed. This effect was initially observed 
24 hours after treatment and up to a maximal 7 days after treatment. During the 
first 48 hours, the cell bodies changed from a flat, triangular shape to a more 
rounded one (Figure 7). RA is a light sensitive compound that is not very stable 
under culture conditions therefore cells had to be fed with fresh medium 
containing 10 µM RA every 48 hours. In preliminary experiments, feeding the 
cells less than twice a week dramatically reduced the degree of RA-induced 
differentiation observed in the cultures. 
It was important to test whether the morphological differences observed had a 
molecular basis that could be measured. Therefore, changes in specific neuronal 
(β3-tubulin, VAMP1) and non-differentiated cell markers (DCX) were evaluated 
by Western blotting. 
 
Figure 8. RA and NGF increase the expression of neuronal markers in SH-SY5Y 
cells.Western immunoblotting and histograms of the quantification analyses of β3-tubulin 
(A, D), synaptic protein VAMP1 (B, E) and proliferation marker doublecortin (DCX; C, F) after 
3 and 7 day treatments with RA (10 μM) or NGF(50 ng/ml). Bars represent mean ± SEM in 
arbitrary units of optical density (OD). GAPDH was used as a house-keeping protein and 
results were normalised to the control. *p<0.05 One-way ANOVA followed by Dunnett’s test. 
n=4. 
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Cells treated with 10 µM RA showed an increase in the expression of β3-tubulin 
as early as 72 h after treatment (Figure 8-a). This increase was maintained up to 
7 days after treatment (Figure 8-d). In contrast, the expression of VAMP1 was 
not different from control levels after 72 h of treatment (Figure 8-c). However, 
7 days after treatment, the expression of VMAP-1 was significantly increased 
when compared to control cells (Figure 8-e). Accordingly, RA successfully caused 
a decrease in the expression of the proliferation marker DCX (Figure 8-f) 7 days 
after treatment. 
Cells treated with 50 ng/ml NGF showed a significant increase in the expression 
of β3-tubulin three days after treatment (Figure 8-a). The expression of β3-
tubulin remained high 7 days after treatment (Figure 8-a, d).The expression of 
VAMP1 did not change during the first three days. NGF significantly increased 
VAMP1 expression 7 days after treatment (Figure 8d, e) when compared to 
proliferative cells. Contrastingly to what happened with RA treatment, NGF did 
not cause changes in the expression of DCX at any of the time points evaluated 
(Figure 8-c, f).  
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3.3.3 Hydrogen peroxide is a potent inducer of cell death in SH-
SY5Y cells 
SH-SY5Y cells were grown for 72 h in medium containing 10% FBS. After this 
time, the medium in the plates was gently aspirated and replaced with fresh 
medium containing 10% FBS alone (control) or with H2O2 at 3 different 
concentrations (100 µM, 250 µM, 500 µM). Cells were placed back in the 
incubator for 2 hours after which viability was assessed by FDA. Additionally, the 
same treatments were delivered in medium containing either 1000U/ml CAT or 
300U/ml of superoxide dismutase (SOD). The initial stock was a 30% aqueous 
solution of H2O2 (9.79M), this was diluted in fresh 10% FBS medium to prepare 
the desired final concentrations. A total of 3 independent experiments were 
carried out, using fresh solutions each time 
To rule out any interference of catalase (Gedik et al., 2005) with the FDA 
readings, it was decided to design a cell-free preparation using a 96-well 
microplate. Each well contained 10µL of CAT at different concentrations 
(2500U/ml, 3125U/ml, 6250U/ml, 12500U/ml and 25000U/ml) and 100µL of 
growing medium (10% FBS). The volumes chosen were similar to the ones 
generally used to treat cells in a 96-well microplate. The plate was incubated 
for 2 hours and a normal FDA assay performed (see chapter 2.2.1). A total of 6 
independent experiments were carried out, using fresh solutions each time. 
Indeed, the presence of CAT at concentrations higher than 3125 u/ml caused an 
increase in the optical density readings (Figure 9a). The relationship between 
the optical density obtained and the concentration of CAT applied was dose-
dependent. This relationship was nonlinear and, once plotted, it exhibited a 
sigmoidal behaviour that was best described (R2= 0.972) by the following 4 
parameter logistic nonlinear regression (Figure 9a, insert): 
𝑓 = −52.8788 +
241.9217
1+(
𝑥
2798.1819
)
−0.9978  
This increase in the reading was not caused by cellular esterase activity since 
there were no cells in the wells treated. Therefore, to avoid any interference in 
future FDA readings, which could be wrongly interpreted as an increase in cell 
viability, the final concentration of CAT used in all experiments was 1000 U/ml. 
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This having been established, SH-SY5Y cells were exposed to H2O2 (100–500 µM) 
for 2 hours and cell viability was assessed by FDA. After 2 hours, exposure to 100 
µM, 250 µM and 500 µM H2O2 decreased cell viability, when compared to control, 
in a dose dependent manner to 79% ± 2.8, 60% ± 3.8, 38% ± 3.9 respectively 
(Figure 9b), P<0.0083 for 3 different experiments. 
The effect of SOD and CAT on H2O2-induced cell death was evaluated. As 
expected, incubation with 300U/ml SOD did not exert any protection from H2O2-
induced cell death. The same doses 100 µM, 250 µM and 500 µM in combination 
with 300U/ml SOD continued to reduce cell viability to 79% ± 2, 69% 2.9, 39% ± 
1.9 respectively (Figure 9c), P<0.0014 for 6 different experiments. 
 
Figure 9. Catalase protects SH-SY5Y cells against H2O2-induced toxicity.A) Histogram 
indicating the FDA relative fluorescent emission values of a cell-free preparation containing 
medium plus catalase (2500-25000 U/m. B) Viability of SH-SY5Y cells treated for 2 h with 
different concentrations of H2O2 (100-500μM) in the presence of either catalase (Black bar; 
1000U/ml) or SOD (grey bar; 300U/ml). For graph A) results are expressed as FDA relative 
fluorescence emission (RFE). For graph B), results are expressed as percentage of control 
RFE. Bars represent mean ± SEM. *P<0.05, **P<0.0083, ***P<0.0014, ****P<0.0001. One-way 
ANOVA followed by Dunnett’s test (A) and Two-way ANOVA followed Tukey’s test (B). n=6. 
Contrastingly, 1000 U/ml CAT rescued the SH-SY5Y cells from H2O2-induced 
damage at 100 µM and 250 µM, restoring the viability to a level comparable to 
that of control wells. For the highest concentration of H2O2 used (500 µM), CAT 
protection was only partial, managing to increment the viability by 
approximately 10% when compared to cells treated with 500 µM H2O2 only. 
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The same experiments were carried out using the Alamar blue viability assay. 
The results obtained were similar to the FDA results. Therefore, it was decided 
to continue using the FDA assay for future experiments. 
3.4 Discussion 
This set of experiments confirmed that the SH-SY5Y cell line acquired from 
ECACC behaves similarly to what has been reported in the literature in terms of 
its growing profile, its ability to differentiate as well as its susceptibility to toxic 
insults (Constantinescu et al., 2007; Weinreb et al., 2008; Cheung et al., 2009).  
An article by Lin et al. (2009) shows that exposure of SH-SY5y cells to 100 µM 
H2O2 for 3 hours results in approximately a 40% reduction of cell survival (Lin et 
al., 2009). The data herein contained confirmed that exposure to 100 µM H2O2 
for 2 hours causes a 20% reduction in cell viability (Figure 9-b). 
Furthermore, it was confirmed that differentiation of SH-SY5Y cells could only 
occur in medium with a low serum concentration. It has been suggested that the 
presence of growth and mitogenic factors (cAMP, NGF, bFGF, PDGF, EGF, 
steroids, insulin, IGF-I and II.) in serum inhibit differentiation of SH-SY5Y cells 
(Glick et al., 2000; Zheng et al., 2006) 
The data gathered in this study are in agreement with previous reports that 
show that an increase in the expression of neuronal markers occurs with the 
concomitant decrease in the expression of proliferation markers in SH-SY5Y 
(Lopes et al., 2010). Although an increase in the immunocontent of β3-tubulin 
was found as early as 72 h after differentiation was initiated, there was an equal 
amount of DCX in proliferative cells and in those treated for 72 h with RA, which 
means that cells were at a very early differentiation stage. Seven days after 
treatment with RA, there was a clear decrease in the expression of DCX, which 
points out to a cease in cellular division, and the adoption of a fully mature 
neuronal phenotype. The period of time in which RA effectively induced the 
expression of β3-tubulin and a decrease in DCX is similar to what has been shown 
in previous reports (Leondaritis et al., 2009; Agholme et al., 2010). 
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There are conflicting reports regarding SH-SY5Y cell’s responsiveness to NGF. It 
has been classically accepted that the SH-SY5Y cell line does not respond to NGF 
due to its low expression of TRKa receptors, high affinity NGF receptor pp140crrk, 
and the low affinity neurotrophin receptor p75LNGFR (Pahlman et al., 1995; 
Encinas et al., 1999; Olsson et al., 2000; Simpson et al., 2001; Xie et al., 2010). 
However there are several studies that show that SH-SY5Y cells do respond to 
NGF and extend neurites after treatment (Chen et al., 1990; LoPresti et al., 
1992; Poluha et al., 1995). A potential explanation for these contradictory 
reports comes from data showing that, within the SH-SY5Y cell line, there are 
some genetically different cellular subpopulations that are more responsive to 
NGF than others (Oe et al., 2005). Similarly, there is evidence suggesting that 
other differentiating factors influence the responsiveness of the SH-SY5Y cells to 
NGF, such as brain derived neurotrophic factor, neuregulin β1 and vitamin D3 
(Agholme et al., 2010). 
The data presented in this project shows that exposure to 50 ng/ml NGF 
stimulates neurite extension when compared to controls, but to a lesser extent 
than RA does. NGF treatment increased the expression of β3-tubulin and VAMP1 
which supports the morphological assessment proving that cells are 
differentiating. On the other hand, NGF treatment failed to reduce the levels of 
DCX, indicating that proliferation is not completely halted in the cultures. It has 
been suggested that NGF differentiation can be enhanced by blocking cell 
proliferation with inhibitors of α and δ polymerase such as aphidicolin (LoPresti 
et al., 1992). Because of the partial differentiation observed with NGF, RA was 
used instead as a positive control of differentiation as treating SH-SY5Y cells 
with 10 µM RA is one of the most widely accepted stimulus to differentiate SH-
SY5Y cells (Pahlman et al., 1984; Schneider et al., 2011) 
After 7 days of RA differentiation, the expression of DCX decreased significantly. 
DCX, a microtubule associated protein, is expressed in a cell-cycle-dependent 
manner. DCX is downregulated as cells stop dividing and differentiate.  
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3.5 Conclusion 
 Based on the growth curve analysis, the serum from batch 098K3396 is an 
ideal serum to grow, passage and treat SH-SY5Y cells. 
 High concentrations of CAT caused an increase in the optical density 
readings of FDA. Special care has to be taken when using other 
compounds to ensure that they do not interfere with the assays at the 
used concentration. It was also decided to conduct other cell-free 
experiments throughout this study to guarantee that the results obtained 
are not an artefact. 
 RA induces differentiation and so does NG, though to a lesser extent. RA 
treatment can therefore be effectively used as a positive control for 
differentiation in this study. 
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Chapter 4 – CONTRASTING EFFECTS OF 
QUINOLINIC AND 3-HYDROXYANTHRANILIC ACID 
  
4.1 Introduction 
QA is a highly toxic metabolite of Trp; even millimolar concentrations of QA are 
able to cause selective nerve cell degeneration (Schwarcz et al., 1983) either by 
over stimulating the NMDAR or by causing oxidative stress.  
Whetsell and Schwarcz (1989) showed that caudate nucleus cultures or a 
combination culture of frontal cortex and caudate nucleus could be maintained 
in the presence of 100 nM QA for up to 7 weeks without any obvious loss in the 
number of cells. However, upon ultrastructural morphological analysis, they 
demonstrated that cells exhibit increased vacuolization (Whetsell and Schwarcz, 
1989). 
It has been shown that the concentration of enzymes and metabolites of the 
kynurenine pathway is altered in the SK-N-SH neuroblastoma cell line (from 
which the SH-SY5Y cell line was subcloned). For instance, in the SK-N-SH line 
IDO-1 is not constitutively expressed, the concentration of ACMSD is low and QA 
in preferentially metabolised (Guillemin et al., 2007). 
Adams and collaborators (2012) hypothesised that a shift in the kynurenine 
pathway towards QA provides neuroblastomas with an adaptive advantage. 
Briefly, they state that favouring QA production provides neuroblastomas with a 
more steady and reliable source of the NAD+, which in turn sustains the 
enhanced activity of PARP1 (which is found in many cancers) and ultimately 
promotes tumour cell viability and proliferation (Adams et al., 2012). 
This study provides evidence suggesting, for the first time, that QA induces 
neuritogenesis in SH-SY5Y cells. It is proposed that QA induces differentiation 
through a ROS-dependent mechanism. The source of these ROS is believed to be 
NOX (at least partly) since DPI prevented QA-induced differentiation. An early 
consequence of QA treatment was an increase in the expression of NRF2 (12 h 
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after treatment) followed by an increase in the expression of β3-tubulin and 
neurite extension (72 h after treatment). A prospective hypothesis is presented 
in which both ROS production and NAD+ are necessary to induce differentiation 
of the SH-SY5Y line. NAD+ could support neuronal differentiation both 
metabolically and by inhibiting SIRT1 (which represses NRF2). 
If ROS were to play an important role in the differentiation of SH-SY5Y cells, 
then perhaps other oxidant molecules could affect SH-SY5Y survival and/or 
differentiation. Thus, given the effect of QA on the production of ROS and 
neuritogenesis, it was decided to evaluate if other kynurenines such as 3-HAA (a 
well-known inducer of oxidative stress) could exert a similar effect on the 
viability and neuritogenesis of SH-SY5Y cells. Cells were treated with different 
concentrations of 3-HAA and the morphology and viability were assessed 24 h 48 
h and 72 h after treatment. No changes in the morphology or survival could be 
observed 24 h after treatment with 3-HAA. However, after 48 h, cells showed 
clear signs of cellular damage and death 
There are no reports about the effect of 3-HAA on the SH-SY5Y cell line despite 
the fact that 3-HAA has been, to a certain extent, implicated in the pathologies 
that the SH-SY5Y cell line is a model for.  
4.2 Aims and objectives 
 Determine the effect of QA on differentiation. 
 Determine if QA is acting on the NMDAR or affecting the oxidant state of 
the cell. 
 Ascertain whether there exists a relationship between the expression of 
neuronal markers and QA treatments. 
 Evaluate the effect of 3-HAA on cell survival. 
 Ascertain factors involved in the cellular response to 3-HAA. 
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 Determine the effect of 3-HAA on SH-SY5Y cells and whether there is a 
differential response between differentiated and undifferentiated SH-
SY5Y cells. 
  Establish if the levels of ROS are affected by 3-HAA treatment 
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4.3  Results 
4.3.1 QA effect on SH-SY5Y survival and neuritogenesis 
4.3.1.1 QA does not negatively affect the survival of SH-SY5Y cells  
In order to establish if QA had a detrimental effect on cell survival, 
undifferentiated SH-SY5Y cells were fed with fresh 10% FBS medium (control) or 
treated for 72h with increasing concentrations of QA (50 nM, 300 nM, 500 nM, 
25µM, 50 µM, 100 µM, 500 µM, 1mM and 5mM), after which survival was assessed.  
Figure 10 shows that, contrary to what was expected, QA did not have a toxic 
effect on SH-SY5Y cells 72 h after treatment regardless of the concentration 
used. At doses above 25 µM, there seemed to be 10% decrease in the viability; 
nevertheless, after statistical analysis, these differences were not significant. 
 
Figure 10. QA does not promote cell death in SH-SY5Y cells. A) Histogram indicating the 
viability of undifferentiated control SH-SY5Y cells (untreated) and cells treated for 72 h with 
QA (50nM-5mM) in 10% FBS. B) Dose-response curve fitting with a variable Hill slope. R2= 
0.3150. Results are expressed as a percentage of control RFE. Bars represent mean ± SEM. 
No significant differences were found using One-way ANOVA followed by Dunnett’s test. 
n=4. 
The same data were fitted to a dose-response curve (Figure 10, insert) which 
had an R2 value of 0.3150, further confirming that QA does not negatively affect 
cell survival in a dose-dependent manner. 
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4.3.1.2  SOD treatment increases the number of cells in culture. 
Since the original aim of these experiments was to ascertain whether QA could 
affect RA-induced cell differentiation, it was first necessary to establish whether 
a sublethal dose of QA had a toxic effect when administered in combination with 
RA. Therefore SH-SY5Y cells were treated after 3DIV with RA 10 µM, QA 50 nM 
and a combination of both. These treatments were delivered in both 1% FBS 
medium and 10% FBS medium. 
 
Figure 11- SOD increases the number of cells after 72 h treatment with QA plus RA. 
Histogram indicating the viability of undifferentiated SH-SY5Y control cells, and cells 
treated with RA (10 µM) and/or QA (50 nM) in 1 or 10% FBS medium supplemented with SOD 
(300 U/ml, white bars). Control wells received 1% FBS medium exchanges only. The results 
are expressed as a percentage control RFE. Bars represent mean ± SEM. *p<0.05, **p<.0072. 
Two-way ANOVA followed by Tukey’s test. n=4. 
Consistently with previous results (Figure 10), there were no significant changes 
in the number of cells after 72 h of QA incubation when compared to untreated 
cells (Figure 11, 1st bar vs. 9th and 11th). Furthermore, when comparing control 
cell with those treated with both QA and RA, (Figure 11, 1st bar vs. 13th and 15th) 
there were no significant differences in the number of cells. Survival was not 
affected by the concentration of foetal bovine serum in the medium in which RA 
and/or QA was delivered (Figure 11, 5th vs. 7th bar; 9th vs. 11th bar; 13th vs 15th 
bar).  
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When O2•- was removed by supplementing the medium with 300U/ml SOD, there 
was a significant increase in cell viability for the majority of the conditions 
tested. In the previous chapter, it was shown that high concentrations of 
catalase interfered with the FDA readings. Thus to rule out the possibility that 
the effect of SOD observed was an artefact, the FDA assay was performed on 
cell-free plates using solutions of identical composition to the ones used for 
treatments (QA, RA, QA+RA with and without SOD). There were no differences in 
the relative fluorescent emission between either of the tested solutions. 
Compared to untreated controls, a relatively high increase in cell viability was 
noted when SOD was added to cells treated with 10% FBS medium, RA (in 1% and 
10% FBS medium), QA (in 1% and 10% FBS medium) and finally, RA+QA in 10% FBS 
medium (Figure 11, 1st vs. 4th, 6th, 8th, 10th, 12th, 14th and 16th bar).  
Compared to controls, there was a marked and significant increase in the 
viability of cells treated with RA in 10% FBS medium containing SOD. However, 
there were no differences in the viability between cells treated with RA in 10% 
FBS medium and those co-treated with SOD (Figure 11, 7th vs. 8th bar). A 
possibility is that cells in both groups continued to grow, making the net 
differences in viability less pronounced. This is in accordance with several 
reports showing that a high FBS concentration sustains cell growth despite the 
presence of a differentiation-inducing agent. 
Interestingly, when RA+QA+SOD was delivered in 1% FBS medium there were no 
differences in the viability when compared against controls or against the same 
treatments but without SOD (Figure 11, 1st vs. 14th bar; 13th vs 14th bar). This 
may suggest that the joint effect of RA and QA effectively neutralizes the 
proliferative effect of SOD.  
On the other hand, when RA+QA+SOD was delivered in 10% FBS medium, there 
was a significant increase in the viability as compared against controls or against 
the same treatment but without SOD. This may suggest that the proven 
mitogenic effect of a high concentration of FBS in addition to the observed 
proliferative effect of SOD, nullify the joint effect of RA and QA. 
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These initial results suggest that O2•- may directly or indirectly affect the growth 
and/or differentiation of SH-SY5Y cells. To test this hypothesis, the degree of 
differentiation (or acquisition of a neuronal phenotype) was evaluated by 
counting the number of neuritic processes in cells treated with 1% and 10% FBS 
medium containing RA plus QA, with and without SOD. 
4.3.1.3 SOD reduces QA and RA-induced neuritogenesis. 
Three independent experiments were performed to evaluate the cellular 
morphology under the aforementioned conditions. The neurite to soma ratio is 
presented (Figure 12A) along with a set of representative micrographs showing 
the morphological changes and lack of signs of cellular death or damage of 
treated SH-SY5Y cells (Figure 12B). 
Unlike controls, cells treated with 10 µM RA in 1% FBS medium showed a 150% 
increase in the neurite/soma ratio (Figure 12A, 1st vs. 3rd bar). However, cells 
treated with RA in 1% FBS medium containing SOD showed only a 50% increase in 
the neurite/soma ratio when compared to control cells (Figure 12A, 1st and 4th 
bar). When the same drugs were delivered in 10% FBS medium, no differences 
were found in the neurite/soma ratio between treated and untreated controls 
(Figure 12A, 1st and 5th /6th bar). Observations of SH-SY5Y morphology 72 h after 
treatment with 10 µM RA in 1% FBS medium indicated that these cells started to 
acquire a neuronal phenotype with extensive neurite networks (Figure 12B 3rd 
and previously shown in Figure 7, micrograph C and F). 
Similarly, in cells treated with 50 nM QA delivered in 1% FBS, there was an 
increase in the neurite/soma ratio of approximately 150% as compared to control 
cells (Figure 12A, 1st and 7th bar). Furthermore, the changes in morphology 
caused by QA were more pronounced when the treatment was delivered in 
medium containing 1% FBS rather than in 10% FBS medium (Figure 12B, 7th and 
9th micrograph). Whereas cells treated with QA (50 nM) did not exhibit any 
morphological signs of damage, they did suffer other morphological changes such 
as rounding of the cells bodies, increased number of neurites and phase-bright 
cell bodies. This morphology was very similar to the phenotype of cells treated 
with 10 µM RA which is associated with cell differentiation (Figure 12B, 3rd and 
7th micrograph). 
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Figure 12 Inhibitory effect of SOD on QA and RA-induced neuritogenesis. A) Histogram 
indicating the neurite/soma ratio of SH-SY5Y cells counted from micrographs (by triplicate) 
taken 72 h after treatments with RA (10 µM) and/or QA (50 nM) in medium (1% FBS or 10% 
FBS) supplemented with SOD (300 U/ml, white bars). Control wells received 1% FBS 
medium exchanges only. B) Bright-field micrographs corresponding to the aforementioned 
treatments (neurite, arrow; round soma, arrowhead). Results are expressed as percentage 
of the control. Bars represent mean ± SEM. *p<0.05, **p<.0072, ***p<.0006, **** p <0.0001 
Two-way ANOVA followed by Tukey’s test. n=3. Scale bar = 50µm  
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Under these conditions, the addition of SOD reduced the neurite/soma ratio by 
1/3, therefore now at 100% above control levels (Figure 12A, 1st and 8th bar). 
However, when cells were treated with QA, in 10% FBS medium, there was only a 
50% increase in the neurite/soma ratio when compared against controls (Figure 
12A, 1st vs 9th bar). This is in contrast to what was observed for RA, delivered in 
10% FBS, where no changes in the neurite ratio were found. The increase in the 
neurite ratio after QA, in 10% FBS medium, was completely eliminated by the 
addition of SOD (Figure 12A, 10th bar).  
Co-treatment with QA and RA in 1% FBS medium further increased the 
neurite/soma ratio (Figure 12A, 1st vs. 11th bar) regardless of the presence of 
SOD (Figure 12A, 12th bar). However when the same drugs were delivered in 10% 
FBS medium, there were no changes in the neurite/soma ratio (Figure 12A, 1st vs 
13th and 14th bar). In contrast, in cultures where serum was reduced at the time 
of addition of RA QA, a homogeneous population of cells with neuronal 
morphology was obtained. In these cultures, cells showed rounded, phase-bright 
bodies and a profuse neuritic arborisation forming extensive networks over the 
culture dish surface (Figure 12B). 
A correlation analysis between cell viability and the number of neurites was 
performed using the results presented in Figure 11 and Figure 12, respectively. 
However, no significant correlation between these two variables was found 
(p=0.1855). A possibility is that the time point selected (72 h) was too early for 
either proliferation to be completely halted or for terminal differentiation to 
occur. Another possibility is that, under certain circumstances, an increase in 
the number of viable cells results in an increase in the number of neurites and 
vice versa; an ending of proliferation can lead to an increase in the number of 
neurites. 
To gain a better insight into the molecular basis sustaining the morphological 
changes caused by QA, the expression of β3-tubulin and DCX was evaluated. 
Additionally MK-801 was used in order to ascertain whether blocking NMDAR 
activation affects QA-induced differentiation. Taking into account that a low FBS 
concentration is needed for the induction of differentiation, after 3DIV, cells 
were treated with RA, QA, RA+QA in 1% FBS medium. In accordance with 
previous experiments (Figure 8), 72 h after RA treatment there was an increase 
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in the expression of β3-tubulin of approximately 140% above control levels 
(Figure 13A). However, at this time point, RA did not downregulate the 
expression of DCX (Figure 13C). In cells treated for 7 days with RA, the 
expression of β3-tubulin continued to be above control levels but only by 40%, at 
this time point, RA significantly decreased the expression of DCX. 
 
Figure 13 QA increases the levels of Β3-tubulin without decreasing those of doublecortin. 
Western immunoblotting and quantification analyses of β3-tubulin (A, B), Doublecortin (C, 
D) after 3 and 7 day treatments with QA (50 nM), RA (10 µM), MK-801 (400 nM) in 1% FBS 
medium. Bars represent mean ± SEM in arbitrary units of optical density (OD). GAPDH was 
used as a house-keeping protein and results were normalised to the control. *p<0.05, 
**p<0.005, ****p <0.0001. One-way ANOVA followed by Dunnett’s test. n=4. 
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The addition of MK-801 had no effect on QA-induced neuritogenesis or DCX 
expression at any of the time points evaluated.  
Similarly, treatment with QA for 72 h and 7 days caused a significant increase in 
the expression of β3-tubulin, comparable to the levels obtained with RA. 
However, the expression of DCX was not affected at either of the time points 
evaluated (Figure 13). There are several possibilities as to why QA did not 
reduce proliferation (viability and DCX): a) in SH-SY5Y cells, the expression of 
β3-tubulin could perhaps be independent of the cell cycle phase, which would 
allow QA to induce neuritogenesis without leading to terminal differentiation, b) 
There are different subpopulations within the SH-SY5Y cell line with different 
responsiveness to QA-induced differentiation. 
Whereas RA alone reduced the expression of DCX, the co-application of RA+QA 
did not reduce the expression of DCX at either 72 h or 7 days. A possibility is 
that the process by which QA induces neuritogenesis interferes with RA-induced 
differentiation or alternatively QA promotes cell growth in a specific SH-SY5Y 
subpopulation. 
4.3.1.4  QA causes an early and transient increase in the level of ROS 
Given that the presence of SOD caused an increase in the viability for all of the 
conditions tested (except for RA+QA in 1% FBS medium) as well as a decrease in 
the neurite/soma ratio for all of the tested conditions, it was decided to further 
study the involvement of ROS in these processes. To evaluate if QA had an effect 
on the level of ROS, the DHE assay was used (see chapter 2.4). For this set of 
experiments, cells were treated with two concentrations of QA (50 nM and 300 
nM) alone or in combination with 10 µM RA. All treatments were delivered in 1% 
FBS with and without 300 U/ml of SOD.  
For all experiments the xanthine (Xa)/xanthine oxidase (XO) system was used as 
a positive control of O2•- production as previously described by Schuck (2007a). 
Briefly, 2 hours before the DHE assay was started, the medium was changed with 
one containing 100 µM Xa. Cells were left in this medium for 1 hour before 
adding 0.05 U/ml of XO to the cells. Cells were incubated for an additional hour 
after which the ethidium fluorescence was analysed using a microplate reader. 
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Xa/XO treatment significantly increased ROS production in all of the 
experiments (Figure 14A, C, D; 13th bar). The addition of SOD effectively 
decreased the levels of O2•- produced by Xa/XO (Figure 14 A, C, D; 14th bar)  
 
Figure 14- QA promotes the early formation of ROS in SH-SY5Y cells. Time course 
evaluation of ROS production in undifferentiated SH-SY5Y cells measured by ethidium 
fluorescence on a micro-plate reader 24 (A), 48 (C) and 72 h (D) after treatment with QA (50 
or 300 nM) and/or RA (10 µM) with and without SOD (300 U/ml), Control wells received 
medium exchanges only. Xanthine (50 µM) Xanthine oxidase (0.05 U/ml) served as a positive 
control. b) DHE fluorescence and corresponding bright field micrographs of SH-SY5Y 
cultures photographed 24 h after incubation with QA and/or RA. Results are expressed as 
percentage of control. Bar graphs represent mean ± SEM. *p<0.05, **p<.0072, ***p<.0006, **** 
p <0.0001. Two-way ANOVA followed by Tukey’s test, n=5(A), n=8(C), n=6 (D). Scale bar = 50 
µm. 
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24 h after QA treatment, there was a significant increase in the levels of ROS 
when compared to control cells (Figure 14A, 1st vs 7th column). This effect can 
also be observed in the corresponding micrographs as bright red fluorescence in 
the nucleus of the cells (Figure 14B). The increase in ROS was not so clearly 
reflected in the micrographs for the 10 µM RA in 1% FBS treatments, yet when 
the experiments were performed using a micro-plate reader, a peak of ROS was 
observed at 24 hours for both conditions. No significant changes in the levels of 
ROS were found 48 or 72 h after treatment (Figure 14C, D). 
Co-applying SOD with RA and QA, alone or in combination, significantly 
decreased the levels of ROS 24 h after treatment. This effect was more 
pronounced in cells treated with 50 nM QA than in those treated with 300 nM QA, 
which indicates that small fluctuations in the concentration of QA had a big 
impact on the oxidant state of the cell. When cells were treated with 300 nM 
QA, SOD was unable to significantly decrease the concentration of ROS. 
A significant (p=0.0041) positive correlation (r=0.6845) was found between the 
number of neurites and the amount of ROS produced 24 h after QA. Conversely, 
a significant (p= 0.0062) negative (r= -0.4735) correlation was found between 
the number of cells and the levels of ROS for all tested conditions, further 
strengthening the prospective role of ROS in the regulation of proliferation and 
neuritogenesis in SH-SY5Y cells.  
4.3.1.5  NMDA does not affect the survival or neuritogenesis of SH-SY5Y 
cells.  
The effect of NMDA on differentiated and undifferentiated SH-SY5Y cells was 
studied in order to establish whether there were similarities as to the effect of 
QA on the cultures. The initial hypothesis was that if NMDA could elicit the same 
cellular response as QA treatment, then perhaps QA could be acting on the 
NMDAR. SH-SY5Y cells were grown for 72 h in 10% FBS after which they were 
treated with different concentrations of NMDA (50 µM, 100 µM, 500 µM, 1mM, 
2mM, 5mM, 10 mM,) delivered in 10% FBS medium. Alternatively cultures were 
differentiated for 7 days with 10 µM RA before treating them with NMDA (50 µM, 
100 µM, 500 µM, 1mM, 2mM, 5mM, 10 mM,) in 1% FBS medium. For all 
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experiments, the viability and morphology were analysed on the 3rd day after 
treatment. 
 
Figure 15- NMDA does not induce cell death in SH-SY5Y cells. A, B) Histogram and 
micrographs showing the viability and morphology of undifferentiated control cells 
(untreated) and cells treated with the indicated concentrations of NMDA for 72 h in 10% FBS 
medium. C, D) Histogram and micrograph showing the viability and morphology of cells 
previously differentiated with RA for 7 days and then treated with fresh 1% FBS medium 
containing the indicated concentrations of NMDA for 72 h. Results are expressed as a 
percentage of the RFE with respect to control. Bars represent mean ± SEM. One-way 
ANOVA followed by Dunnett’s test, no significant differences were found. n=3 (A). n=4 (C). 
Scale bar= 100 µm 
In these experiments, NMDA did not cause a significant decrease in cell viability 
(Figure 10 and Figure 15). However, in some experiments there seemed to be a 
slight decrease in the viability of cells (approximately 20%). It was expected that 
NMDA would be a more potent inducer of cell death than QA since QA is a weak 
NMDAR agonist.  
There were no evident morphological signs of damage in cells treated with NMDA 
for three days. However, in all of the micrographs of undifferentiated cells 
treated with NMDA, some dead cells can be observed (dark round bodies) which 
could represent a small fraction of the cell population that is susceptible to 
NMDA toxicity (Figure 15B) or, more likely, it represents the normal fraction of 
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cells that die in growing cultures. These micrographs show that there are fewer 
cells in the differentiated state when compared to the undifferentiated ones, 
yet, there were no marked differences in the viability between these two groups 
(Figure 15). Therefore, the difference in the number of cells is not caused by 
NMDA treatment but rather by 7 days of RA-induced differentiation which ends 
proliferation.  
4.3.1.6 Kynurenic acid (KA) does not affect cell survival 
It has been reported that KA, an NMDA antagonist, reduces the proliferation of 
certain cancerous cells (Walczak et al., 2012; Walczak et al., 2014). For this 
reason, and in order to further characterise the lack of toxicity of QA and NMDA 
as well as the lack of effect of MK-801, undifferentiated cells were treated with 
different concentrations (1 µM, 10 µM, 100 µM, 500 µM, 1 mM, 5 mM, 10 mM) of 
KA delivered in 1 and 10% FBS. 
 
Figure 16 Lack of effect of KA on the survival of SH-SY5Y cells. Undifferentiated cells were 
treated for 72 h with KA (1µM-10 mM) in 10% and 1% FBS medium. Results are expressed as 
percentage of control RFE. Bars represent mean ± SEM. No statistical differences were 
found with one-way ANOVA followed by Dunnett’s test. n=8. 
The assessment of SH-SY5Y treated with KA did not show any significant changes 
in the viability of cells at either of the tested concentration. Furthermore, when 
cells were observed under the microscope, there were no evident differences in 
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any of the parameters of interest (toxicity, neurite number and length) between 
control and treated cells. 
4.3.1.7 GluN1 expression was not detected in SH-SY5Y cells 
An antibody against all the isoforms of the GluN1 subunit (predicted to react in 
human, rats and mice) was used for western blotting, yet no expression could be 
detected on SH-SY5Y cells at either 72 h or 7 days, regardless of the given 
differentiation stimuli. The positive control for these experiments was rat brain 
homogenate and this band could be easily quantified. The lack of NMDAR 
explains the low toxicity of both NMDA and QA. It also explains why MK-801 and 
KA had no effect on the cultures. 
 
Figure 17. Western blotting showing the lack of GluN 1 expression in SH-SY5Y cells. Cells 
were incubated for 3 (A) and 7 (B) days in 10% FBS medium (Lane 7, red box) or induced to 
differentiate with RA (10 µM) in 1% FBS medium (Lane 2, red box). Cells were also treated 
with QA (50 nM), RA plus QA, NGF (50 ng/ml), NGF plus RA, nicotinamide (Nam; 100 µM), 
MK-801 (400 nM), QA plus MK-801 and RA plus MK-801 for the indicated durations. Rat’s 
whole brain homogenate (B.H.) was used as a positive control. Actin was used as a loading 
control. 
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4.3.1.8 Nam increases the number of neurites in a dose-dependent manner 
Cells were treated with nicotinamide (Nam; 100 nM, 1µM, 100 µM, 1mM) in 1% 
FBS medium for 72 h. After treatment, cells were photographed and the 
expression of neuronal markers assessed. A total of 4 experiments were used for 
the western blot analysis.  
 
Figure 18. Nicotinamide increases the number of neurites and the expression of β3-tubulin 
in SH-SY5Y cells. Cells were treated with nicotinamide (Nam; 100 nM, 1 µM, 100 µM and 1 
mM) delivered in 1% FBS medium for 72 h, after which the neurite/soma ratio was 
established (A). Control cells received 1% FBS medium exchanges only. Results are 
expressed as percentage of the control, bars represent mean ± SEM. **** P<0.0001 vs. 
control One-way ANOVA followed by Dunnett’s test. n=3. B) Corresponding micrographs of 
the aforementioned treatments. Bar 50 µm. C) Representative blots and quantification of β3-
tubulin from cells exposed to the same Nam treatment. Bars represent mean ± SEM in 
arbitrary units of optical density (OD). Actin was used as a house-keeping protein and 
results were normalised to the control. **p<0.0038, ***p<0.0008, ****p <0.0001. One-way 
ANOVA followed by Dunnett’s test. n=4. 
Nam, another precursor of NAD+ besides QA, mimicked the neuritogenesis 
observed after QA treatment as evidenced by an increase in the neurite/soma 
ratio (Figure 18A). The micrographs of SH-SY5Y cells clearly show that there is 
an increase in the number of neurites as well as a reduction in the number of 
cells after Nam treatment (Figure 18B). This morphology is consistent with the 
phenotype adopted by SH-SY5Y cells after differentiation is induced. 
Furthermore, 72 h after treatment, Nam increased the overall expression of the 
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neuronal marker β3-tubulin. The neurite outgrowth assay confirmed that Nam 
promotes neurite extension (Figure 18C). 
Based on these results, two Nam concentrations (100 µM and 1mM) were 
selected to be delivered in 1% FBS medium and used in the experiments 
evaluating neurite projection by means of the neurite outgrowth kit. A total of 6 
samples belonging to 3 different experiments were used for this purpose (section 
4.3.1.9, Figure 19C). 
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4.3.1.9 Neurite Outgrowth assay and DPI inhibition of neuritogenesis 
The neurite/soma ratio method. previously used as an indicator of cell 
differentiation, tends to underestimate the total content of neurites present in 
culture as it only takes into account the number of neurites that exceed a given 
length and ignores the differences that may exist in networks with a different 
architecture. For example, branched neurites with several branch points and 
neurite bifurcations tend to be severely underestimated. Conversely, the 
neurite/soma ratio tends to overestimate the neurite extension of cells in which 
elongation, rather than neuritogenesis, occurs. To overcome this limitation, it 
was decided to use a neurite outgrowth assay-kit that effectively quantifies the 
total content of neurite mass, as previously described in the methods’ section 
(section 2.3). 
 
Figure 19. Inhibitory effect of DPI (but not MK-801) on QA-induced neuritogenesis. The 
neurite outgrowth assay was performed 72 h after treating the SH-SY5Y cells with: A) RA (10 
µM), QA (50, 100 and 150 nM), and MK-801 (400 nM); B) RA+QA (50nM), and QA (50nM) + Mk-
801 (400nM); C) RA, QA (50nM), QA (150nM) + DPI (1 µM) and nicotinamide (Nam; 100 µM 
and 1 mM). All drugs were delivered in 1% FBS medium, thus, sham controls were also 
switched 1% FBS medium. Results are expressed as percentage of controls. Bars represent 
mean ±SEM in arbitrary units of optical density (OD). *P < 0.022, **P < 0.004, ****P < 0.0001 
One-way ANOVA followed by Dunnett’s test. n=3 for A, B and C. 
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Similarly, in order to corroborate that the mechanism of action of QA is not 
through NMDAR activation, cells were treated with 50 nM QA alone or in 
combination with 400 nM MK-801, delivered in 1% FBS medium. The untreated 
control for this set of experiments received 1% FBS medium exchanges only and 
the positive control of differentiation selected was 10 µM RA.  
In accordance with previous experiments, treatment with RA alone or in 
combination with QA caused an increase in neurite mass. Treatment with MK-801 
on its own did not have a negative effect on cells. Interestingly, the degree of 
neurite extension never exceeded 50% above control levels (Figure 19A). In 
contrast to what had been previously shown to occur using the neurite/soma 
ratio, the degree of neurite extension induced by QA alone (or in combination 
with RA) was not of a higher magnitude than that of RA alone (Figure 19A and 
Figure 12A). Similarly, the estimate of neuritogenesis obtained by Western 
blotting quantification of β3-tubulin (Figure 13) was much higher than the one 
obtained using the neurite outgrowth assay. This could be partly due to the fact 
that the Western blot analysis yields the total amount of β3-tubulin present (in 
both soma and neurites) whereas the neurite outgrowth assay quantifies only the 
amount of the neuritic fraction. 
 Figure 19B presents the dose-dependent increase in neurite mass after QA 
treatment as well as the lack of effect of MK-801 on QA-induced neuritogenesis. 
The effect of DPI (a NOX) on QA-induced neuritogenesis was assessed. DPI 
treatment on its own had no significant effect on the cells but in contrast to 
NMDAR antagonists, DPI significantly reduced the neurite extension of cells 
treated with QA (Figure 19C). In accordance with previous experiments, 
nicotinamide (100 µM and 1 mM) caused a significant increase in neurite mass. 
4.3.1.10 QA increases NRF2 expression 
Preliminary results showed that the expression of the NRF2 was markedly 
enhanced 12 h after treatment with RA (10 µM). The increase in the expression 
of NRF2 using different doses of QA (50, 100, 150 nM) seemed to be dose-
dependent. The expression of NRF2 did not seem to be affected by NGF (50 
ng/ml) treatment (Figure 20). 
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Figure 20 QA increases the expression of NRF2 in SH-SY5Y cells. Western blot and 
quantification analysis of undifferentiated control cells (untreated) and cells treated with QA 
(50, 100, 150 nM), RA (10 μM) or NGF (50 ng/ml) for 12 hours. Controls received 1% FBS 
medium exchanges only. Bars represent mean ± SD (n=2) in arbitrary units of optical 
density (OD). GAPDH was used as a house-keeping protein and results were normalised to 
the control.  
The number of experiments should have been increased in order to confirm that 
the results are significant. However, for data with a normal distribution, 
approximately 95% of the samples will have values within 2 standard deviations 
of the mean. Therefore, given the small dispersion from the mean (standard 
deviation) of the data presented, it is expected that future experiments will fall 
within similar values, not majorly changing the interpretation of these results. 
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4.3.2 Effect of 3-HAA on SH-SY5Y survival and neuritogenesis 
4.3.2.1 3-HAA induces cell death in SH-SY5Y cells 
In order to establish if 3-HAA had a detrimental effect on cell survival, 
undifferentiated SH-SY5Y cells were fed with 10% FBS medium (control) or 
treated with increasing concentrations of 3-HAA (1µM, 10 µM, 50 µM, 100 µM, 
500 µMµM, 1 mM 10 mM) for 48 h or and 72 h, after which the viability was 
assessed by FDA and a dose-response curve was plotted (Figure 21A, B). 
 
Figure 21. Cellular death is induced by 3-HAA in SH-SY5Y cells. A Fitted Log(inhibitor) vs 
normalised response curve is displayed for cells incubated for either 48 h (A) or 72 h (B) 
with 3-HAA delivered in 10% FBS after which the toxicity was evaluated by FDA. IC50 values 
were obtained by non-linear regression analysis (Dose-response inhibition; Prism Graphpad 
v. 6.0f. The average IC50 are listed in each graph and are summarized in Table 4. For graph 
(C) results are expressed as percentage of control RFE. Bars represent mean ± SEM for 3 
different experiments (n=3). **p<0.004, ***p<0.0005, ****p <0.0001. One-way ANOVA followed 
by Dunnett’s test. D) 72 h after treatment cells were photographed without fixing using a 
phase-contrast microscope (Bar=100 µM). 
No signs of cellular death could be observed 24 h after treatment with 3-HAA. 
However 48 h after treatment, 3-HAA in 10% FBS caused a dose-dependent 
decrease in the viability of cells. It became immediately clear that 3-HAA 
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induced cell death and not neuritogenesis or differentiation, as it had been the 
case for QA and RA, respectively. 
The IC50 value for 3-HAA, delivered in 10 % FBS medium, was calculated by a 
non-linear regression analysis of the toxicity-concentration curve, obtaining a 
value of 132.9 ± 15.55 μM and 138.2 ± 16.74 μM after 48 h and 72 h of exposure, 
respectively (Table 4). No significant changes in the IC50 values were found 
between cells exposed for 48 h and those exposed for 72 h. Thus, the latter time 
point was selected to assess the viability and the IC50 values in subsequent 
experiments.  
SOD has been shown to protect against the toxic effects caused by ROS 
production in several models, therefore a first approximation was conducted to 
determine the mechanism through which 3-HAA induced toxicity: its aim was to 
co-apply SOD and evaluate whether it exerted any protection. Surprisingly, the 
addition of SOD caused a shift in the IC50 value for 3-HAA delivered in 10% FBS 
medium. The IC50 value for 3-HAA + SOD, delivered in 10 % FBS, decreased to 
81.87 ± 15.55 μM after 72 h exposure, which suggested that the combined 
treatment with 3-HAA and SOD was more toxic to the cells (Table 4). This can be 
clearly observed in Figure 25, in both the histogram graphs for day 2 and 3 (A, B) 
and in the presented micrographs (C). 
 
Table 4. SOD causes a shift in the IC50 values for 3-HAA treatment. A one-way ANOVA 
followed by Sidak's test was used to compare the difference of the IC50 values between 48 h 
and 72 h exposure to 3-HAA. Pooled data from dose-response curves, generated from the 
different responses to 3-HAA in the presence of 1% and 10% FBS with and without SOD. 
Shown in Figure 22. SOD shifted the 3-HAA concentration–response curves to the left with 
and with highly similar slopes. 
Similarly, an assessment of cell viability was performed 48 h and 72 h after 
exposure to 3-HAA ± SOD but this time treatments were delivered in 1% FBS 
medium. The concentration of FBS did not have a significant effect on the 
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toxicity of 3-HAA. The IC50 for 3-HAA delivered in 1% had a value of 150.1 ± 17.7 
(Table 4).  
Interestingly, the co-treatments with 3-HAA and SOD delivered in 1% FBS 
medium, increased the toxicity caused by all previous 3-HAA concentrations 
delivered in 1% FBS. The addition of SOD caused a significant reduction 
(p<0.0001) of the IC50 (69.01± 4.33 µM) value for the 3-day exposure to 3-HAA in 
1% FBS medium (Table 4). 
 
Figure 22 The IC50 of 3-HAA is reduced when co-applied with SOD.  Effect of single 3-HAA 
treatment delivered in 1 and 10% FBS medium supplemented with SOD (300 U/ml) on cell 
viability after 48 h and 72 exposure. A Fitted Log(inhibitor) vs normalised response curve is 
displayed for cells incubated for either 48 h (A, B) or 72 h (C,D) with 3-HAA delivered in 
10%(A, C) and 1% (B, D) FBS medium supplemented with SOD (Solid Blue and Green lines) 
after which the toxicity was evaluated by FDA. IC50 values were obtained by non-linear 
regression analysis (Dose-response inhibition; Prism Graphpad v. 6.0f. The average IC50 
are listed in each graph and are summarized in Table 4. 
Observations of SH-SY5Y morphology after 72h exposure to 3-HAA provided 
confirmation of the viability assay findings. A clear relationship could be 
observed between the concentration of 3-HAA and the reduction in the number 
of cells per optic field. The appearance of opaque spots in the micrographs are 
an indication that dead cells are present in the cultures (Figure 21D). The lowest 
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3-HAA dose to cause a significant decrease in the viability was 50 µM (Figure 
21C). However, morphologically, signs of damage were more obvious when cells 
were treated with 100 µM. At this concentration, there were more detached 
cells as well as cellular debris. The following concentration used (500 µM) 
completely obliterated the cell population and only cellular debris could be 
observed on the plates (Figure 21D). 
4.3.2.2 SOD increases the levels of ROS in cells treated with 3-HAA  
To better understand the mechanism through which SOD (300 U/ml) interacts 
with 3-HAA (10 µM-100 µM) to generate damage, the level of ROS in cultures was 
studied using the DHE assay. The presence of ROS was determined in cells 
treated with 3-HAA delivered in 1% FBS (Figure 24) and 10% FBS (Figure 23) 
containing medium. 
 
Figure 23. SOD exacerbates the production of ROS induced by single 3-HAA treatment. 
Evaluation of ROS production in undifferentiated SH-SY5Y cells assessed by ethidium 
fluorescence 24 h after treatment with 3-HAA (10 µM, 50 µM and 100 µM) in 10% FBS 
medium supplemented with SOD (300 U/ml). Control wells received 10% FBS medium 
exchanges only. DHE fluorescence and corresponding bright field micrographs taken 24 h 
after incubation with the aforementioned treatments in 10% FBS medium with or without 
SOD. Scale bar = 100 µm. 
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Figure 24. SOD exacerbates the production of ROS induced by single 3-HAA treatment 
Evaluation of ROS production in undifferentiated SH-SY5Y cells assessed by ethidium 
fluorescence 24 h after treatment with 3-HAA (10 µM, 50 µM and 100 µM) in 1% FBS medium 
supplemented with SOD (300 U/ml). Control wells received 1% FBS medium exchanges only. 
DHE fluorescence and corresponding bright field micrographs taken 24 h after incubation 
with the aforementioned treatments in 1% FBS medium with or without SOD. Scale bar = 100 
µm. 
3-HAA treatment caused an increase in the levels of ROS (Figure 24). When cells 
were treated with 3-HAA and 300 U/ml SOD, there was a marked increase in the 
DHE fluorescence indicating that the production of ROS is exacerbated by co-
applying 3-HAA. SOD and 3-HAA increased ROS production in both 1% and 10% 
FBS medium (Figure 23). These results, however, do not provide evidence as to 
the identity of the ROS involved but do confirm that there is an increase in the 
levels of ROS following 3-HAA treatments. This condition was intensified by the 
addition of SOD. 
4.3.2.3 Catalase prevents the death of SH-SY5Y induced by 3-HAA+SOD 
Due to the upsurge of cellular death and ROS production when 3-HAA was co-
applied with SOD, it was initially expected that 3-HAA could be increasing the 
levels of O2•- and that the addition of SOD, by dismutating it, could be increasing 
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the levels of H2O2. To test this hypothesis, cells were treated on day 0 with 3-
HAA (100 µM) alone or in combination with catalase (CAT; 1000U/ml) in either 
1% or 10% FBS medium with and without SOD (300 U/ml), obtaining the following 
combination of treatments: 
•100 µM 3-HAA 10% FBS   •100 µM 3-HAA 1% FBS 
•100 µM 3-HAA+CAT 10% FBS  •100 µM 3-HAA+CAT 1% FBS 
•100 µM 3-HAA+SOD 10% FBS  •100 µM 3-HAA+SOD 1% FBS 
•100 µM 3-HAA+CAT+SOD 10% FBS •100 µM 3-HAA+CAT+SOD 1% FBS 
 
Viability was assessed by FDA 48 h and 72 h after treatments and a total of 3 
independent experiments were carried out, using fresh solutions prepared each 
time. 
48 h and 72 h exposure to 100 µM 3-HAA in 10% FBS medium caused a ≈20% 
reduction in the viability when compared to untreated controls which was 
prevented by CAT only in cells exposed for 48 h but not in those exposed for 72 
h. In cells treated with 100 µM 3-HAA+SOD 10% FBS there was a further decrease 
in the viability (80%) when compared to control cells; the addition of catalase 
completely averted SOD-induced death (Figure 25A, B). 
A similar reduction in cell viability (≈20%) was observed in cells exposed for 48 h 
and 72 h to 100 µM 3-HAA 1% FBS. Under these conditions, CAT protected cells 
exposed for 48 h as well as those exposed for 72 h to 3-HAA (Figure 25A, B) 
which may indicate that whereas the concentration of FBS in the medium does 
not affect the IC50 of 3-HAA (Table 4), it does affect the mechanism by which 
cells die.  
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Figure 25. Catalase protects against the exacerbated toxicity of combined treatment with 3-
HAA and SOD. Cells were treated for 48 h (A) or 72 h (B) with 3-HAA (100 µM) in 1% and 10% 
FBS medium supplemented with SOD (300 U/ml) alone or in combination with CAT (100 
U/ml). Control wells received medium exchanges only. C) Corresponding bright field 
micrographs of SH-SY5Y cultures photographed 72 h after the aforementioned treatments. 
Results are expressed as percentage of control. Bars represent mean ± SEM. **P<0.0078, 
***P<0.0003, **** P<0.0001 Two-way ANOVA followed by Tukey’s test. n=3. Scale bar = 100 
µm. 
The toxicity results, obtained by FDA and previously described, are in 
accordance to the morphology of cells exposed to the different combinations of 
3-HAA treatments. In the micrographs presented, it is clearly observed that 100 
µM 3-HAA causes cell death, as evidenced by the presence of dark spots. 
Similarly, in wells treated with 100 µM 3-HAA+SOD, all cells have completely 
detached from the plates (Figure 25C). 
4.3.2.4  3-HAA affects RA-induced differentiation in SH-SY5Y cells  
Some cultures were specifically plated to be photographed under a bright field 
microscope at day 1, 2 and 3. Using these micrographs, a corresponding neurite 
count was performed.  
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The same methodology used to assess neuritogenesis in QA-treated cells was 
applied to cell treated with 3-HAA. However, the neurite/soma ratio did not 
reflect the cellular processes that were taking place. In some cases, neurites 
remained attached to the culture plates despite the large number of dead cells 
present. This could be wrongly misinterpreted as an increase in neuritogenesis. 
For this reason, the data from the neurite/soma ratios is presented in section 
6.3 of the appendix (Figure 32 and Figure 33). Instead, the expression of NeuN 
(post-mitotic neuronal marker) is presented below in which a clear dose-
dependent effect can be observed. 
 
Figure 26. Effect of a single 3-HAA treatment delivered in 1% FBS medium on the 
expression of NeuN 72 h after treatment. Immunocytochemistry was performed 72 h after 
SH-SY5Y cells were treated with various concentrations of 3-HAA (10 µM, 50 µM and 100 µM) 
in 10% FBS medium alone, or in combination with 10 µM RA. 
In these experiments cells were treated once at day 0 with 1% FBS (Figure 26) or 
10% FBS (Figure 27) medium alone (control), or either one of those 
supplemented with 3-HAA (10 µM, 50 µM and 100 µM) or RA (10 µM). The cultures 
were incubated under these conditions for 72 h. 
As expected, the FBS concentration in the medium affected the degree of 
differentiation of the cells. The expression of NeuN was reduced when the 
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medium used had a higher concentration of FBS (10%). The higher the 
concentration of 3-HAA used, the less expression of NeuN was found. 
 
Figure 27- Effect of a single 3-HAA treatment delivered in 10% FBS medium on the 
expression of NeuN, 72 h after treatment. 
Immunocytochemistry was performed 72 h after SH-SY5Y cells were treated with various 
concentrations of 3-HAA (10 µM, 50 µM and 100 µM) in 1% FBS medium alone, or in 
combination with 10 µM RA. 
4.3.2.5 SH-SY5Y cells recover from a single 3-HAA treatment 
It has been widely reported that differentiation alters the way SH-SY5Y cells 
respond to toxic insults (Cecchi et al., 2008; Cheung et al., 2009; Xie et al., 
2010; Schneider et al., 2011). Therefore it was decided to evaluate whether 
there were differences in the toxicity of 3-HAA between differentiated and 
undifferentiated SH-SY5Y cells. All the results presented in this section originate 
from experiments in which a single 3-HAA treatment was applied on day 0 and 
the viability assessed 72h and 7 days after the initial treatment. 
After 3DIV, undifferentiated SH-SY5Y cells growing in 10% FBS medium were 
treated with 10% FBS medium alone (control) or medium containing different 
concentrations of 3-HAA (1µM-10 mM). After an additional 72 h or 7 days, phase-
contrast micrographs were taken and the viability assessed. The cultures that 
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had been growing for 7 days were fed on the 3rd day with 10% FBS medium 
without 3-HAA. This was done to study whether cells were able to recover from 
the initial treatment. A total of 3 independent experiments were carried out, 
using fresh solutions prepared each time. 
Another set of experiments studied whether RA-induced differentiation had an 
effect on the cell’s susceptibility to damage and recovery following exposure to 
3-HAA. For these experiments, cells were differentiated for 7 days with RA and 
then transferred to medium containing 1% FBS alone (control) or the same 
medium containing 3-HAA (1µM-10 mM) and incubated for either 72 h or 7 days 
before viability was assessed. Similarly, cells that were incubated for 7 days 
were fed on the 3rd day with 1% FBS medium alone. A total of 3 independent 
experiments were carried out, using fresh solutions each time 
 
Figure 28- Viability recovery from single 3-HAA treatment. The viability of differentiated and 
undifferentiated cells treated for 3 or 7 days with 3-HAA. Undifferentiated cells treated with 
fresh 10% FBS medium alone (control) or in combination with 3-HAA (1µM-10 mM) for 72 h 
(black bars) or 7 days (dark grey bars). Differentiated cells switched to 1% FBS medium 
alone (control) or in combination with 3-HAA (1µM-10 mM) for 72 h (white bars) or 7 days 
(light grey bars). Results are expressed as percentage of control. Mean ± S.E.M. for 5 
different experiments. *P<0.0001 vs. control, *P<0.0001 vs. 7 days undifferentiated. 
*P<0.0001 vs. 7 days differentiated. 
When cells were treated with 3-HAA either in the differentiated or 
undifferentiated state there were no apparent changes in toxicity susceptibility 
at the highest dose used. 10 mM 3-HAA was lethal in both states (Figure 28). 
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When differentiated and undifferentiated cells were treated with 500 µM and 
1mM 3-HAA for 72 h, no metabolic activity was detected by the FDA assay. 
However, when the assessment was performed 7 days after the initial and only 
treatment, there was a 20% increase in the viability (Figure 28). This shows that 
the few cells that survive the initial 3-HAA treatment slowly manage to 
repopulate the dishes. 
As expected, the undifferentiated cells showed a faster rate at repopulating the 
dishes than the differentiated cells (dark grey bar compared to light grey bar). 
The fact that cells, that had been differentiated for 7 days with RA, manage to 
grow again indicates that 10 µM RA and 1% FBS need to be constantly present to 
avoid de-differentiation. 
Another interesting observation is that, in the group of cells that had been 
differentiated for 7 days, low doses of 3-HAA which previously had been 
innocuous (1µM and 10 µM) to the cells, now successfully caused a 20% decrease 
in viability when assessed 72 h after treatment (Figure 28, white bars). This 
effect was no longer noticeable when assessed 7 days after treatment (light grey 
bars) which once again indicates that even though cells had been differentiated 
for 7 days, they can continue to grow if given enough time without RA.  
It is important to note that the ability of differentiated cultures to repopulate 
the petri dish following 3-HAA treatment is more pronounced in cells treated 
with 10% FBS containing medium than those treated with 1% FBS medium. This 
can be seen more clearly when comparing the 100 µM concentration (Figure 28). 
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4.3.2.6 HPLC quantification of 3-HAA in medium of cultures and cell-free 
preparation (Samples were processed by Dr. Alexandra Ferguson) 
The recovery results presented above suggested that that 3-HAA was being 
broken down within the first 3 days after treatments as recovery successfully 
occurred between day 3 and day 7. Similarly these results indicate that the 
addition of SOD increased the toxicity of 3-HAA probably by increasing H2O2 
production as catalase afforded total protection. In view of all presented thus 
far, it was hypothesised that SOD could be promoting the autoxidation of 3-HAA 
, as per descriptions in section 1.3.3.2). To test this hypothesis, the 
concentration of 3-HAA was measured by HPLC. Four time points were chosen; 
day 0, day 1, day 2 and day 3.  
 
Figure 29- Concentration of 3-HAA in cultures and cell-free preparation determined by 
HPLC. The samples were obtained as described previously in section 2.11.1.1 processed 
and analysed by Dr Alexandra Ferguson (see Appendix). 
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The HPLC analysis shows that 3-HAA with the addition of SOD did promote the 
breakdown of 3-HAA in both cell-free preparations as well as in cultures. 
Additionally, it can be observed that 3-HAA breaks down slightly faster in 10% 
FBS medium than in 1% FBS medium in accordance with the cellular viability 
results, which points to the induction of different mechanisms of death (yet not 
overall toxicity) depending on the serum concentration used to deliver 3-HAA. 
Contrary to what was expected, 3-HAA was degraded faster in cell-free 
preparations than in the presence of cells. This could be due to many factors 
including O2 availability, pH levels, metabolic activity, etc. Based on these 
results, a non-linear regression was performed from which the half-life of 3-HAA 
(100 µM) was determined: 
 
Table 5. Half-life values for 3-HAA in cell-free preparations and in cell cultures. Data 
obtained by non-linear regression (One phase decay, Prism Graphpad v. 6.0f), from the 
HPLC analysis of the concentrations of 3-HAA in 1% and 10% FBS with and without SOD. 
An important observation resulting from this data is that the greater part of 3-
HAA decay occurs within the first 24 h after treatment which explains why the 
toxicity did not increase in cells exposed for longer periods of time. The 
presence of SOD increased the breakdown rate of 3-HAA; from the HPLC 
analysis, it can be inferred that this process occurs within minutes. Since the 
experiment was not designed to evaluate short time points, a non-linear 
regression could not be applied to evaluate the decay rate. A different setting 
would have been required to evaluate 3-HAA breakdown in real time. 
Nevertheless, it became evident that the cellular death observed in cells treated 
with 3-HAA and SOD is not directly caused by 3-HAA but by a product(s) of its 
degradation.  
4.3.2.7 SH-SY5Y cell viability after daily 3-HAA treatment for 72 h 
Taking into account the HPLC results showing that 3-HAA breakdown occurs 
within the first 24 h after treatment, it was decided to examine the effect of 
daily 3-HAA treatments on the survival of undifferentiated SH-SY5Y cells. In 
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order to ensure the frequent replenishment of 3-HAA, cells were treated on day 
0, 1 and 2 with 10% FBS medium (control) or with increasing concentrations of 3-
HAA (1µM, 10 µM, 50 µM, 100 µM, 500 µM, 1 mM 10 mM). Cells were then 
incubated for an additional 24 h after the initial treatment, at which point the 
viability was assessed by FDA and a dose-response curve was plotted. Thereby 
cells, in which the viability was evaluated at day 2 (Figure 30), received two 
treatments (first on day 0 and then again 24 h afterwards) and cells assessed at 
day 3 (Figure 31) received 3 treatments (first on day 0, then 24 h after that, and 
finally 48 h after the initial treatment). 
In contrast to the effect observed with a single treatment of 3-HAA, the addition 
of fresh drugs on a daily basis further reduced the IC50 for 3-HAA-treated cells. 
There were no differences in the effect of the drugs regardless of the medium in 
which they were delivered. Since damage levels had increased, all the other 
subtle differences caused by the concentration of FBS in the medium were no 
longer noticeable. 
 
Table 6. Daily treatments cause a shift in the IC50 values for 3-HAA. One-way ANOVA 
followed bySidak's test was used to compare the difference of the IC50 values between 48 h 
and 72 h exposure to daily 3-HAA treatments. Pooled data from dose-response curves, 
generated from the different responses to daily 3-HAA treatments in the presence of 1% and 
10% FBS with and without SOD. Shown in Figure 30 and Figure 31. *p<0.0189. 
A one-way ANOVA was used to test the difference among IC50 values from single 
and daily 3-HAA treatments (Table 6). The IC50 of 3-HAA daily treatments 
delivered in 10% FBS medium (82 µM) was significantly different (p=0.0424) than 
the IC50 of a single 3-HAA treatment delivered in 10% FBS medium (138.2 µM). 
Similarly, the IC50 of 3-HAA+SOD daily treatments delivered in 10% FBS medium 
(38.76 µM) was significantly different (p=0.0016) than the IC50 of a single 3-
HAA+SOD treatment delivered in 10% FBS medium (81.87 µM).  
This was also the case for the comparison performed between single and daily 3-
HAA treatments delivered in 1% FBS. For instance, the IC50 of 3-HAA daily 
Chapter 4   
171 
treatments delivered in 1% FBS medium (68.39 µM) was significantly different 
(p=0. 0.0010) to the IC50 of a single 3-HAA treatment delivered in 1% FBS medium 
(150.1 µM). The IC50 of daily 3-HAA+SOD treatments delivered in 1% FBS medium 
(36.74 µM) was significantly different (p=0.0079) than the IC50 of a single 3-
HAA+SOD treatment delivered in 1% FBS medium (69.01 µM). 
Similarly, the effect of daily treatments with 3-HAA (100 µM) alone, or in 
combination with catalase (CAT; 1000U/ml), in either 1% or 10% FBS medium, 
with and without SOD (300 U/ml) was assessed 48 h (Figure 30) and 72h (Figure 
31) after the initial treatment, obtaining the following combination of 
treatments: 
•100 µM 3-HAA 10% FBS   •100 µM 3-HAA 1% FBS 
•100 µM 3-HAA+CAT 10% FBS  •100 µM 3-HAA+CAT 1% FBS 
•100 µM 3-HAA+SOD 10% FBS  •100 µM 3-HAA+SOD 1% FBS 
•100 µM 3-HAA+CAT+SOD 10% FBS •100 µM 3-HAA+CAT+SOD 1% FBS 
 
As expected, daily 3-HAA treatments caused a cumulative decrease in cell 
viability and a reduction in the protection afforded by catalase. In cells treated 
2 and 3 times with 100 µM 3-HAA 10% FBS there was a ≈40% reduction in the 
viability when compared to untreated controls (Figure 30 and Figure 31). The 
addition of CAT no longer afforded any protection in cells treated either 2 or 3 
times. In cells treated twice with 100 µM 3-HAA+SOD in 10% FBS medium, there 
was a decrease in the viability (80%) when compared to control cells (Figure 30), 
however a third treatment did not cause any further reduction in cell viability 
(Figure 31). In this third treatment, the addition of catalase exerted some 
protection, however the viability was not restored to control levels (Figure 31).  
A similar reduction in cell viability (≈40%) was observed in cells treated twice 
and three times with 100 µM 3-HAA 1% FBS (Figure 30 and Figure 31). Under 
these conditions, CAT protected cells treated twice but not those receiving an 
additional treatment (Figure 31). Interestingly, the viability of cells treated with 
100 µM 3-HAA+SOD in 1% and 10% FBS medium did not change between day 2 and 
day 3. 
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Figure 30. Catalase protects against the exacerbated toxicity of 2 daily 3-HAA treatments. 
SH-SY5Y cells were treated on day 0 and day 1 with 3-HAA delivered in 1 and 10% FBS 
medium supplemented with SOD (300 U/ml). The toxicity was assessed 48 h after the initial 
exposure. A Fitted Log(inhibitor) vs normalised response curve is displayed for cells 
incubated for 48 h (treated twice) with 3-HAA delivered in 10%(A) and 1% (B) FBS medium 
supplemented with SOD (Solid Blue and Green lines) after which the toxicity was evaluated 
by FDA. IC50 values were obtained by non-linear regression analysis (Dose-inhibition; Prism 
Graphpad v. 6.0f). C) Cells were treated with 3-HAA (100 µM) in 1% and 10% FBS medium 
with/without SOD (300 U/ml) alone or in combination with CAT (100 U/ml). Control wells 
received medium exchanges only. Results are expressed as percentage of control. Bars 
represent mean ± SEM. *P<0.05, ***P<0.0004, **** P<0.0001 Two-way ANOVA followed by 
Tukey’s test. n=3. The average IC50 are listed in each graph and are summarized in Table 6. 
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Figure 31. Catalase protects against the exacerbated toxicity of 3 daily 3-HAA treatments. 
SH-SY5Y cells were treated on day 0, day 1 and day 2 with 3-HAA delivered in 1 and 10% 
FBS medium supplemented with SOD (300 U/ml). The toxicity was assessed 72 h after the 
initial exposure. A Fitted Log(inhibitor) vs normalised response curve is displayed for cells 
incubated for 72 h (treated three times) with 3-HAA delivered in 10%(A) and 1% (B) FBS 
medium supplemented with SOD (Solid Blue and Green lines) after which the toxicity was 
evaluated by FDA. IC50 values were obtained by non-linear regression analysis (Dose-
response inhibition Prism Graphpad v. 6.0f). C) Cells were treated with 3-HAA (100 µM) in 
1% and 10% FBS medium with/without SOD (300 U/ml) alone or in combination with CAT 
(100 U/ml). Control wells received medium exchanges only. Results are expressed as 
percentage of control. Bars represent mean ± SEM. *P<0.0183, **P<0.001, ***P<0.0008, **** 
P<0.0001 Two-way ANOVA followed by Tukey’s test. n=3. The average IC50 are listed in 
each graph and are summarized in Table 6. 
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4.4 Discussion  
The results of the QA experiments show that there are no changes in the 
viability of SH-SY5Y cells at any of the concentrations tested which was an 
exciting discovery. However, during the development of this project, the 
resistance of SH-SY5Y cells against QA toxicity was reported (Wszelaki and 
Melzig, 2011). Since QA selectively activates NMDAR with the subunit 
combination GluN1+GluN2A and GluN1+GluN2B (de Carvalho et al., 1996), it was 
initially thought that perhaps the specific subunit composition in SH-SY5Y cells 
could account for the lack of toxicity of QA. 
Furthermore, the QA-induced expression of β3-tubulin and DCX was not affected 
by blockade of the NMDAR with MK-801 or KA, at neither of the time points 
evaluated. KA (NMDAR antagonist) has been reported to affect cancer growth 
(Walczak et al., 2012; Walczak et al., 2014), thus its effect on the survival of 
SH-SY5Y cells was evaluated. Consistently with the lack of effect of MK-801, the 
viability of cells treated with KA was not affected at any of the concentrations 
tested. 
Since QA is a weak agonist of the NMDAR, the effect of NMDA on the survival and 
neuritogenesis of SH-SY5Y cells was evaluated. NMDA treatment of 
undifferentiated SH-SY5Y cells for 72 h had no significant effect on cell survival. 
In some experiments, NMDA caused a small decrease in the viability but not in a 
dose-dependent manner. Since it had previously been reported that RA-induced 
differentiation correlated with the appearance of GluN1 mRNA in the SH-SY5Y 
cells (Kulikov et al., 2007), it was decided to assess whether differentiation 
modified the susceptibility of cells to NMDA. Surprisingly, the response to NMDA 
was identical in differentiated and undifferentiated cells. There are 
discrepancies in the literature regarding the lethal concentration of NMDA in SH-
SY5Y cells. Park and collaborators (2012) report a 20% decrease in cell viability 
after a 24 hour incubation of 100 µM NMDA (Park et al., 2012). Contrastingly, 
other reports show that 24 h exposure to NMDA at doses below 1 mM have no 
consistent effect on SH-SY5Y cell viability and that high doses (5mM) are 
necessary to cause an increase of LDH leakage (Tetich et al., 2004). 
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The lack of effect of NMDA (and its antagonists) suggests that no functional 
NMDARs exist in the SH-SY5Y cell line, which would be in accordance with two 
previous studies that specifically selected this cell line as a negative control for 
the presence of GluRs (Uberti et al., 1997; Glantz et al., 2007). However, these 
authors provide no direct evidence or references to support their claim. 
Furthermore several other studies on SH-SY5Y cells have implicated NMDAR 
activation to a myriad of processes, from toxicity to preconditioning stimulation 
which indirectly provided evidence that this receptor is present in the SH-SY5Y 
cell line (Nair et al., 1996b, a; Singh and Kaur, 2005, 2007; Park et al., 2012). 
The results presented in this dissertation provide evidence to demonstrate that 
the GluN1 subunit is not present in the SH-SY5Y cell line. It could be argued that 
the antibody used in this study does not recognise human GluN1, given that the 
positive control used was rat brain homogenate while the SH-SY5Y cells are of 
human origin. However this is an unlikely possibility as that the epitope (highly 
conserved) recognised by the antibody is identical in both human and rat. 
Furthermore, the GluN1 antibody used in this project has been shown to bind to 
the GluN1 subunit in human embryonic stem cells (Francis and Wei, 2010) and in 
cells from human cerebrospinal fluid (Gleichman et al., 2012). 
The absence of GluN1 subunit could explain the low toxicity of both of QA, NMDA 
and KA in these cells. Another possibility to explain the low toxicity of QA, NMDA 
and the lack of response to MK-801 and KA could be the presence of an 
alternative form of NMDAR with a different subunit composition. For instance, 
there are studies showing that co-expression of the GluN1/GluN3A-B will form 
excitatory glycine receptors insensitive to Glu, NMDA, MK-801, memantine and 
competitive antagonists (Chatterton et al., 2002). In human embryonic kidney 
cells (HEK293), the GluN1/GluN3A or GluN1/GluN3B receptor combination does 
not express well on the surface (Smothers and Woodward, 2007). Therefore, if 
this subunit combination is present in the SH-SY5Y cells, then the lack of 
detection could possibly be explained. 
Unfortunately, the expression profile, localization, arrangement and functional 
characterisation of the NMDAR has never been fully studied in the SH-SY5Y cell 
line. The majority of studies of SH-SY5Y cells, which attribute an effect to the 
NMDR, base their theoretical framework on research performed on RA-
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differentiated SK-N-SH cells (Pizzi et al., 2002). However, the SK-N-SH cell line 
is morphologically and biochemically different to the SH-SY5Y cell line (Cohen et 
al., 2003); therefore the possibility exists that functional NMDARs exist in one 
cell line but not in the other.  
As previously mentioned, in one report it is suggested that functional NMDARs 
are present in SH-SY5Y cells. However, the only supporting evidence provided, 
was the presence of GluN1 mRNA (interestingly, not that of GluN2A-D and GluN3) 
yet, the actual levels of GluN1 protein were not reported (Kulikov et al., 2007). 
A more recent report shows that the constitutive expression of GluN2A increases 
after RA-induced differentiation and that in vitro ischemia-reperfusion increases 
its tyrosine-phosphorylation (Beske and Jackson, 2012). Conflictingly, a 
microarray study, evaluating the transcriptional changes that occur in SH-SY5Y 
after RA-induced differentiation, shows that whereas GRIN1 (the gene codifying 
for GluN1) expression can be detected, its expression does not change among 
undifferentiated and RA-differentiated cells SH-SY5Y (Korecka et al., 2013). 
Furthermore, electrophysiological studies of the NMDAR in SH-SY5Y cell lines are 
virtually non-existent. In a study that set out to determine the effect of 
βintegrin-1 on amyloid-β1−42 (Aβ1−42) enhancement of NMDAR activation in SH-
SY5Y cells, Uhasz and collaborators (2010) report that βintegrin-1 blocks the 
increase in the intracellular concentration of Ca2+ (measured using the Fluo-4NW 
Calcium Assay Kit) that generally follows Aβ1−42 treatment (Uhasz et al., 2010). 
However, in a previous patch-clamp study, it is reported that NMDA treatment 
does not evoke any detectable ionotropic responses in these cells, indicating 
that either the NMDAR is absent or that it is found in an inactive state (Jantas et 
al., 2008). The same authors then report that NMDA has antiapoptotic actions 
against staurosporine and salsolinol-induced death (Jantas and Lason, 2009) by a 
mechanism that would require functional NMDAR. It is therefore recognised that 
research performed using the SH-SY5Y cell line would greatly benefit from a full 
and exhaustive characterization of the NMDAR composition and its 
electrophysiology. 
It is surprising that despite accumulating evidence suggesting that the NMDAR is 
not present in SH-SY5Y cells, there are still several reports in which the effects 
observed are attributed to NMDAR activation (Masuko et al., 2012; Shin et al., 
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2014; Zhou et al., 2014). Partially addressing these inconsistencies, Sun and 
collaborators propose that some of the effects of Glu and its antagonists on SH-
SY5Y cells could be attributed to oxidative Glu toxicity and not calcium 
disturbances mediated by NMDARs (Sun et al., 2010). 
It has been reported that QA can cause an increase in the levels of ROS by 
inactivating endogenous antioxidant molecules (Rodriguez-Martinez et al., 
2000). Furthermore, in rat cerebral slices (cortex, hippocampus and striatum) 
MK-801 does not prevent the QA-induced formation of ROS, which suggests a 
mechanism independent of NMDAR activation (Dobrachinski et al., 2012). It has 
been suggested that QA directly activates NOX thus increasing the levels of O2•- 
(Santamaria et al., 2001). There is an increasing body of evidence that points to 
ROS as promoters of cell differentiation at low concentrations; this has been 
observed in immortalised human fibroblast lines (Takahashi et al., 2006). More 
directly, in SH-SY5Y cells, a recent report showed that docosahexaenoic acid 
induces neuritogenesis via activation of ERK1/2 through the generation of ROS 
(Wu et al., 2009).  
The results herein contained suggest that QA-induced neuritogenesis occurs 
independently of NMDAR activation. Therefore, the role of ROS in the 
differentiation induced by RA and QA was studied. Several probes have been 
designed to quantify the intracellular levels of ROS. For example, the oxidation 
of dihydroethidium (DHE) as an indicator of O2•- production has been widely used 
since the 1980s (Robinson et al., 2008). Despite controversies regarding the 
specificity of DHE to react with O2•-, the DHE oxidation assay is still considered 
a valid method to study the overall oxidative state of the cell. This is especially 
true when DHE is used in combination with a pharmacological approach (use of 
antioxidants) to discern the particular ROS that is being produced. Therefore, 
the oxidation of DHE was the method selected to evaluate ROS production in SH-
SY5Y cells. 
SOD treatment increased the number of cells present in the cultures. This 
increase in viability and decrease in the number of neurite bearing cells by SOD 
points to an involvement of reactive oxygen species (ROS), in particular O2•-, in 
the proliferation of SH-SY5Y cells. In this sense, ROS could be slowing down cell 
proliferation, perhaps through the action of tumour suppressors hence allowing 
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differentiation to occur or they could be directly inducing differentiation 
through the activation of transcription factors responsive to oxidative stress. The 
transient and oscillating levels of ROS suggest that they may be acting as 
signaling molecules during the first day after QA treatment.  
These data may indicate that SH-SY5Y cells have a high intrinsic production of 
ROS that maintain a balance between proliferation and differentiation and that 
a small shift towards an oxidant condition could be down-regulating cell growth 
and therefore promoting differentiation. Indeed, there is evidence suggesting 
that decreasing the amounts of ROS with antioxidants promotes proliferation in 
precancerous cells and in cancer cell lines that have not yet lost p53 function 
(via a mechanism involving NFRF2) which occurs late in tumour progression 
(Sayin et al., 2014). Notably, whereas loss of p53 function is a common feature 
in human cancers, it is of rare occurrence in neuroblastoma and its derived cell 
lines. Mutations in p53 are found almost exclusively in progressive and relapsed 
neuroblastoma (Janardhanan et al., 2009). However further experiments would 
be needed to explain the increase in viability caused by SOD in SH-SY5Y cells and 
whether SOD addition has a down-regulating effect on p53 and NRF2. 
When cells are treated with RA in medium containing SOD, there was a clear 
reduction in the soma/neurite ratio as compared to medium without SOD. These 
results offer additional evidence to support that ROS are involved in the 
differentiation exerted by RA and QA. In accordance with this, it has been 
previously demonstrated that RA has a pro-oxidant effect one week after 
treatment and that reducing the levels of ROS reduces the degree of 
differentiation (Konopka et al., 2008). A more recent report shows that RA 
increases differentiation and ROS through the activation of NADPH oxidase (Nitti 
et al., 2010) 
Da Frota and collaborators (2011) reported that the addition of Trolox to SH-
SY5Y cultures increases both the proliferation (cell number) and neuritogenesis 
(neurite/soma ratio) however it is not mentioned how both processes can 
simultaneously occur. Coincidentally, under these conditions, the levels of SOD 
are reduced. Furthermore the authors suggest that an antioxidant-strategy could 
avoid the premature death of cells entering differentiation programmes (da 
Frota Junior et al., 2011) though they do not take into account the neoplastic 
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nature of the SH-SY5Y cell line and the negative outcome that such strategies 
would have in reality. 
Furthermore, the time-course assessment presented here indicates that 24 hours 
after RA treatment there is an increase in the levels of ROS, which is completely 
eliminated by co-incubation with SOD. Serum reduction also increases the levels 
of ROS in SH-SY5Y cells but this stimulus is not sufficient to cause differentiation 
on its own. The levels of ROS in QA-treated cells are significantly higher than the 
levels of ROS found in cells kept in 10% FBS medium (control), 1% FBS medium or 
RA. The effect of RA and QA on ROS production is additive as evidenced by 
increased DHE fluorescence.  
SOD significantly decreased the levels of free radical generation and 
differentiation in all of the experimental conditions. The effect of SOD as well as 
the positive DHE signal, which preferentially reacts with O2•-, suggested that this 
is the main ROS involved in the differentiation observed after RA and QA 
treatment. RA a caused an increase in the number of neurites which correlated 
with an increase in the expression of Β3-tubulin after 3 and 7 days and a 
decrease in the expression of DCX after 7 days. Furthermore, by using a neurite 
outgrowth assay, it was possible to determine that the changes in β3-tubulin 
come from the neuritic fraction and that indeed RA promotes neurite extension 
as early as 72 h after treatment. 
As expected, none of the treatments delivered in 10% FBS induced 
differentiation, this had been previously reported and it is due to the action of 
mitogenic factors present in the serum (Zheng et al., 2006) that promote cell 
growth. Differentiation only occurs when the cells are treated with 1% FBS 
(Meghani et al., 1993) since proliferation signals are incompatible with the 
differentiation programme (Strehl et al., 2002). 
Surprisingly, cells treated with QA showed morphological similarities to cells 
treated with RA, such as an increase in the length and number of neurites and 
rounding of the cell bodies.  
Since most of the evidence supporting a differentiating effect of QA came from a 
morphological assessment, and taking into account the sample bias from 
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choosing random fields, other molecular tools were used to confirm these 
observations. If indeed cells are acquiring a more neuronal phenotype with QA 
and RA, then this ought to be reflected by an increase in neuronal markers. 
QA treatment caused an increase in β3-tubulin at 3 and 7 days. The results 
obtained from the neurite outgrowth assay indicate that QA treatment promotes 
cell differentiation, which is dose dependant. This is a very relevant discovery 
since it is the first time that QA has been shown to have a positive effect on 
neuritogenesis in mammalian cells. From an oncogenic point of view, it may 
suggest that it induces tumour regression (at least in a significant fraction of the 
cells) which contributes to the accumulating body of evidence suggesting that 
whereas persistently high levels of ROS promote cell growth, an acute oxidising 
condition decreases it. 
QA failed to significantly decrease the expression of DCX at either 3 or 7 days, 
which indicates that some cells retain the ability to divide. This may suggest 
that the differentiation induced by QA is only partial and that inducing a 
complete stop in proliferation may be necessary to elicit a fully differentiated 
phenotype.  
The inability of QA to reduce proliferation may suggest that as regards to SH-
SY5Y cells, at least two independent stimuli are necessary for complete neuronal 
differentiation. This could be due to the transformant nature of the SH-SY5Y cell 
line in which the ability to exit the cell cycle in the absence of exogenous 
mitogens has been lost. For instance, NGF-induced differentiation is also partial 
unless aphidicolin is added to the cultures (LoPresti et al., 1992). Similarly, a 
homogenous population of neural cells can be obtained when SH-SY5Y cells are 
sequentially treated with RA and brain-derived neurotrophic factor (BDNF). 
These cells adopt a neuronal morphology which correlates with a termination of 
DNA replication (Encinas et al., 2000; Jamsa et al., 2004). Other differentiation-
inducing compounds behave in a similar manner. For example, in the absence of 
mitotic inhibitors, SH-SY5Y cells treated with RA or 12-O-tetradecanoyl phorbol-
13 acetate (TPA) continue to proliferate and thus far only staurosporine has 
been able to induce terminal differentiation that is neurotrophin-independent 
(Prince and Oreland, 1997). Interestingly, RA increases the levels of Bcl-2 and 
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decreases those of p53, whereas staurosporine decreases Bcl-2 and increases p53 
levels in SH-SY5Y (Tieu et al., 1999). 
According to the clonal expansion model, both N-type and S-type cells are 
simultaneously present in a normal SH-SY5Y culture (Cohen et al., 2003). Thus, 
it seems more likely that the neuritogenic effect of QA is exerted on the N-type 
fraction of the cultures which is more susceptible to differentiating stimuli. It 
has also been shown that after differentiation is induced in SH-SY5Y cells, the S-
type subpopulation continues to divide leading to its selection (over the non-
dividing N-type) and clonal expansion (Encinas et al., 2000) which would explain 
why the expression of β3-tubulin decreased 7 days after QA treatment when 
compared to its expression 3 days after treatment. Furthermore, it has been 
suggested that the SH-SY5Y cell line provided by ATCC (American Type Culture 
Collection) differentiates more easily than the one provided by ECACC due to an 
increased presence of the S-type subpopulation in the latter (Nishida et al., 
2008).  
Interestingly, it has been reported that QA is preferentially produced (over PIC) 
in SK-N-SH cells, where it causes an increase in cell proliferation (Guillemin et 
al., 2007). To what extent and how this relates to the results obtained in this 
study is hard to determine given the many genetic and functional differences 
between the SK-N-SH cell line and the SH-SY5Y cell line. The more obvious one is 
the unquestionable presence of functional NMDARs (Pizzi et al., 2002) in the SK-
N-SH cell line, which could potentially confer this cell line with the ability to use 
both Glu and QA to stimulate growth in an autocrine manner (Adams et al., 
2012). However it is tempting to speculate that the dissimilar response elicited 
by QA in the SK-N-SH and SH-SY5Y cell line may underlie, at least in part, the 
enhanced capability of the SH-SY5Y cell line to undergo differentiation as 
opposed to the SK-N-SH cell line, where 80% of the population (the S-type) does 
not differentiate (Nishida et al., 2008) 
Given that both the neurite/soma ratio evaluation and the neurite outgrowth 
assay produced results consistent with an increase in neuritogenesis, it was of 
interest to establish whether the results attained with each method were 
comparable. The estimates of neurite extension obtained with the neurite 
outgrowth assay were more conservative compared to the neurite/soma ratio 
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and the β3-tubulin western blot quantification. This suggests that QA causes a 
major change in the neuritic architecture; mainly by causing the elongation of 
neurites and, to a lesser (yet still significant) extent, by causing an increase in 
the overall neuritic mass. Similarly, the differences in the expression of β3-
tubulin between the Western blot analysis and the neurite outgrowth assay may 
indicate that QA causes an increase in the expression of β3-tubulin mainly in the 
soma and to a lesser but still significant extent in the neurites. 
QA (a precursor of NAD+) has been reported to induce oxidative stress through 
NOX-activation (Maldonado et al., 2010) and NOX has been shown to mediate the 
differentiation of stem cells (Chan et al., 2009), it was decided to study the role 
of NOX in QA-induced neuritogenesis.  
The neurite outgrowth assay showed that when cells are treated with QA and 
DPI, differentiation is eliminated. The data presented here is consistent with 
reports showing that, in SH-SY5Y cells treated with RA, the acquisition of a 
neuronal phenotype is accompanied by an increase in the activity of NOX and 
that its inhibition with DPI decreases RA-induced neurite elongation (Nitti et al., 
2007; Nitti et al., 2010). However, since O2•- can be generated by other 
mechanisms that do not involve NOX, the possibility of additional sources of O2•- 
during QA-induced differentiation cannot be discarded. 
For instance, when xanthine/xanthine-oxidase was used as a positive control for 
O2•- formation, there was no indication that differentiation was taking place 
which further strengthens the hypothesis that in addition to oxidative stress 
another stimulus is necessary to promote cell differentiation. Nevertheless, the 
effect of xanthine/xanthine-oxidase on neuritogenesis was never quantitatively 
studied. The study of the xanthine/xanthine oxidase system may represent an 
important element to elucidate the role of ROS in the differentiation of SH-
SY5Y. 
NRF2 is a protein that mediates the cellular response to oxidative stress and 
which has been shown to play a role in differentiation. NRF2 is released when 
Keap-1 is oxidised at several cysteine residues. NRF2 then migrates to the 
nucleus where it activates the transcription of genes with antioxidant response 
element box (ARE) in their promoters. In a liver carcinoma cell line and in a 
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myelogenous leukaemia line, SIRT1 decreases acetylation of NRF2 as well as 
NRF2-dependent gene transcription. Furthermore, selective inhibitors of SIRT1 
(EX-527 and Nam) increase the transcription of genes regulated by NRF2 whereas 
activating Sirt1 with resveratrol inhibits NRF2 (Kawai et al., 2011). 
Since QA treatment caused a marked increase in the levels of ROS, it was 
decided to evaluate the expression of NRF2. QA induced a marked increase in 
the expression of NRF2 which was detectable 12 hours after treatment. This is in 
accordance with reports showing that ROS-mediated differentiation induces the 
expression of NRF2 in SH-SY5Y cells (Zhao et al., 2009). More recently, it has 
been shown that neuronal differentiation of SH-SY5Y cells causes an increase in 
NRF2, a transcription factor regulating the endogenous antioxidant response and 
neuronal differentiation (Korecka et al., 2013) 
To further study the process by which QA induces differentiation, it was decided 
to treat SH-SY5Y cells with different concentrations of Nam, another precursor 
of NAD+ (and an inhibitor of SIRT1). Nam treatment induced differentiation as 
evidenced by an increase in neurite formation and expression of β3-tubulin. The 
fact that QA increased the levels of NRF2 and that Nam mimicked the effect of 
QA may indicate that the mechanism through which QA is exerting its actions is 
by altering the metabolism of NAD+/Nam/Nicotinic acid. 
Interestingly, trigonelline (essentially a methylated form of nicotinic acid found 
in plants) and 1-Methylnicotinamide cause an increase in the number of neurites 
in SK-N-SH cells (Tohda et al., 1999; Thomas et al., 2013). Trigonelline increases 
the susceptibility of pancreatic cancer cells to apoptosis through a mechanism 
that involves the inhibition of NRF2 (Arlt et al., 2013). 
The exact mechanism by which Nam promotes cell neuritogenesis was not 
studied rigorously. However, based on the data presented in this project, a 
prospective series of hypotheses are presented, which could form the basis for 
future venues of research. 
Hypotheses: 
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1.- QA may induce neuritogenesis and an increase of ROS through the activation 
of NOX followed by activation of antioxidant response elements. The results 
presented here show an increase in NRF2 after QA treatment. NRF2 binds to the 
antioxidant response element in the promoter of genes such as NAD(P)H:quinone 
oxidoreductase (Vomhof-Dekrey and Picklo, 2012).  
2.- QA may cause differentiation by increasing the intracellular concentration of 
NAD+, thereby affecting the NAD+/NADH ratio. 
3.- An increase in the availability of NAD+ will in turn affect the intracellular 
concentration of Nam (since Nam is both a product and a precursor of NAD+). 
The hypothesis that Nam accumulates in the SH-SY5Y cell line is partly supported 
by the fact that the pathway involved in Nam elimination is compromised. The 
SH-SY5Y cell line lacks nicotinamide N-methyltransferase, an enzyme that is 
involved in the elimination of Nam by causing its N-methylation to form 1-
methylnicotinamide (Parsons et al., 2011). Interestingly, trigonelline (essentially 
a methylated form of nicotinic acid found in plants) and 1-Methylnicotinamide 
cause an increase in the number of neurites in SK-N-SH cells (Tohda et al., 1999; 
Thomas et al., 2013). Trigonelline increases the susceptibility of pancreatic 
cancer cells to apoptosis through a mechanism that involves the inhibition of 
NRF2 (Arlt et al., 2013). 
4.- An increase in the intracellular concentration of Nam decreases the activity 
of SIRT1 which in turn will increase the activity of NRF2. Even though the mutual 
cooperation of SIRT1 and NRF2 has been extensively reported, in particular the 
activation of NRF2 by SIRT1 (Huang et al., 2013; Kulkarni et al., 2014), it has 
also been shown that Sirt1 causes a decrease in the acetylation of NRF2 and a 
reduction in the expression of genes regulated by NRF2 (Kawai et al., 2011). 
Furthermore, there is evidence suggesting that sirtuins may be involved in 
carcinogenesis based on a recent study which shows that cancer cells require 
SIRT1 for survival (Ford et al., 2005; Deppert, 2008). Taking into account the 
transformant nature of the SH-SY5Y cell line, the hypothesis that Nam is 
inhibiting SIRT1 and that this is causing proliferation to stop and an increase in 
NRF2 is further strengthened. In any case, the importance of studying the 
interaction between NRF2 and SIRT1 during QA-induced differentiation in SH-
SY5Y cells is evident. A link between SIRT1 and neuroprotection has also been 
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found in several models including in vivo, in vitro and ex vivo. For instance, in 
mice with Wallerian degeneration slow (Wlds), the overexpression of Nmnat1, 
protects cells against axonal degeneration through a pathway that involves SIRT1 
as a downstream effector (Araki et al., 2004). 
5.-NRF2 is affecting the expression of genes involved in differentiation. It has 
already been shown that NRF2 plays a role in the RA-induced differentiation of 
SH-SY5Y cells (Zhao et al., 2009). 
Based on the results obtained using QA to treat the SH-SY5Y cells, it was decided 
to evaluate the effect of 3-HAA on SH-SY5Y differentiation. However, SH-SY5Y 
cells presented signs of damage upon exposure to 3-HAA. 3-HAA caused cell 
death and increased the levels of ROS. This damage was potentiated upon 
addition of SOD to the cultures which is in agreement with reports showing that 
SOD promotes the autoxidation of 3-HAA and further production of ROS (Liochev 
and Fridovich, 2001). It needs to be noted that DHE preferentially labels O2•- 
however this can only be irrefutably proven when the assay is used in 
combination with drugs that specifically detoxify a particular ROS (as it was 
done for QA with SOD). Since SOD increased DHE fluorescence, other 
antioxidants should have been used to identify the ROS in cultures. Alternatively 
a different method to identify ROS could have been used. 
Whereas CAT protected against 3-HAA-induced cellular death, SOD enhanced its 
cytotoxicity. This is also in agreement with previous reports showing that at 
physiological pH, 3-HAA generates O2•- and H2O2 in a copper-dependent manner 
which can be detected by DHE (Goldstein et al., 2000). SH-SY5Y cells are very 
sensitive to H2O2 attack (Weinreb et al., 2008). 
The data herein contained suggest that both O2•- and H2O2 could account for 3-
HAA toxicity depending on the concentration of FBS in the media in which the 
treatment is delivered. FBS did not cause a shift in the IC50 but it did affect the 
response to catalase.  
One possibility is that H2O2 is not the main ROS responsible for the induction of 
cellular death in cells treated with 3-HAA in 10% FBS, and that therefore CAT 
treatment cannot exert protection. Conversely, the protective effect of catalase 
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indicates that H2O2 is the main ROS produced in cells exposed to 3-HAA in 1% FBS 
as well as in those exposed to 3-HAA+SOD in either 1% or 10% FBS for 48 and 72 
h. 
Cu-Zn-SOD is extracted from bovine erythrocytes and foetal bovine serum (FBS) 
is also obtained from blood plasma. It is therefore a very likely possibility that 
Cu-Zn-SOD is present in bovine serum. Indeed, early reports have shown that Cu-
Zn-SOD is present in FBS at concentration ranging from 12-4400 ng/ml, enough 
to exert an anticlastogenic effect, depending on the batch and heat inactivation 
protocol used (Baret and Emerit, 1983). Given that the specific activity of SOD is 
not disclosed, it was not possible to convert ng/ml to U/m in order to ascertain 
how this concentration compares to the ones used and what its effect would be. 
Alternatively, it has also been shown that FBS has an effect on the level of SOD 
produced by cell in cultures (Rahman et al., 2011), which may also explain why 
in our preparation FBS had an effect on the extent to which catalase could 
protect.  
As mentioned in the introduction, the autoxidation of 3-HAA leads to the 
production of O2•- and H2O2. The results herein contained confirmed that the 
addition of SOD promotes the autoxidation of 3-HAA but that there is also a 
significant production of H2O2 during 3-HAA autoxidation, perhaps caused by the 
dismutation of O2•- into H2O2. 
When cells were treated only once, at day 0 with 3-HAA, recovery was observed. 
Thus, it was hypothesised that 3-HAA could be breaking down within the first 24 
hours. The HPLC results showed that indeed, this is the case. When cells were 
treated every day with 3-HAA for three days, the viability was reduced and no 
signs of recovery were observed. 
It has been widely reported that differentiation alters the way SH-SY5Y cells 
respond to toxic insults (Cecchi et al., 2008; Cheung et al., 2009; Xie et al., 
2010; Schneider et al., 2011). However, this effect has also been reported to be 
due to the lack of appropriate controls and adjustments necessary to compare 
the viability or cytotoxicity between undifferentiated (proliferative) and 
differentiated cells (arrested). This is particularly relevant for studies such as 
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this one in which cell death occurs several days after the initial treatment with 
3-HAA whereby untreated controls continue to grow. 
It has been suggested that in growing cultures, the cells are unsynchronised, 
which causes uncertainty in toxicity measurements. For example, the MTT assay 
of Aβ-peptides might lead to false results when non-differentiated 
neuroblastoma cells are used, because Aβ-peptides act mostly on the neurites of 
the neuroblastoma cells (Datki et al., 2003). 
Furthermore, when determining the differential toxicity of a compound between 
proliferative and non-proliferative cells it is necessary to determine if the 
decrease in “viability” is due to an increase in the number of dead cells, less 
proliferation or less metabolic activity without death. If the number of cells 
cannot be kept constant, then an adjustment/correction needs to be performed 
unless the redox activity of the cells is confirmed to be directly proportional to 
the toxicity 
Working with non-differentiated cells involves some disadvantages since the 
number of cells is continuously growing during the experiments. This makes 
undifferentiated SH-SY5Y cells a less than ideal neuronal model to evaluate the 
events that follow an initial toxic insult since some cells will recover after time. 
Using differentiated cultures to assess toxicity has been presented by some as an 
alternative (Datki et al., 2003; Cecchi et al., 2008). However, differentiated SH-
SY5Y cells can dedifferentiate after time even when maintained in 1% FBS 
medium supplemented with RA (Constantinescu et al., 2007). Then there is also 
the risk that the drug being analysed is interfering with RA differentiation and 
cell proliferation resumes which can cause misinterpretation of data.  
For instance, the differences in viability found 72 h after a single 3-HAA 
treatment between differentiated and undifferentiated cells could have been 
interpreted as a different susceptibility to 3-HAA between differentiated and 
undifferentiated cells when in fact the mechanism behind this difference in 
viability was the different proliferation rates of differentiated cells vs 
undifferentiated cells. A more exact estimate of the toxicity could have been 
obtained by using propidium iodide or LDH release to adjust the data. Even then, 
the total number of cells would have continued to skew the values. 
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Direct oxidation of unidentified substrates by Cu-Zn-SOD has been proposed to 
account for the deleterious effects sometimes reported to accompany 
overproduction or overadministration of this enzyme (Liochev and Fridovich, 
2001; Lindskog et al., 2006). This work supports this hypothesis by establishing 
that Cu-Zn-SOD is capable of causing such oxidations. A possibility exists that 
both O2•- , H2O2 and cinnabarinic acid caused the toxicity associated with co-
treatment with 3-HAA and SOD (Hiramatsu et al., 2008). 
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4.5 Future Avenues 
This study leaves abundant room for further progress in kynurenine research in 
the context of cancer pathogenesis. In future investigations, it might be possible 
to use a different cell line like the SK-N-SH, in addition to the SH-SY5Y, to 
compare their responses to kynurenines and attempt to determine the reason 
behind any possible differences. 
There are several experimental approaches to test each of the aforementioned 
hypothetical points. For instance, an important issue would be determining the 
precise effect of QA on cell proliferation, for instance assessing proliferation by 
bromodeoxyuridine (BRDU) to determine whether cells continue to proliferate 
after QA treatment.  
Assessing the activity of NOX after QA treatment can further strengthen the 
hypothesis that NOX is the source of O2•- since DPI caused a decrease in neurite 
extension. 
Several questions remain at present unanswered, for instance it would be 
necessary to determine whether the increase in NRF2 expression is causing 
differentiation or whether it is an independent antioxidative response against 
the increase in ROS caused by QA. To accomplish this, the activity of NRF2 would 
need to be blocked and quantified in order to determine if neuritogenesis is 
affected. Even though recent advances have been made in the development of a 
direct inhibitor of keap1-NRF2 (Arlt et al., 2013; Hu et al., 2013), the main 
reliable method to inhibit it continues to be through siRNA gene silencing.  
In order to ascertain if the effect of QA is mediated by downstream metabolites 
of NAD+ metabolism, an initial approach could be to measure the ratio of NAD+/ 
NADH and NADP/NADPH after QA treatment as well as the concentration of Nam. 
An additional approach would be to inhibit the enzymes that transform QA into 
NAD+ (quinolinate phosphoribosyltransferase, nicotinamide mononucleotide 
adenylyltransferase, nicotinamide methyltransferase and NAD+ synthetase) and 
assess if neuritogenesis is affected. 
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It is necessary to evaluate the expression and activity of SIRT1 after QA 
treatment. The use of resveratrol during RA and QA treatment could shed some 
light on its role during differentiation and NRF2 expression. 
Assessing whether NRF2 expression alone is sufficient to induce cell 
differentiation. This could be performed using a recently described method in 
which the Neh2 domain of NRF2 is deleted, thereby eliminating the Keap1 
binding site, which in turn generates a constitutively active transcription factor 
(Vargas et al., 2013). 
The results obtained from exposing SH-SY5Y cells to 3-HAA are a first 
approximation to what could be a very interesting mechanism of cell death. To 
determine the mechanism of cell death induced by 3-HAA, the use of ZVAD could 
determine whether apoptosis is being induced. If this is the case, as it is in other 
cell lines, this could turn out to be a model to study the induction of apoptosis in 
neuroblastoma by an increase in ROS production.  
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Chapter 5 – GENERAL DISCUSSION 
  
Throughout the development of this study, it was noted that many fundamental 
aspects of SH-SY5Y biology remain a matter of debate. The most relevant to this 
study were discussed (presence of NMDAR, NGF responsiveness, effectiveness of 
differentiating protocols, genetic make-up, karyotyping, etc.). Several attempts 
have been made to unify and explain previous and ongoing inconsistencies (Ross 
et al., 1995; Encinas et al., 2000; Spengler et al., 2002; Cohen et al., 2003; Sun 
et al., 2010; Kovalevich and Langford, 2013). Perhaps all these contradictions in 
vitro are a reflection of the multilevel heterogeneity found in neuroblastomas in 
vivo (Speleman et al., 2011), which is another reason why this cell line is a 
wonderful tool to study the molecular basis of neuroblastoma.  
However, the research to date has tended to focus on how to render the SH-
SY5Y cell line into a more reliable neuronal model (Xie et al., 2010) for the 
study of toxicity and neurite extension. A major problem with this type of 
approach is that the transformant nature of the SH-SY5Y cell line is often 
ignored and may, in fact, underlie these discrepancies. This attitude is beginning 
to change, as evidenced by an increase in the number of articles concerned with 
establishing the transcriptional profile of SH-SY5Y cells in order to determine if 
they are indeed a good dopaminergic neuronal model (Korecka et al., 2013). 
Yusuf and collaborators (2013) have recommended that neuroscientists using 
neuroblastoma cell lines (to study Parkinson’s, Alzheimer’s or Autism spectrum 
disorders), ensure that their research is passage number- and karyotype-
informed, precisely because of the genetic aberrations that these cell lines are 
prone to as they continue to proliferate.  
As previously mentioned, there is a wide gap between the study of 
differentiation in SH-SY5Y cells and its applicability in the treatment of 
neuroblastomas. SH-SY5Y cells have been used to study either the molecular 
pathways that cause tumour regression or, neuronal toxicity and neuronal 
differentiation. How the information regarding the SH-SY5Y cells is interpreted 
depends upon the particular goals of each research group. For instance the 
effect of (-)-epigallocatechin-3-gallate on SH-SY5Y cells has been reported to be 
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neuroprotective by some research groups (Levites et al., 2001; 2002; 2003) and 
anticarcinogenic by others (Mohan et al., 2011; Hossain et al., 2012).  
In this thesis, special care was taken to highlight the results of differentiation 
and toxicity while bearing in mind the intrinsic transformant nature of the SH-
SY5Y cell line. The main finding of this study was that SH-SY5Y neuroblastoma 
cells were very susceptible to both QA and 3-HAA treatment. These compounds 
had an effect on the oxidative state of the cells, with profound and varied 
consequences to their physiology. 
For instance, in this study it was shown that ROS elicit at least 3 different 
responses in SH-SY5Y cells: 1) they slow down proliferation (as evidenced by a 
marked increase in the viability after SOD treatment); 2) they induce 
neuritogenesis (Correlation between neurites and ROS production after QA 
treatment); 3) they induce cell death (by 3-HAA). Even though these may seem 
contradictory effects, they are all separate but fully compatible processes. 
Persistently high ROS levels in cancer cells often lead to increased cell 
proliferation and adaptive responses that may contribute to tumourigenesis, 
metastasis, and treatment resistance. Further exposure to exogenous ROS is 
hypothesized up to a threshold whereby tumour cells (with already very high 
levels of ROS) can no longer cope with oxidative stress, cell division is then 
halted and, depending on the severity of the oxidative-associated damage, cell 
death is induced. Therefore, regulation of the intracellular redox state with 
neuritogenic QA and toxic 3-HAA (by forcing their intracellular accumulation or 
by direct administration) may represent an additional strategy to selectively 
sensitize cancer cells (oxidative stress-inducing therapy). 
Small molecules targeting specific components of NAD+ and Trp metabolism are 
rapidly transitioning into the clinic for neuroblastoma. Furthermore, it may be 
possible to exploit the unique features of neuroblastoma differentiation with 
respect to QA. In this sense, QA could represent an example of differentiation 
therapy whereby malignant cells could become benign. However, differentiation 
therapy only targets a subgroup of cancer cells that are already more susceptible 
to differentiating stimuli (transit-amplifying cells). Although metabolites used in 
single-agent-targeted strategies may provide some relief, their curative 
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potential in neuroblastoma is likely to require multifaceted treatments 
exploiting multiple metabolic pathways and careful integration with other 
agents, such as chemo/radio/immunotherapy, to actively induce cell death The 
results herein contained demonstrate, for instance, that not all SH-SY5Y cells 
respond homogenously to 3-HAA yet that their repopulating capabilities are 
extraordinary. 
The possibility of using compounds that induce cellular death and differentiation 
in neuroblastoma cell lines opens exciting therapeutic perspectives: if these 
observations can be confirmed in vivo they could impact the treatment of 
patients with neuroblastoma where inhibitors of Trp metabolism are currently 
being used. 
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Appendix 
  
6.1 Methods carried out by others 
HPLC (Dr A. Ferguson, IBLS, University of Glasgow, Glasgow, UK) 
Since 3-HAA is a highly unstable and light sensitive compound an antioxidant was 
added to the samples before being processed and analysed. 250µL of cell culture 
supernatant were mixed with 25µL of ascorbic acid (AA, 1.3mM) and 25µL of 3-
nitrotyrosine (3NTYR, 240 µM). The samples were then vortexed and 25 µl 
perchloric acid (PCA, 2M) were added in order to change the isoelectric point and 
precipitate any proteins present in the medium. After treatment with PCA the 
samples were vortexed for exactly 30 seconds to avoid differences in the samples 
due to extraction efficiency. After mixing samples were centrifuged at 5000g for 10 
minutes at 4°C (to get rid of all the protein precipitates that if left in the samples 
could cause the HPLC machinery to block).  
The supernatants were transferred to Alltech filter tubes using centrifugation at 
10,000g for 10 minutes at 4°C. The filtered samples were then transferred to 
chilled autosampler vials. The injection volume of filtered sample extract was 
100μl. The analysis of 3-HAA was performed with isocratic reverse phase HPLC at 
30°C, using a Synergi Hydro column C18. The mobile phase was a solution of 
25mM sodium acetate buffer (pH 5) pumped at a flow rate of 1ml/min. 3-HAA was 
detected by fluorescence using an excitation wavelength of λex 320 nM and 
emission wavelength of λem 420 nM. 
The internal standard, 3NTYR, was determined by the absorbance detector at 
365nm, which was connected in series with the fluorescence detector. 0.1357gr 
of 3NTYR were dissolved in 1mL HCL (1M) and 49mL HPLC-grade water, from this 
stock solution (12mM). 1 ml of NTYR 12mM was diluted in 49mL HPLC-grade to 
have a final concentration of 240 µM. 
A standard solution of 3-HAA (2mM) was prepared, since 3-HAA has to be 
protonated to dissolve, 40 mM hydrochloric acid was used as a solvent. Ascorbic 
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acid (µM) was added to stop 3-HAA breakdown. These stock solutions were 
frozen in aliquots of 600µL at -40°C. 
For each experimental run, a standard curve was prepared. The stock solutions 
of standard 3-HAA were defrosted and mixed together using serial dilutions of up 
to 1 in 20 as follows: 
200 µM = 0.5mL 2mM 3-HAA + 0.5ml AA + 4mL 100 µM ascorbic acid  
20 µM = 0.5mL 200 µM 3-HAA + 4.5mL 100 µM ascorbic acid 
4µM = 1ml 20 µM 3-HAA + 4ml 100 µM ascorbic acid 
To make the standards comparable with the experimental samples, various 
volumes of these mixed standards were diluted with water, ascorbic acid and 
PCA. A blank of ascorbic acid and PCA was also prepared (see Table 7). 
STD 3-haa 
(nM) 
AA 
(nM) 
Mix 
STD 
Vol 
STD 
100 µM 
vol asc 
acid 
300 µM 
vol asc 
acid 
3-NTYR 
VOL IS 
(µL) 
1 M Vol 
PCA 
(µL) 
1 1 1 3 25 225 25 25 25 
2 4 4 3 100 150 25 25 25 
3 7 7 3 175 75 25 25 25 
4 12 12 2 37.5 212.5 25 25 25 
5 16 16 2 50 200 25 25 25 
6 24 24 2 75 175 25 25 25 
7 32 32 2 100 150 25 25 25 
8 40 40 1 25 225 25 25 25 
BLANK 0 0 - 0 275 25 25 25 
Table 7 Preparation of standard solutions for calibrations curves of 3-HAA. Standard (Std), 
4M perchloric acid (PCA) 
The 8 standards plus the blank were filtered using 0.2µm Alltech filter tubes by 
centrifugation at 10,000g for 10 minutes at 4°C. 
The standard solutions were intercalated with the experimental samples (every 8 or 
10 vials) to check for any changes in the retention times of the metabolites. A 
new calibration curve was run after any shutdown of the HPLC. A blank, 
containing only water, ascorbic acid and PCA was run with each calibration curve 
to ensure the baseline was completely flat at the retention times for the peaks 
of interest 
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6.2 Table of clinical trials targeting IDO in the treatment 
of cancer 
Title Identifier Status Goal 
1.- IDO Inhibitor Study 
For Relapsed Or 
Refractory Solid 
Tumours 
NCT00739609 Terminated Determine the safety and efficacy of D1-MT in 
patients with recurrent or refractory solid 
tumours. Establish the toxicities of D1-MT and 
define any dose-limiting toxicities 
2.- IDO2 Genetic 
Status Informs The 
Neoadjuvant Efficacy 
Of Chloroquine (CQ) In 
Brain Metastasis 
Radiotherapy 
NCT01727531 Recruiting Phase I trial to study effects and optimal dose 
of 1-DMT in treating patients with metastatic 
or refractory solid tumours that cannot be 
removed by surgery. 
3.- D1-MT and 
Docetaxel in treating 
patients with 
metastatic solid 
tumours 
NCT01191216 Recruiting Phase I trial to study the effects and best dose 
for giving D1-MT and Docetaxel together in 
treating patients with metastatic solid 
tumours. 
4.- Vaccine therapy in 
treating patients with 
metastatic breast 
cancer 
NCT01042535 Recruiting Randomized Phase I/II trial to study the side-
effects and best dose of giving vaccine therapy 
and to assess the effectiveness in treating 
patients with metastatic breast cancer. 
5.- Study Of 
Chemotherapy In 
Combination With IDO 
Inhibitor In Metastatic 
Breast Cancer 
NCT01792050 Recruiting  To compare the effects of Docetaxel(standard 
treatment) with/without the co-administration 
of 1-DMT. Metastatic Breast Cancer 
6.- Phase II study of 
Sipuleucel-T and 
Indoximod for patients 
with refractory 
metastatic prostate 
cancer 
NCT01560923 Recruiting Phase II trial studying the effect of Indoximod 
or placebo after the completion of standard of 
care treatment Sipuleucel-T. 
7.- Peptide Vaccine 
And Temozolomide For 
Metastatic Melanoma 
Patients 
NCT01543464 Recruiting Phase II studying the clinical benefit rate of an 
IDO/survivin peptide vaccine malignant 
melanoma Malignant Melanoma 
8.- A Phase 1/2 
Randomized, Blinded, 
Placebo Controlled 
Study Of Ipilimumab In 
Combination With 
INCB024360 Or Placebo 
In Subjects With 
Unresectable or 
Metastatic Melanoma 
NCT01604889 Recruiting Study the safety, tolerability, optimal dose 
and effect of the combination of INCB024360 
and ipilimumab in patients with metastatic 
Melanoma 
9.- A Phase 2 Study Of 
The IDO Inhibitor 
INCB024360 Versus 
Tamoxifen For 
Subjects With 
Biochemical-
Recurrent-Only EOC, 
PPC Or FTC Following 
Complete Remission 
With First-Line 
Chemotherapy 
NCT01685255 Active, Not 
Recruiting 
Phase II trial to study the safety and 
tolerability of INCB0243602 as well as the 
progression of solid tumours by assessing the 
expression of cancer antigens and imaging 
techniques. 
10.- 1-Methyl-D-
Tryptophan In Treating 
Patients With 
Metastatic Or 
Refractory Solid 
Tumours That Cannot 
Be Removed By 
Surgery 
NCT00567931 Completed Phase I trial studying the expression of IDO, 
the pharmacokinetics of 1-DMT as well as 
changes in the Trp/kynurenine ratio and in the 
number of circulating CD4+ CD25+ Treg cells in 
unspecified adult solid tumours. 
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11.- Phase II 
INCB024360 Study For 
Patients With 
Myelodysplastic 
Syndromes (MDS) 
NCT01822691 Active Not 
Recruiting 
Phase II trial studying the best overall 
response rate and progression of 
Myelodysplastic Syndromes treated with 
INCB024360  
15.- Indoleamine 2,3-
Dioxygenase (IDO) 
Activity In Patients 
With Chronic 
Lymphocytic 
Leukaemia (CLL) 
NCT01397916 
 
Completed Prospective study assessing the activity of IDO 
in patients with CLL 
16.- IDO Peptide 
Vaccination for Stage 
III-IV Non Small-cell 
Lung Cancer Patients. 
NCT01219348 
 
Completed Phase I trial assessing the toxicity and the 
immunological /clinical responses after 
peptide IDO vaccination in Non-small-cell-
lung-carcinoma 
 17.- INCB024360 and 
Vaccine Therapy in 
Treating Patients With 
Stage III-IV Melanoma 
NCT01961115 Recruiting Phase II trial evaluating the immune response 
(number/character/transcriptome of CD8+, 
CD4+, T and NK cells) as well as the adverse 
effects following peptide vaccination (12 class 
I MHC-restricted melanoma peptides and a 
class II MHC-restricted tetanus toxoid helper 
peptide) and IDO inhibitor in melanoma 
18.- Vaccine Therapy 
and IDO1 Inhibitor 
INCB024360 in Treating 
Patients With 
Epithelial Ovarian, 
Fallopian Tube, or 
Primary Peritoneal 
Cancer Who Are in 
Remission 
NCT01982487 Withdrawn Phase I/II trial studying the maximum 
tolerated dose of IDO1 inhibitor INCB024360 
and the related immunological response in 
several types of uterine cancer. 
19.- INCB024360 
Before Surgery in 
Treating Patients With 
Newly Diagnosed Stage 
III-IV Epithelial 
Ovarian, Fallopian 
Tube, or Primary 
Peritoneal Cancer 
NCT02042430 Recruiting Pilot clinical trial studying the 
number/character/transcriptome change in 
tumour infiltrating cells, peripheral blood 
mononuclear cells, and ascites as well as the 
change viral responses and the Trp/Kyn ratio 
in fallopian tube cancer following pre-surgical 
treatment with an IDO inhibitor 
20.- IDO Inhibitor 
Study for Advanced 
Solid Tumours 
NCT02048709 Recruiting Phase I studying the safety, maximum 
tolerated dose and pharmacokinetics of IDO-1 
inhibitor as well as the overall survival of 
patients with solid Lung, Breast, pancreas 
tumours 21.- Study of IDO 
Inhibitor and 
Temozolomide for 
Adult Patients With 
Primary Malignant 
Brain Tumours 
NCT02052648 Recruiting Phase I/II trial comparing the 
safety/tolerability/pharmacokinetics of IDO 
inhibitors and temozolomide treatment against 
historical controls of temozolomide alone in 
patients with glioblastoma.  
 
22.- Study of IDO 
Inhibitor in 
Combination With 
Ipilimumab for Adult 
Patients With 
Metastatic Melanoma 
NCT02073123 Recruiting Phase I/II trial studying safety/tolerability as 
well as overall survival and the mechanisms 
underlying the activity/resistance to 
IDO/CTLA-4 inhibitor therapy.  
24.- Study of IDO 
Inhibitor in 
Combination With 
Gemcitabine and Nab-
Paclitaxel in Patients 
With Metastatic 
Pancreatic Cancer 
NCT02077881 Not yet 
recruiting 
Phase I/II trial studying dosing/toxicity of IDO 
inhibitor co-administered with a 
chemotherapeutic agent (gemcitabine) and a 
microtubule stabiliser (nab-paclitaxel) as well 
as the overall survival and response time. 
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25.- Intraperitoneal 
Natural Killer Cells and 
INCB024360 for 
Recurrent Ovarian, 
Fallopian Tube, and 
Primary Peritoneal 
Cancer 
NCT02118285 Recruiting Phase I trial evaluating the maximum 
tolerated dose of INCB024360, the initial 
tumour response (and duration) as well as 
overall survival and progression-free survival 
in patients with ovarian Cancer, fallopian tube 
carcinoma and Primary Peritoneal Carcinoma 
26.- DEC-205/NY-ESO-
1 Fusion Protein CDX-
1401, Poly ICLC, and 
IDO1 Inhibitor 
INCB024360 in Treating 
Patients With Ovarian, 
Fallopian Tube, or 
Primary Peritoneal 
Cancer in Remission 
NCT02166905 Recruiting Phase I/II trial assessing the maximum 
tolerated dose, overall survival as well as the 
frequency and functioning of memory t-
cells/CD8+ and CD4+ T-cells recognizing the 
tumour antigen NY-ESO-1. 
Table 8 Clinical trials targeting the kynurenine pathway enzyme Indolamine 2,3-
dioxygenase. Information obtained and modified from http://Clinicaltrials.gov. 
 
6.3 Neurite/soma ratio after 3-HAA treatment 
 
Figure 32 Effect of a single 3-HAA treatment on the Neurite/Cell body ratio, 48 h after 
treatment. Micrographs were taken 48 h after treatment with different concentrations of 3-
HAA (10 µM, 50 µM and 100 µM) in 1% FBS medium or 10% FBS medium. Some cultures 
were co-incubated with 300u/ml SOD and 10 µM RA. Results are expressed as percentage of 
control. Mean ± S.E.M. for 4 different experiments. * P<0.05 vs. control. a P<0.05 vs. same 
treatment with SOD. b P<0.05 vs. same treatment in 1% FBS medium. c P<0.05 vs. RA in 1% 
FBS medium 
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Figure 33 Effect of a single 3-HAA treatment on the Neurite/Cell body ratio, 72 h after 
treatment. Micrographs were taken 72 h after treatment with different concentrations of 3-
HAA (10 µM, 50 µM and 100 µM) in 1% FBS medium or 10% FBS medium. Some cultures 
were co-incubated with 300u/ml SOD and 10 µM RA. Results are expressed as percentage of 
control. Mean ± S.E.M. for 4 different experiments. * P<0.05 vs. control. a P<0.05 vs. same 
treatment with SOD. b P<0.05 vs. same treatment in 1% FBS medium. c P<0.05 vs. RA in 1% 
FBS medium. 
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